<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004162.pub2" GROUP_ID="SCHIZ" ID="946002091009241969" MERGED_FROM="" MODIFIED="2013-01-10 14:33:38 +0000" MODIFIED_BY="Claire Irving" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.2.1 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2013-01-10 14:33:38 +0000" MODIFIED_BY="Claire Irving">
<TITLE>Antipsychotic drug treatment for elderly people with late-onset schizophrenia</TITLE>
<CONTACT MODIFIED="2013-01-10 14:33:38 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="7425" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Adib</FIRST_NAME><LAST_NAME>Essali</LAST_NAME><POSITION>Head of Centre</POSITION><EMAIL_1>adib-essali@hotmail.com</EMAIL_1><EMAIL_2>adib-essali@hotmail.com</EMAIL_2><MOBILE_PHONE>00963933212321</MOBILE_PHONE><ADDRESS><DEPARTMENT>Psychiatry Centre</DEPARTMENT><ORGANISATION>Teshreen Hospital</ORGANISATION><ADDRESS_1>27 Al Zahraw Street</ADDRESS_1><ADDRESS_2>Rawdad</ADDRESS_2><CITY>Damascus</CITY><COUNTRY CODE="SY">Syrian Arab Republic</COUNTRY><PHONE_1>+ 963 11 444 1510</PHONE_1><FAX_1>+ 963 11 512 5737</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-01-10 14:33:38 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="7425" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Adib</FIRST_NAME><LAST_NAME>Essali</LAST_NAME><POSITION>Head of Centre</POSITION><EMAIL_1>adib-essali@hotmail.com</EMAIL_1><EMAIL_2>adib-essali@hotmail.com</EMAIL_2><MOBILE_PHONE>00963933212321</MOBILE_PHONE><ADDRESS><DEPARTMENT>Psychiatry Centre</DEPARTMENT><ORGANISATION>Teshreen Hospital</ORGANISATION><ADDRESS_1>27 Al Zahraw Street</ADDRESS_1><ADDRESS_2>Rawdad</ADDRESS_2><CITY>Damascus</CITY><COUNTRY CODE="SY">Syrian Arab Republic</COUNTRY><PHONE_1>+ 963 11 444 1510</PHONE_1><FAX_1>+ 963 11 512 5737</FAX_1></ADDRESS></PERSON><PERSON ID="94293291819028291070090818143144" ROLE="AUTHOR"><FIRST_NAME>Ghassan</FIRST_NAME><LAST_NAME>Ali</LAST_NAME><EMAIL_1>dghassanali@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Centre of Psychiatry</DEPARTMENT><ORGANISATION>Tichrin Hospital</ORGANISATION><ADDRESS_1>Barzeh</ADDRESS_1><CITY>Damascus</CITY><COUNTRY CODE="SY">Syrian Arab Republic</COUNTRY><PHONE_1>++96 395 548 5970</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-01-09 09:40:54 +0000" MODIFIED_BY="Samantha Roberts">
<UP_TO_DATE>
<DATE DAY="4" MONTH="10" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="1" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="11" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2003"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2012"/>
</DATES>
<WHATS_NEW MODIFIED="2013-01-10 14:25:07 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-01-09 11:33:03 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Update search of Cochrane Schizophrenia Group's Trial Register (see <A HREF="http://archie.cochrane.org/sections/documents/view?version=44705070754671417758120516110605&amp;format=REVMAN#SEARCH_METHODS">Search methods for identification of studies</A>), 48 studies added to awaiting classification.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-01-10 14:25:07 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-01-10 14:25:07 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>As result of search in 2010, one new study added to the included studies table, most data from this study were unusable and conclusions are not altered.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-01-10 14:25:05 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>Updated with 211 new references.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2012-01-05 11:53:35 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="12" YEAR="2002"/>
<DESCRIPTION>
<P>Substantive amendment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Faculty of Medicine, Khon Kaen University</NAME>
<COUNTRY CODE="TH">Thailand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Yale University School of Medicine</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Brown University School of Medicine</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>University of Leeds</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-01-10 14:29:51 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-12-07 09:51:51 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-02 14:27:57 +0100" MODIFIED_BY="[Empty name]">Antipsychotic drugs for elderly people with late-onset schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2011-12-07 09:51:51 +0000" MODIFIED_BY="[Empty name]">
<P>A significant proportion of the world's growing elderly population suffers from schizophrenia that started very late in life. Antipsychotic drugs are often used to treat this distressing and severe illness. In this review we attempted to find good quality trial-based evidence to support this practice but found none. Currently this vulnerable group is not well served by the research community.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-01-09 11:36:01 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-01-04 14:36:51 +0000" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is usually considered an illness of young adulthood. However, onset after the age of 40 years is reported in 23% of patients hospitalised with schizophrenia. At least 0.1% of the world's elderly population have a diagnosis of late-onset schizophrenia which seems to differ from earlier onset schizophrenia on a variety of counts including response to antipsychotic drugs.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of antipsychotic drugs for elderly people with late-onset schizophrenia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-01-09 11:35:37 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Schizophrenia Group Trials Register (January 2010) which is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO. We inspected references of all identified studies for further trials. We contacted relevant authors of trials for additional information.</P>
<P>We updated this search Janurary 2013 and added 48 new trials to the awaiting classification section.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-05-26 21:09:50 +0100" MODIFIED_BY="[Empty name]">
<P>All relevant randomised controlled trials that compared antipsychotic drugs with other treatments for elderly people (at least 80% older than 65 years) with a recent (within five years) diagnosis of schizophrenia or schizophrenia like illnesses.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-01-04 14:32:07 +0000" MODIFIED_BY="[Empty name]">
<P>For the 2010 search, two new review authors (AE, AG) inspected all citations to ensure reliable selection. We assessed methodological quality of trials using the criteria recommended in the <I>Cochrane Handbook for Systematic Reviews of Interventions. </I>AE and AG also independently extracted data. For homogenous dichotomous data, we planned to calculate the relative risk (RR) and 95% confidence interval (CI).<BR/>
</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-01-04 14:33:14 +0000" MODIFIED_BY="[Empty name]">
<P>There were no included studies in the original version of this review (2002 search). The 2010 search for the current update produced 211 references, among which we identified 88 studies. Only one study met the inclusion criteria and was of acceptable quality. This was an eight-week randomised trial of risperidone and olanzapine in 44 inpatients with late-onset schizophrenia. All participants completed the eight-week trial, indicating that both drugs were well tolerated. Unfortunately, this study provided little usable data. We excluded a total of 81 studies, 77 studies because they either studied interventions other than antipsychotic medication or because they involved elderly people with chronic - not late-onset - schizophrenia. We excluded a further four trials of antipsychotics in late-onset schizophrenia because of flawed design. Five studies are still awaiting classification, and one is on-going.<BR/>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-01-09 11:36:01 +0000" MODIFIED_BY="[Empty name]">
<P>There is no trial-based evidence upon which to base guidelines for the treatment of late-onset schizophrenia. There is a need for good quality-controlled clinical trials into the effects of antipsychotics for this group. Such trials are possible. Until they are undertaken, people with late-onset schizophrenia will be treated by doctors using clinical judgement and habit to guide prescribing.</P>
<P>Note: the 48 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-01-10 14:28:10 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-12-07 09:52:52 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-12-07 09:52:52 +0000" MODIFIED_BY="[Empty name]">
<P>Although schizophrenia is commonly thought of as an illness of young adulthood, it can both extend into and first appear in later life. It has been recognised that schizophrenia may have a late-onset ever since schizophrenia was first described (<LINK REF="REF-Kraepelin-1909" TYPE="REFERENCE">Kraepelin 1909</LINK>), and contemporary diagnostic criteria for schizophrenia, such as DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) and ICD-10 (International Classification of Diseases), place no restrictions on age of onset for a diagnosis to be made.</P>
<P>Variously referred to as paraphrenia, late paraphrenia, paranoia, involutional paranoid disorder and late-onset schizophrenia, there has been no general agreement on the definition of late onset. Different studies defined late-onset as onset after 40, 45, 60, or 65 years of age (<LINK REF="REF-Harris-1988" TYPE="REFERENCE">Harris 1988</LINK>). The International Late-Onset Schizophrenia Group Consensus Statement recommended the diagnoses of late-onset schizophrenia (illness onset after 40 years of age) and very-late-onset schizophrenia-like psychosis (onset after 60 years) (<LINK REF="REF-Howard-1992b" TYPE="REFERENCE">Howard 1992b</LINK>; <LINK REF="REF-Howard-1993" TYPE="REFERENCE">Howard 1993</LINK>; <LINK REF="REF-Howard-2000" TYPE="REFERENCE">Howard 2000</LINK>). The diagnosis of late-onset schizophrenia is further complicated by the fact that it is often difficult to determine the age of onset of schizophrenia, especially in older people (<LINK REF="REF-Harris-1988a" TYPE="REFERENCE">Harris 1988a</LINK>).</P>
<P>At least 12% of elderly people in the community have mental disorders, and about 0.1% of them have a diagnosis of late-onset schizophrenia (<LINK REF="REF-Regier-2000" TYPE="REFERENCE">Regier 2000</LINK>). Only 5.7% of people with late-onset schizophrenia-like psychosis live in their own home and 24% live in sheltered accommodation (<LINK REF="REF-Henderson-1998" TYPE="REFERENCE">Henderson 1998</LINK>). Twenty-three per cent of patients hospitalised for schizophrenia were reported to have had onset of their illness after the age of 40; 13% in their forties, 7% in their fifties, and 3% after age 60 (<LINK REF="REF-Harris-1988" TYPE="REFERENCE">Harris 1988</LINK>). The prevalence of late-onset schizophrenia-like psychosis within a community has been reported to be as high as 7.5% (<LINK REF="REF-Henderson-1998" TYPE="REFERENCE">Henderson 1998</LINK>). The estimated one-year prevalence rate of schizophrenia in individuals between ages 45 and 64 is 0.6% (<LINK REF="REF-Keith-1991" TYPE="REFERENCE">Keith 1991</LINK>), and between 0.1% to 0.5% in individuals over 65 years of age (<LINK REF="REF-Castle-1993" TYPE="REFERENCE">Castle 1993</LINK>; <LINK REF="REF-Copeland-1992" TYPE="REFERENCE">Copeland 1992</LINK>; <LINK REF="REF-Copeland-1998" TYPE="REFERENCE">Copeland 1998</LINK>; <LINK REF="REF-Kua-1992" TYPE="REFERENCE">Kua 1992</LINK>). The incidence rate of DSM-III-R-defined schizophrenia with first onset after 44 years is reported to be 12.6 per 100,000 population per year (<LINK REF="REF-Copeland-1998" TYPE="REFERENCE">Copeland 1998</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-10-04 14:24:49 +0100" MODIFIED_BY="[Empty name]">
<P>Neuroleptics remain the most effective treatment for schizophrenia, but their use in elderly people with psychosis is based on clinical data extrapolated from studies of these agents in younger populations (<LINK REF="REF-Devanand-1998" TYPE="REFERENCE">Devanand 1998</LINK>; <LINK REF="REF-Frenchman-1997" TYPE="REFERENCE">Frenchman 1997</LINK>; <LINK REF="REF-Katz-1999" TYPE="REFERENCE">Katz 1999</LINK>). An extremely limited body of published studies suggests that the benefits of neuroleptics may extend to elderly people with late-life schizophrenia (<LINK REF="REF-Jeste-1993" TYPE="REFERENCE">Jeste 1993</LINK>). Elderly people with chronic schizophrenia have been shown to benefit from typical neuroleptics such as acetophenazine, trifluoperazine, haloperidol, fluphenazine and thioridazine (<LINK REF="STD-Branchey-1978" TYPE="STUDY">Branchey 1978</LINK>; <LINK REF="REF-Honigfeld-1965" TYPE="REFERENCE">Honigfeld 1965</LINK>; <LINK REF="REF-Tsuang-1971" TYPE="REFERENCE">Tsuang 1971</LINK>). The newer atypical antipsychotics are thought to be well tolerated, since they have less potential for producing extrapyramidal side effects and tardive dyskinesias (<LINK REF="REF-Jeste-1996" TYPE="REFERENCE">Jeste 1996</LINK>; <LINK REF="REF-Jeste-1998" TYPE="REFERENCE">Jeste 1998</LINK>; <LINK REF="REF-Jeste-1999" TYPE="REFERENCE">Jeste 1999</LINK>; <LINK REF="REF-Jeste-1999a" TYPE="REFERENCE">Jeste 1999a</LINK>). The atypical antipsychotics do have some side effects of their own; clozapine has a high risk of spontaneous white blood cell decline (agranulocytosis), olanzapine causes significant weight gain (<LINK REF="REF-Duggan-2001" TYPE="REFERENCE">Duggan 2001</LINK>) and possibly induces diabetes (<LINK REF="REF-Koro-2002" TYPE="REFERENCE">Koro 2002</LINK>; <LINK REF="REF-Wirshing-1998" TYPE="REFERENCE">Wirshing 1998</LINK>). Risperidone can also cause significant weight gain (<LINK REF="REF-Allison-1999" TYPE="REFERENCE">Allison 1999</LINK>), and movement disorders (<LINK REF="REF-Gilbody-2002" TYPE="REFERENCE">Gilbody 2002</LINK>; <LINK REF="REF-Kennedy-2001" TYPE="REFERENCE">Kennedy 2001</LINK>). In addition, neuroleptics do not produce complete remission of all the symptoms of schizophrenia in most patients. In one series of people with late-onset schizophrenia, 24% did not show any signs of improvement after typical antipsychotic treatment (<LINK REF="REF-Pearlson-1989" TYPE="REFERENCE">Pearlson 1989</LINK>). Another series found that, after a minimum of three months of typical antipsychotic treatment, about 42% of people with late-onset schizophrenia-like psychosis showed no response, 31% of people partially improved, and 27% had remission of their symptoms (<LINK REF="REF-Howard-1992a" TYPE="REFERENCE">Howard 1992a</LINK>). The foremost barriers to the widespread use of atypical antipsychotic medications in older adults are (1) the lack of well-designed and well-conducted studies to demonstrate the effectiveness and safety of these medications in older patients with multiple medical conditions, and (2) the higher cost of these medications relative to typical neuroleptics (<LINK REF="REF-Thomas-1998" TYPE="REFERENCE">Thomas 1998</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2011-10-04 14:24:49 +0100" MODIFIED_BY="[Empty name]">
<P>Neuroleptic drugs are generally thought to work through blocking certain neurotransmitter receptors in the brain. The ability of typical neuroleptics to diminish psychotic symptoms was shown to be initiated by blockade of dopamine D<SUB>2</SUB> receptors in defined areas of the brain (<LINK REF="REF-Creese-1976" TYPE="REFERENCE">Creese 1976</LINK>; <LINK REF="REF-Davis-1991" TYPE="REFERENCE">Davis 1991</LINK>; <LINK REF="REF-Meltzer-1976" TYPE="REFERENCE">Meltzer 1976</LINK>). Atypical neuroleptics cause potent serotonin (5-hydroxytryptamine, 5-HT) receptor subtype 5-HT2A relative to DA D<SUB>2</SUB> receptor blockade (<LINK REF="REF-Arndt-1998" TYPE="REFERENCE">Arndt 1998</LINK>; <LINK REF="REF-Meltzer-1989" TYPE="REFERENCE">Meltzer 1989</LINK>), with the exception of aripiprazole, a partial dopamine agonist (<LINK REF="REF-Lawler-1999" TYPE="REFERENCE">Lawler 1999</LINK>), and amisulpride, a selective D<SUB>2</SUB>/D<SUB>3</SUB> antagonist (<LINK REF="REF-Di-Giovanni-1998" TYPE="REFERENCE">Di Giovanni 1998</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2011-10-04 14:24:49 +0100" MODIFIED_BY="[Empty name]">
<P>The elderly population is expected to grow substantially worldwide. The number of people over 65 increased from about 17 million in 1900 to 342 million in 1992, and is expected to increase to 2.5 billion (20% of the total population) by 2050 (<LINK REF="REF-Olshansky-1993" TYPE="REFERENCE">Olshansky 1993</LINK>). The aging of the general population will be associated with ever elevated numbers of elderly people with late-onset schizophrenia; the annual incidence of schizophrenia-like psychosis in people over the age of 60 increases by 11% with each five-year increase in age (<LINK REF="REF-Van-Os-1995" TYPE="REFERENCE">Van Os 1995</LINK>). Accordingly, the treatment of late-onset schizophrenia is gaining increased importance, and a review of the effects of neuroleptics on people with late-onset schizophrenia is particularly important for at least two reasons. First, pharmacotherapy in the older patient is complicated by alterations in pharmacokinetic and pharmacodynamic responses; small doses of neuroleptics are usually sufficient for improvement in older patients, and particular side effects might prove dangerous (<LINK REF="REF-Lohr-1992" TYPE="REFERENCE">Lohr 1992</LINK>). Second, most published studies do not distinguish between people with late-onset schizophrenia and elderly people with early-onset schizophrenia despite studies showing that the inclusion of late-onset schizophrenia into the diagnosis of early-onset schizophrenia or delusional disorder has poor empirical and theoretical bases (<LINK REF="REF-Almeida-1995" TYPE="REFERENCE">Almeida 1995</LINK>). Compared with early-onset schizophrenia, late-onset schizophrenia shows a two to 10 times higher prevalence in women than in men (<LINK REF="REF-Harris-1988" TYPE="REFERENCE">Harris 1988</LINK>), has a different genetic risk (<LINK REF="REF-Howard-1997" TYPE="REFERENCE">Howard 1997</LINK>), has a different symptom profile, (<LINK REF="REF-DeLisi-1992" TYPE="REFERENCE">DeLisi 1992</LINK>; <LINK REF="REF-Howard-1993a" TYPE="REFERENCE">Howard 1993a</LINK>) and has a better prognosis (<LINK REF="REF-Castle-1991" TYPE="REFERENCE">Castle 1991</LINK>; <LINK REF="REF-Harris-1988" TYPE="REFERENCE">Harris 1988</LINK>). People with late-onset schizophrenia seem to respond differently to treatment in comparison with people with an earlier onset of illness (<LINK REF="REF-Jeste-1995" TYPE="REFERENCE">Jeste 1995</LINK>; <LINK REF="REF-Jeste-1997" TYPE="REFERENCE">Jeste 1997</LINK>; <LINK REF="REF-Jeste-1998" TYPE="REFERENCE">Jeste 1998</LINK>; <LINK REF="REF-Lohr-1997" TYPE="REFERENCE">Lohr 1997</LINK>)</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-07-23 15:22:07 +0100" MODIFIED_BY="[Empty name]">
<P>To review the beneficial and harmful effects of antipsychotic drugs for elderly people with late-onset schizophrenia-like psychosis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-01-09 11:43:51 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-01-04 14:47:59 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-10-04 14:24:49 +0100" MODIFIED_BY="[Empty name]">
<P>All relevant randomised controlled trials. Where trials were described as 'double-blind' and it was implied that the studies were randomised, we planned to include these trials in a sensitivity analysis. If there was no substantive difference within primary outcomes when these 'implied randomisation' studies were added, then we would have included them in the final analysis. If there was a substantive difference, we planned to use only clearly randomised trials and the results of the sensitivity analysis described in the text. We excluded quasi-randomised studies, such as those allocating by using alternate days of the week.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-05-26 21:10:13 +0100" MODIFIED_BY="[Empty name]">
<P>Elderly people (at least 80% of whom should be over 65 years of age) with a recent (within five years) diagnosis of schizophrenia or schizophrenia like illness such as delusional disorder, schizoaffective disorder, schizophreniform psychosis or paraphrenia.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-10-06 05:36:48 +0100" MODIFIED_BY="[Empty name]">
<P>Any typical or atypical antipsychotic drug, at any dose and mode or pattern of administration, compared to placebo, no intervention or to any other typical or atypical antipsychotic drug, at any dose and mode or pattern of administration. For the purposes of the planned sensitivity analyses outlined below, we defined low doses as follows; amisulpride, aripiprazole, clozapine (&lt; 50 mg/day), iloperidone (&lt; 4 mg/day), olanzapine (&lt; 5 mg/day), quetiapine (&lt; 50 mg/day), risperidone (&lt; 2 mg/day) , sulpiride, ziprasidone (&lt; 40mg/day), zotepine (&lt; 100 mg/day).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-01-04 14:47:59 +0000" MODIFIED_BY="[Empty name]">
<P>The patient-oriented outcome measures that are important for this review are mortality (suicide or natural causes), global clinical response as defined by each included study, quality of life, adverse events, cost and service utilisation ( hospital admission, number of days in hospital). As schizophrenia is often a life-long illness, and antipsychotic drugs are used as an ongoing treatment, we grouped outcomes according to time periods into acute (less than six weeks), short-term (less than three months), medium-term (three to six months) and long-term outcomes (more than 6 months).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-05-27 13:20:22 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Suicide</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Hospital admission</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Clinically significant response in global state - as defined by each of the studies</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Clinically significant response in mental state - as defined by each of the studies</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Leaving the study early</HEADING>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-01-04 14:47:59 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Death due to natural causes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Service utilisation as measured by the number of days in hospital</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Average score/change in global state</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Mental state</HEADING>
<P>4.1 Average score/change in mental state<BR/>4.2 Clinically significant response in positive symptoms- as defined by each of the studies<BR/>4.3 Average score/change in positive symptoms<BR/>4.4 Clinically significant response on negative symptoms- as defined by each of the studies<BR/>4.5 Average score/change in negative symptoms</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Behaviour</HEADING>
<P>5.1 Clinically significant response in behaviour - as defined by each of the studies<BR/>5.2 Average score/change in behaviour</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Extrapyramidal side effects</HEADING>
<P>6.1 Incidence use of antiparkinson drugs<BR/>6.2 Clinically significant extrapyramidal side effects - as defined by each of the studies<BR/>6.3 Average score/change in extrapyramidal side effects</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7. Other adverse effects, general and specific</HEADING>
<P>7.1 Number of patients leaving the study early due to adverse effects<BR/>7.2 Cardiac effects<BR/>7.3 Anticholinergic effects<BR/>7.4 Antihistamine effects<BR/>7.5 Prolactin related symptoms</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8. Social functioning</HEADING>
<P>8.1 Clinically significant response in social functioning - as defined by each of the studies<BR/>8.2 Average score/change in social functioning</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">9. Economic outcomes</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">10. Quality of life</HEADING>
<P>10.1 Quality of life/ satisfaction with care for either recipients of care or carers<BR/>10.2 Significant change in quality of life/satisfaction - as defined by each of the studies<BR/>10.3 Average score/change in quality of life/satisfaction</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">11. Cognitive functioning</HEADING>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-01-09 11:43:51 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2013-01-09 09:58:04 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>1. Cochrane Schizophrenia Group Trials Register (January 2010)</B>
</P>
<P>We searched the register using the phrase:</P>
<P>[((old* or * old * in title) or (*elderly* or *paraphrenia* or *late onset* in title, abstract, and index terms or title) or ((aged* in index terms) terms of REFERENCE) or (elderly in participants of STUDY))].</P>
<P>This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see <A HREF="http://mrw.interscience.wiley.com/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>).</P>
<P>For previous electronic searches for earlier versions of this review, please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>
<B>2. Cochrane Schizophrenia Group Trials Register (January 2013)</B>
</P>
<P>The Trials Search Co-ordinator searched the Cochrane Schizophrenia Group&#8217;s Trials Register (9th Janurary 2013) using the phrase</P>
<P>[(* old * in title) or (*older adult* or *elderly* or *paraphrenia* or *late onset* in title, abstract, and index terms of REFERENCE) or (*older adults* in participants of STUDY))].</P>
<P>The Cochrane Schizophrenia Group&#8217;s Trials Register is compiled by systematic searches of major databases, handsearches and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">group module</A>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-01-09 11:43:51 +0000" MODIFIED_BY="[Empty name]">
<P>Please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-01-04 14:54:03 +0000" MODIFIED_BY="[Empty name]">
<P>For previous data and collection methods, please see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<STUDY_SELECTION MODIFIED="2012-01-04 14:54:03 +0000" MODIFIED_BY="[Empty name]">
<P>In order to ensure reliable selection, two review authors, AE and GA independently inspected all study citations identified by the searches and obtained full reports of the studies of agreed relevance. Where disputes arose, we resolved disagreements by discussion or, if doubt remained, by acquiring the full article for more detailed scrutiny. If doubt still remained, we added these trials to the list of those awaiting assessment pending acquisition of further information and we contacted the authors of studies. For details of previous author contributions in study selection see <LINK TAG="ACKNOWLEDGEMENTS" TYPE="SECTION">Acknowledgements</LINK>.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-01-04 14:52:02 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Data extraction</HEADING>
<P>We extracted data from included trials onto standard, simple forms. The review author GA extracted data from the included study, helped by Mohannad Othman, and this was inspected by AE. We discussed disagreements, documented our decisions and, if necessary, contacted the authors of studies for clarification. When uncertainty persisted, we allocated the trial to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK> while we contacted the authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Summary of findings table</HEADING>
<P>If usable data were available, we planned to use the GRADE approach to interpret findings (<LINK REF="REF-Sch_x00fc_nemann-2008" TYPE="REFERENCE">Schünemann 2008</LINK> and used GRADE profiler (<A HREF="http://www.ims.cochrane.org/gradepro">GRADEPRO</A>) to import data from RevMan 5 (<A HREF="http://www.ims.cochrane.org/revman">Review Manager</A>) to create a 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient-care and decision making.<BR/>
</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-10-04 14:24:49 +0100" MODIFIED_BY="[Empty name]">
<P>Working independently, AE and GA assessed risk of bias using the tool described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases. Accordingly, we categorised the risk of bias in every study into low, high or unclear risk of bias. We did not include studies where sequence generation was at high risk of bias or where allocation was clearly not concealed. If disputes arose as to which category a trial has to be allocated, again, we resolved this by discussion.</P>
<P>Earlier versions of this review used a different, less well-developed, means of categorising risk of bias (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-12-07 10:00:58 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous (binary) data:</HEADING>
<P>For binary (yes/no) outcomes, we planned to calculate a standard estimation of the fixed-effect risk ratio (RR) and its 95% confidence interval (95% CI). If heterogeneity had been found, we would have used a random-effects model.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data:</HEADING>
<P>We included continuous data from rating scales in this review only if the measuring instrument had been described in a peer-reviewed journal and the instrument was either a self-report or completed by an independent rater or relative (not the therapist). Where possible, we made efforts to convert continuous outcome measures to binary data by identifying cut-off points on rating scales and dividing participants accordingly. Otherwise, endpoint data would have been presented and if both endpoint and change data had been available for the same outcomes, only the former would have been reported in this review. We planned to estimate mean difference (MD) between groups as a summary statistic for continuous data, and, if heterogeneity had been found, we would have applied a random-effects model.</P>
<P>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, the following standards would have been applied to all data before inclusion: (a) standard deviations (SDs) and means are reported in the paper or are obtainable from the authors; (b) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>); (c) if a scale starts from a positive value the calculation described above in (b) should be modified to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S-Smin), where S is the mean score and Smin is the minimum score. Endpoint scores on scales often have a finite start and end point and these rules can be applied to them. When continuous data are presented on a scale which includes a possibility of negative values (such as change on a scale), there is no way of telling whether data are non-normally distributed (skewed) or not. It is thus preferable to use scale end point data, which typically cannot have negative values. If end point data was not available, then we would have used change data, but these would not have been subjected to a meta-analysis, and would have been reported in the 'Additional data' tables.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-10-04 14:24:49 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Cluster trials</HEADING>
<P>Where clustering had been incorporated into the analysis of primary studies, we would have presented these data as if from a non-cluster randomised study, but adjusted for the clustering effect. Otherwise, clustering would have been dealt with in this review as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK> Section 16.3).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cross-over design</HEADING>
<P>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. This makes cross-over trials inappropriate for unstable conditions such as schizophrenia. Accordingly, we would have only used data of the first phase of cross-over studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Studies with multiple treatment groups</HEADING>
<P>Where a study involved more than two treatment arms, if relevant, we would have presented the additional treatment arms in comparisons. Where the additional treatment arms were not relevant, we would not have reproduced these data.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-12-07 10:01:51 +0000" MODIFIED_BY="[Empty name]">
<P>We planned to carry out an intention to treat analysis. Studies would have been excluded from this review if they reported an attrition rate higher than 50% of participants in any group. In studies with less than 50% attrition rates, people leaving early would have been considered to have had the negative outcome, except for the event of death. We would also have analysed the impact of including studies with high attrition rates in a sensitivity analysis. If inclusion of data from this latter group had resulted in a substantive change in estimate of effects of the primary outcomes, we would have presented their data separately.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-10-04 14:24:50 +0100" MODIFIED_BY="[Empty name]">
<P>We would have considered all included studies without any comparison to judge clinical heterogeneity. We planned to investigate statistical heterogeneity by visual inspection of graphs and by calculating the I<SUP>2</SUP> statistic. The I<SUP>2</SUP> test provides an estimate of the percentage of heterogeneity thought to be due to chance, and it indicates high levels of heterogeneity when it gives a result of 75% or more (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). We would then have re-analysed the data using a random-effects model to see if this made a substantial difference. If it did, and the I<SUP>2</SUP> statistic fell below 75% indicating more consistent results, we would have added the studies to the main body of trials. If using the random-effects model did not make a difference and heterogeneity remained high, data would not have been summated, but presented separately and reasons for heterogeneity investigated.<BR/>
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-10-04 14:24:50 +0100" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. These are described in section 10.1 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). We would have tried to locate protocols of included trials. If the protocol was available, we would have compared outcomes in the protocol and in the published report. If the protocol was not available, we would have compared outcomes listed in the methods section of the trial report with actually reported results. In addition, we would have attempted to use a funnel plot (included trial effect size versus included trial size) in an attempt to investigate the likelihood of publication bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-10-04 14:24:50 +0100" MODIFIED_BY="[Empty name]">
<P>Where possible, we would have employed a fixed-effect model for analyses. However, as discussed above, we would have applied a random-effects model if heterogeneity had been found.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-10-04 14:24:50 +0100" MODIFIED_BY="[Empty name]">
<P>It has been proposed that elderly people may be more sensitive to neuroleptic drugs, and that the outcome may be affected by the specific diagnosis of late-onset psychosis. Accordingly, we would have performed subgroups analyses to test these proposals.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-10-04 14:24:50 +0100" MODIFIED_BY="[Empty name]">
<P>We intended to undertake an analysis of the primary outcomes comparing the results when completer-only data were used with analyses on an intention-to-treat basis. We would have also performed a sensitivity analysis to compare between low-quality and high-quality studies. A third sensitivity analysis would have compared between acute, short-term, medium-term and long-term (as defined above) randomised controlled trials.<BR/>
</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-01-10 14:28:10 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-01-10 14:28:10 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2011-10-06 07:05:53 +0100" MODIFIED_BY="[Empty name]">
<P>The search of the Cochrane Schizophrenia Groups trials register for the initial version of this review resulted in 119 references. Of the 38 studies identified, 37 were excluded and one study added to <LINK TAG="ONGOING_STUDIES" TYPE="SECTION">Ongoing studies</LINK> (<LINK REF="STD-Lacro-2001" TYPE="STUDY">Lacro 2001</LINK>). The current updated search resulted in 211 references, from which we identified 88 studies, 81 excluded studies, one included study, one additional ongoing study and five awaiting classification.<BR/>
</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-10-04 14:24:50 +0100" MODIFIED_BY="[Empty name]">
<P>The original version of this review included no studies. We have included one study in the current update (<LINK REF="STD-Huang-2007" TYPE="STUDY">Huang 2007</LINK>). The characteristics of this study were as follows (Please also see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Length of study</HEADING>
<P>Eight weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Setting</HEADING>
<P>Hospital inpatient.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Participants</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Diagnosis</HEADING>
<P>People with schizophrenia diagnosed according to CCMD-3 (Chinese Classification of Mental Disorders (third revision)).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Age</HEADING>
<P>People with a mean age of 64.3 ± 3.2 years for the risperidone group and a mean age of 63.3 ± 3.9 years for the olanzapine group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Sex</HEADING>
<P>Twelve male and 10 female patients in the risperidone group and 11 male and 11 female patients in the olanzapine group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4 History</HEADING>
<P>Participants in the risperidone group had been ill for 1.6 ± 1.1 (mean ± SD) years. Participants in the olanzapine group had been ill for 1.8 ± 1.4 (mean ± SD) years.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Study size:</HEADING>
<P>The number of people randomised was 44.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Interventions</HEADING>
<P>5.1 Risperidone at a fixed dose of 4.1 ± 2.1 (mean ± SD) mg/day.</P>
<P>5.2 Olanzapine at a fixed dose of 10.2 ± 5.9 mg/day.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Leaving the study early</HEADING>
<P>All participants completed the eight-week study.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7. Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">7.1 General remarks</HEADING>
<P>All measures were obtained at baseline, four and eight weeks following the intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.2 Outcome Scales</HEADING>
<P>No scales provided usable data.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7.3 Missing Outcomes</HEADING>
<P>Missing outcomes were social functioning, economic outcomes, quality of life and cognitive functioning.</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-01-10 14:28:10 +0000" MODIFIED_BY="[Empty name]">
<P>The original version of this review excluded 37 trials, largely because they did not include or report specifically on people with late-onset schizophrenia. Four randomised controlled trials involved people with schizophrenia, and included a minority who suffered from paraphrenia (<LINK REF="STD-Seager-1955" TYPE="STUDY">Seager 1955</LINK>; <LINK REF="STD-Svestka-1972" TYPE="STUDY">Svestka 1972</LINK>; <LINK REF="STD-Svestka-1973" TYPE="STUDY">Svestka 1973</LINK>; <LINK REF="STD-Svestka-1987" TYPE="STUDY">Svestka 1987</LINK>). These studies, however, did not report outcomes specifically for people with paraphrenia. <LINK REF="STD-Phanjoo-1990" TYPE="STUDY">Phanjoo 1990</LINK> did focus on the evaluation of antipsychotics for people with late-onset schizophrenia but the two treatments under evaluation, remoxipride and thioridazine, have both been withdrawn from global use. Thioridazine is still available, but remoxipride was last produced by AstraZeneca in 1999.</P>
<P>In the current update, we excluded 81studies. Four studies were not trials (<LINK REF="STD-Li-2002" TYPE="STUDY">Li 2002</LINK>; <LINK REF="STD-Linden-2001" TYPE="STUDY">Linden 2001</LINK>; <LINK REF="STD-Shen-2001" TYPE="STUDY">Shen 2001</LINK>; <LINK REF="STD-Wang-2002" TYPE="STUDY">Wang 2002</LINK>), and four trials were not randomised (<LINK REF="STD-Chen-2003a" TYPE="STUDY">Chen 2003a</LINK>; <LINK REF="STD-Fleischhacker-2003" TYPE="STUDY">Fleischhacker 2003</LINK>; <LINK REF="STD-Lin-2002" TYPE="STUDY">Lin 2002</LINK>; <LINK REF="STD-Wang-2005" TYPE="STUDY">Wang 2005</LINK>). 35 trials were excluded because the intervention was not neuroleptic medication (<LINK REF="STD-Bartels-2005" TYPE="STUDY">Bartels 2005</LINK>; <LINK REF="STD-Bjorndal-1980" TYPE="STUDY">Bjorndal 1980</LINK>; <LINK REF="STD-Blum-1984" TYPE="STUDY">Blum 1984</LINK>; <LINK REF="STD-Burns-2007" TYPE="STUDY">Burns 2007</LINK>; <LINK REF="STD-Chen-2003b" TYPE="STUDY">Chen 2003b</LINK>; <LINK REF="STD-Delapena-2005" TYPE="STUDY">Delapena 2005</LINK>; <LINK REF="STD-Depla-2003" TYPE="STUDY">Depla 2003</LINK>; <LINK REF="STD-Drake-1993" TYPE="STUDY">Drake 1993</LINK>; <LINK REF="STD-Dunn-2002" TYPE="STUDY">Dunn 2002</LINK>; <LINK REF="STD-Dunn-2006" TYPE="STUDY">Dunn 2006</LINK>; <LINK REF="STD-Gerlach-1977" TYPE="STUDY">Gerlach 1977</LINK>; <LINK REF="STD-Granholm-2004" TYPE="STUDY">Granholm 2004</LINK>; <LINK REF="STD-Granholm-2005" TYPE="STUDY">Granholm 2005</LINK>; <LINK REF="STD-Granholm-2007" TYPE="STUDY">Granholm 2007</LINK>; <LINK REF="STD-Granholm-2008" TYPE="STUDY">Granholm 2008</LINK>; <LINK REF="STD-Inouye-2003" TYPE="STUDY">Inouye 2003</LINK>; <LINK REF="STD-Isley-2003" TYPE="STUDY">Isley 2003</LINK>; <LINK REF="STD-Leutwyler-2009" TYPE="STUDY">Leutwyler 2009</LINK>; <LINK REF="STD-Mazeh-2006" TYPE="STUDY">Mazeh 2006</LINK>; <LINK REF="STD-McKibbin-2006" TYPE="STUDY">McKibbin 2006</LINK>; <LINK REF="STD-McQuaid-2001" TYPE="STUDY">McQuaid 2001</LINK>; <LINK REF="STD-Naoki-2003" TYPE="STUDY">Naoki 2003</LINK>; <LINK REF="STD-Ogunmefun-2009" TYPE="STUDY">Ogunmefun 2009</LINK>; <LINK REF="STD-Patterson-2003" TYPE="STUDY">Patterson 2003</LINK>; <LINK REF="STD-Patterson-2005" TYPE="STUDY">Patterson 2005</LINK>; <LINK REF="STD-Patterson-2006" TYPE="STUDY">Patterson 2006</LINK>; <LINK REF="STD-Prat-2009" TYPE="STUDY">Prat 2009</LINK>; <LINK REF="STD-Pratt-2005" TYPE="STUDY">Pratt 2005</LINK>; <LINK REF="STD-Pratt-2008" TYPE="STUDY">Pratt 2008</LINK>; <LINK REF="STD-Shin-2004" TYPE="STUDY">Shin 2004</LINK>; <LINK REF="STD-Twamley-2005" TYPE="STUDY">Twamley 2005</LINK>; <LINK REF="STD-Twamley-2008" TYPE="STUDY">Twamley 2008</LINK>; <LINK REF="STD-Wang-R-2002" TYPE="STUDY">Wang R 2002</LINK>; <LINK REF="STD-Zisook-2002" TYPE="STUDY">Zisook 2002</LINK> ). Another 34 trials were excluded because they did not involve elderly people or involved elderly people with chronic psychoses but not of late-onset (<LINK REF="STD-Anon-2005" TYPE="STUDY">Anon 2005</LINK>; <LINK REF="STD-Anon-2008a" TYPE="STUDY">Anon 2008a</LINK>; <LINK REF="STD-Anon-2008b" TYPE="STUDY">Anon 2008b</LINK>; <LINK REF="STD-Barak-2002" TYPE="STUDY">Barak 2002</LINK>; <LINK REF="STD-Brecher-1998" TYPE="STUDY">Brecher 1998</LINK>; <LINK REF="STD-CATIE-2003" TYPE="STUDY">CATIE 2003</LINK>; <LINK REF="STD-Crosthwaite-2000" TYPE="STUDY">Crosthwaite 2000</LINK>; <LINK REF="STD-Docherty-2002" TYPE="STUDY">Docherty 2002</LINK>; <LINK REF="STD-Glorioso-2005" TYPE="STUDY">Glorioso 2005</LINK>; <LINK REF="STD-Harrigan-2004" TYPE="STUDY">Harrigan 2004</LINK>; <LINK REF="STD-Harvey-2003" TYPE="STUDY">Harvey 2003</LINK>; <LINK REF="STD-Hay-2004" TYPE="STUDY">Hay 2004</LINK>; <LINK REF="STD-Jeste-2005" TYPE="STUDY">Jeste 2005</LINK>; <LINK REF="STD-Kinon-2000" TYPE="STUDY">Kinon 2000</LINK>; <LINK REF="STD-Kinon-2003" TYPE="STUDY">Kinon 2003</LINK>; <LINK REF="STD-Kopala-2003" TYPE="STUDY">Kopala 2003</LINK>; <LINK REF="STD-Lapolla-1969" TYPE="STUDY">Lapolla 1969</LINK>; <LINK REF="STD-Marcelli-2002" TYPE="STUDY">Marcelli 2002</LINK>; <LINK REF="STD-Mintzer-2004" TYPE="STUDY">Mintzer 2004</LINK>; <LINK REF="STD-Myers-2002" TYPE="STUDY">Myers 2002</LINK>; <LINK REF="STD-Nordentoft-1999" TYPE="STUDY">Nordentoft 1999</LINK>; <LINK REF="STD-Pfizer-2006" TYPE="STUDY">Pfizer 2006</LINK>; <LINK REF="STD-Ritchie-1999" TYPE="STUDY">Ritchie 1999</LINK>; <LINK REF="STD-Sikich-2002" TYPE="STUDY">Sikich 2002</LINK>; <LINK REF="STD-Sun-Hui-2008" TYPE="STUDY">Sun Hui 2008</LINK>; <LINK REF="STD-Tollefson-1997" TYPE="STUDY">Tollefson 1997</LINK>; <LINK REF="STD-Tran-1997" TYPE="STUDY">Tran 1997</LINK>; <LINK REF="STD-Tzimos-2007" TYPE="STUDY">Tzimos 2007</LINK>; <LINK REF="STD-Vaglum-2002" TYPE="STUDY">Vaglum 2002</LINK>; <LINK REF="STD-Wang-LiLi-2008" TYPE="STUDY">Wang LiLi 2008</LINK>; <LINK REF="STD-Wang-XiaoQuan-2008" TYPE="STUDY">Wang XiaoQuan 2008</LINK>; <LINK REF="STD-Yamashita-2005" TYPE="STUDY">Yamashita 2005</LINK>; <LINK REF="STD-Yang-2002" TYPE="STUDY">Yang 2002</LINK>; <LINK REF="STD-Yu-AiZhen-2008" TYPE="STUDY">Yu AiZhen 2008</LINK>). Four studies of late-onset schizophrenia were excluded because of flawed sequence generation (<LINK REF="STD-Cheng-2007" TYPE="STUDY">Cheng 2007</LINK>; <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>; <LINK REF="STD-Lin-2006" TYPE="STUDY">Lin 2006</LINK>; <LINK REF="STD-Liu-2007" TYPE="STUDY">Liu 2007</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Ongoing studies</HEADING>
<P>The original version of this review contained a study that may be ongoing (<LINK REF="STD-Lacro-2001" TYPE="STUDY">Lacro 2001</LINK>). However, the limited description of participants acquired by the reviewers did not suggest that late-onset schizophrenia was a focus of this work. The current update identified a study that did not seem to have started yet (<LINK REF="STD-Barnes-2002" TYPE="STUDY">Barnes 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Studies awaiting classification</HEADING>
<P>This review contains five studies from the 2010 search that need further assessment. In order to clarify the age of the participants and the age of onset of schizophrenia, we have been unable to obtain the full text of one study (<LINK REF="STD-M_x00f6_ller-2005" TYPE="STUDY">Möller 2005</LINK>) and the authors of two other studies have not responded to our e-mail enquiries (<LINK REF="STD-Riedel-2009" TYPE="STUDY">Riedel 2009</LINK>; <LINK REF="STD-Ritchie-2003" TYPE="STUDY">Ritchie 2003</LINK>). The sequence generation of two Chinese studies of late-onset schizophrenia was not clear (<LINK REF="STD-Chu-2006" TYPE="STUDY">Chu 2006</LINK>; <LINK REF="STD-Zhe-2007" TYPE="STUDY">Zhe 2007</LINK>); the authors could not be contacted by phone and they are yet to respond to our email enquiries. From the 2013 search 48 new studies were identified and are now also in awaiting assessment.<BR/>
</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-10-04 14:24:50 +0100" MODIFIED_BY="[Empty name]">
<P>Only one study fulfilled the criteria for inclusion in this review (<LINK REF="STD-Huang-2007" TYPE="STUDY">Huang 2007</LINK>). For summary of risk of bias please see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2010-08-10 09:32:28 +0100" MODIFIED_BY="[Empty name]">
<P>The only included study allocated participants according to a random number table.</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-08-10 20:17:39 +0100" MODIFIED_BY="[Empty name]">
<P>The only included study employed no blinding.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2011-10-04 14:24:50 +0100" MODIFIED_BY="[Empty name]">
<P>The only included study reported outcomes for all participants, but presented continuous data without SDs.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-08-10 09:35:10 +0100" MODIFIED_BY="[Empty name]">
<P>We have not been able to obtain the protocol of the only included study, but there is no indication of selective reporting.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-08-10 09:35:17 +0100" MODIFIED_BY="[Empty name]">
<P>None.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-12-07 10:06:03 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Leaving the study early</HEADING>
<P>All participants completed the 8 week trial, indicating that both drugs were well tolerated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Mental state: brief psychiatric rating scale (BPRS) date</HEADING>
<P>The only measure of efficacy in this study was the BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>). Apparently, similar changes in BPRS scores were reported in the risperidone and the olanzapine groups (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>), but we were unable to use this data as they were presented without SDs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Other outcomes</HEADING>
<P>The lack of SDs also prevented us from using data related to harm, which included changes in body mass index, fasting blood glucose, serum cholesterol and serum triglycerides (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-10-04 14:24:50 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">The search</HEADING>
<P>The search for the original version of this review identified only one study that focused on the evaluation of antipsychotics for people with late-onset schizophrenia (<LINK REF="STD-Phanjoo-1990" TYPE="STUDY">Phanjoo 1990</LINK>). The current updated search identified seven studies clearly focused on late-onset schizophrenia; one included study (<LINK REF="STD-Huang-2007" TYPE="STUDY">Huang 2007</LINK>), four excluded studies (<LINK REF="STD-Cheng-2007" TYPE="STUDY">Cheng 2007</LINK>; <LINK REF="STD-Lin-2005" TYPE="STUDY">Lin 2005</LINK>; <LINK REF="STD-Lin-2006" TYPE="STUDY">Lin 2006</LINK>; <LINK REF="STD-Liu-2007" TYPE="STUDY">Liu 2007</LINK>) and two studies awaiting classification (<LINK REF="STD-Chu-2006" TYPE="STUDY">Chu 2006</LINK>; <LINK REF="STD-Zhe-2007" TYPE="STUDY">Zhe 2007</LINK>). This observation may be the result of a newly established access to Chinese publication, but may also reflect a growing research interest in late-onset schizophrenia and can only be welcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Lack of trials and unusable data</HEADING>
<P>Antipsychotic drugs are perceived as beneficial for people with schizophrenia, but there are risks associated with the adverse effects (<LINK REF="REF-Jeste-1998" TYPE="REFERENCE">Jeste 1998</LINK>; <LINK REF="REF-Jeste-1999" TYPE="REFERENCE">Jeste 1999</LINK>). For older people the effects of these drugs may be different from the effects in younger adults (<LINK REF="REF-Salzman-1990" TYPE="REFERENCE">Salzman 1990</LINK>). Another Cochrane review evaluated the evidence for antipsychotic drugs in elderly people with schizophrenia regardless of age of onset (<LINK REF="REF-Marriott-2006" TYPE="REFERENCE">Marriott 2006</LINK>).This review was undertaken to examine the best available evidence on the use of antipsychotic drugs for people whose schizophrenic illness started late in life (onset after 45 years old). Late-onset schizophrenia may be different from schizophrenia with an earlier onset in term of gender distribution, genetic risk, symptom profile, prognosis and response to treatment (see <LINK TAG="IMPORTANCE" TYPE="SECTION">Why it is important to do this review</LINK>).</P>
<P>It is unfortunate that the majority of the studies of antipsychotics for late-onset schizophrenia were excluded from this review because of poor study design (quasi randomisation), and that the only included study comparing olanzapine and risperidone offered little usable data. However, these studies confirm the importance of investigating the effects of antipsychotics for late-onset schizophrenia and demonstrate that randomised studies are possible.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-01-09 11:40:39 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-01-09 11:40:39 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">General</HEADING>
<P>Pharmacological treatment of schizophrenia in late life presents some unique challenges. Conventional neuroleptic agents, have proven effective in managing the &#8220;positive symptoms&#8221; (such as delusions and hallucinations) of many older patients, but these medications have a high risk of potentially disabling and persistent side effects, such as tardive dyskinesia. Recent years have witnessed promising advances in the management of schizophrenia. Studies with mostly younger people with schizophrenia suggest that the newer &#8220;atypical&#8221; antipsychotics, such as clozapine, risperidone, olanzapine, and quetiapine, may be effective in treating those patients previously unresponsive to traditional neuroleptics. Moreover, the newer medications may be more effective in treating negative symptoms and may even yield partial improvement in certain neurocognitive deficits associated with schizophrenia (<LINK REF="REF-Green-1997" TYPE="REFERENCE">Green 1997</LINK>). Most of the research interest in schizophrenia has been focused on younger adults. With the ageing of the general population, there is now an increase in the attention being given to older people with schizophrenia, including those with a late onset of the disorder (<LINK REF="REF-Webster-1998" TYPE="REFERENCE">Webster 1998</LINK>). The literature in this area, however, is still very limited.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">For clinicians</HEADING>
<P>It is likely that clinicians will continue with their current practice, using clinical judgement and prescribing patterns to dictate prescribing because there is no trial-based evidence to help guide their choice of drug. Important ethical questions are raised by current prescribing practices for people with late-onset schizophrenia. It is difficult to know whether current practice is justified without well-designed, well-conducted, reported randomised studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">For people with late-onset schizophrenia or their relatives</HEADING>
<P>It would be understandable that people with late-onset schizophrenia or their relatives closely question their clinicians as regards the effects of antipsychotic drugs. In the light of the limited evidence, people with late-onset schizophrenia would be justified to be disappointed in the medical/research fraternity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">For policy makers and funders</HEADING>
<P>Currently policy makers have no trial-based evidence upon which to base guidelines for late-onset schizophrenia. They are likely to continue to rely on opinion and habit when making their recommendations. Funders of studies may wish to make this important subgroup of people a priority for future research.</P>
<P>Note: the 48 new citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.<BR/>
</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-10-04 14:24:50 +0100" MODIFIED_BY="[Empty name]">
<P>At present, there is no convincing evidence to support the use of antipsychotic medication for people with late-onset schizophrenia. Clinically meaningful randomised studies are needed to help guide clinicians in their management of elderly people with schizophrenia. Available publications prove that studies of antipsychotic drugs for late-onset schizophrenia are possible. There is a need for well-designed randomised clinical trials of late-onset psychoses, i.e., schizophrenia, delusional disorder, psychotic depression, etc. Comparisons of early-onset and late-onset psychoses are warranted, with meaningful outcome measures such as quality of life and activities of daily living functioning.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-01-10 14:29:51 +0000" MODIFIED_BY="[Empty name]">
<P>This review was initiated by Suwanna Arunpongpaisal who wrote the protocol, undertook the search and data extraction and drafted the previous version of the review. Suchat Paholpak, Irshad Ahmed and Noorulain Aqeel helped write the protocol and the previous version of this review.</P>
<P>We would like to acknowledge the help of the AstraZeneca Medical Information Department who tracked down several trials of remoxipride. Many thanks to Chunbo Li for contacting Chinese authors by phone and email, and to Norah Essali for her help with RevMan. We are most grateful for the ongoing support of Claire Irving, Samantha Roberts and Lindsey Air at the Cochrane Schizophrenia Group editorial base.</P>
<P>We would also like to thank Mohannad Othman who helped in the 2010 search and data extraction.</P>
<P>The Cochrane Schizophrenia group provide a standard template for their methods section and other parts of the protocol. We have used this template and adapted it accordingly.</P>
<P>The additional text for the amendment following 2013 search has been added by the editorial base of the Cochrane Schizophrenia Group.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-01-05 11:04:34 +0000" MODIFIED_BY="[Empty name]">
<P>Adib Essali - undertook the 2010 update search and data extraction, updated the full review.</P>
<P>Ghassan Ali - trial selection and data extraction.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-01-05 11:05:02 +0000" MODIFIED_BY="[Empty name]">
<P>The protocol used for this update has been changed and updated: taken from the most recent methodology of the Cochrane Schizophrenia Group, it acknowledges changes in Cochrane methodology since this review was first published - for example use of 'Summary of findings' tables instead of calculating NNT/NNH and changes in the 'Risk of bias' tables. We do not think the use of these new methods affects the results or integrity of the review.</P>
<P>For previous methodology please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-01-09 10:55:23 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-01-09 10:55:23 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-01-04 13:41:19 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Huang-2007" MODIFIED="2012-01-04 13:41:19 +0000" MODIFIED_BY="[Empty name]" NAME="Huang 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-01-04 13:41:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang X, Zhong Z, Zhang J</AU>
<TI>The effects of risperidone and olanzapine on the glucose metabolism and lipid metabolism in elderly patients with schizophrenia</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>1</NO>
<PG>1-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-01-09 10:43:25 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anon-2005" MODIFIED="2011-09-21 14:18:43 +0100" MODIFIED_BY="[Empty name]" NAME="Anon 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-08-09 10:42:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anon</AU>
<TI>Drug update This older schizophrenia drug is as effective as newer ones</TI>
<SO>RN</SO>
<YR>2005</YR>
<VL>68</VL>
<NO>11</NO>
<PG>81, 84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anon-2008a" MODIFIED="2011-09-21 14:18:54 +0100" MODIFIED_BY="[Empty name]" NAME="Anon 2008a" YEAR="2008">
<REFERENCE MODIFIED="2010-07-25 12:59:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anon</AU>
<TI>Paliperidone extended release in elderly schizophrenia patients</TI>
<SO>Brown University Geriatric Psychopharmacology Update</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>4</NO>
<PG>3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anon-2008b" MODIFIED="2011-09-21 14:19:08 +0100" MODIFIED_BY="[Empty name]" NAME="Anon 2008b" YEAR="2008">
<REFERENCE MODIFIED="2010-06-23 16:45:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anon</AU>
<TI>Atypical vs older antipsychotics for early-onset schizophrenia</TI>
<SO>Brown University Child and Adolescent Psychopharmacology Update</SO>
<YR>2008</YR>
<VL>10</VL>
<NO>11</NO>
<PG>3-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bamrah-2000" MODIFIED="2011-08-22 20:36:39 +0100" MODIFIED_BY="[Empty name]" NAME="Bamrah 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-08-22 20:36:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bamrah S</AU>
<TI>A multicentre, double-blind, randomised, parallel group comparison of seroquel and haloperidol in the treatment of elderly patients presenting with dementia and psychosis</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barak-2000" MODIFIED="2008-10-22 08:30:01 +0100" MODIFIED_BY="[Empty name]" NAME="Barak 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-10-22 08:30:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barak Y, Shamir E, Weizman R</AU>
<TI>Risperidone compared with typical neuroleptic treatment in elderly schizophrenic patients</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl. 1</NO>
<PG>122</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barak-2002" MODIFIED="2010-06-23 16:50:48 +0100" MODIFIED_BY="[Empty name]" NAME="Barak 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-06-23 16:50:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barak Y//Shamir E//Zemishlani H//Mirecki I//Toren P//Weizman R</AU>
<TI>Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>2002</YR>
<VL>26</VL>
<PG>1199-202</PG>
<EN>6</EN>
<CY>England</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12452546"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bartels-2005" MODIFIED="2010-06-23 17:00:48 +0100" MODIFIED_BY="[Empty name]" NAME="Bartels 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-06-23 17:00:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bartels SJ</AU>
<TI>Rehabilitation and health care for elderly with SMI</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berman-1995" MODIFIED="2008-10-21 14:31:23 +0100" MODIFIED_BY="[Empty name]" NAME="Berman 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Berman I, Allan ER, Pappas D, Sison CE, Merson A</AU>
<TI>The cognitive effect of risperidone in elderly schizophrenic patients a pilot double-blind comparison study with haloperidol</TI>
<SO>150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, USA</SO>
<YR>1997</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95208930"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-21 14:31:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berman I, Merson A, Allan E, Alexis C, Losonczy M</AU>
<TI>Effect of risperidone on cognitive performance in elderly schizophrenic patients: a double-blind comparison study with haloperidol</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1995</YR>
<VL>31</VL>
<NO>3</NO>
<PG>552</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="75116103"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Berman I, Pappas D, Patel C, Chang H, Goff D</AU>
<TI>Effect of risperidone on cognitive function in schizophrenia</TI>
<SO>151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4; Toronto, Canada</SO>
<YR>1998</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="91029658"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bjorndal-1980" MODIFIED="2012-01-04 13:41:38 +0000" MODIFIED_BY="[Empty name]" NAME="Bjorndal 1980" YEAR="1980">
<REFERENCE MODIFIED="2012-01-04 13:41:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjørndal N, Casey DE, Gerlach J</AU>
<TI>Enkephalin, morphine, and naloxone in tardive dyskinesia</TI>
<SO>Psychopharmacology</SO>
<YR>1980</YR>
<VL>69</VL>
<NO>2</NO>
<PG>133-6</PG>
<CY>GERMANY,-WEST</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6779305"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blum-1984" MODIFIED="2012-01-04 13:42:01 +0000" MODIFIED_BY="[Empty name]" NAME="Blum 1984" YEAR="1984">
<REFERENCE MODIFIED="2012-01-04 13:42:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blum I, Munitz H, Shalev A, Roberts E</AU>
<TI>Naloxone may be beneficial in the treatment of tardive dyskinesia</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1984</YR>
<VL>7</VL>
<NO>3</NO>
<PG>265-7</PG>
<CY>United States of America</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6386154"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:41:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blum I, Nisipeanu PF, Roberts E, Casey DE, Korsgaard S, Gerlach J</AU>
<TI>Des-tyr-gamma-endorphin in tardive dyskinesia</TI>
<SO>Proceedings of the 3rd World Congress of Biological Psychiatry; 1981 Jun 28 - Jul 3; Stockholm, Sweden</SO>
<YR>1981</YR>
<VL>93</VL>
<PG>538</PG>
<EN>0033-3158</EN>
<CY>KARLA; NOTCSG; BIN; CASE CONTROL</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Branchey-1978" MODIFIED="2008-10-21 14:23:34 +0100" MODIFIED_BY="[Empty name]" NAME="Branchey 1978" YEAR="1978">
<REFERENCE MODIFIED="2008-10-21 14:23:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Branchey MH, Lee JH, Amin R, Simpson GM</AU>
<TI>High and low potency neuroleptics in elderly psychiatric patients</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1978</YR>
<VL>239</VL>
<NO>18</NO>
<PG>1860-2</PG>
<IDENTIFIERS MODIFIED="2008-10-21 14:23:32 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-21 14:23:32 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="78153981"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brecher-1998" MODIFIED="2013-01-09 10:42:58 +0000" MODIFIED_BY="[Empty name]" NAME="Brecher 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-01-04 13:42:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berry SA, Gudelsky GA, Mahmoud RA</AU>
<TI>Serum prolactin levels in schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>8</NO>
<PG>22S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:42:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conley RR, Mahmoud R. Risperidone Study Group</AU>
<TI>Risperidone vs. olanzapine in patients with schizophrenia and schizoaffective disorder</TI>
<SO>Biological Psychiatry</SO>
<YR>2000</YR>
<VL>47</VL>
<PG>32S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:42:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Conley RR, Mahmoud R</AU>
<TI>Risperidone and olanzapine in people with schizophrenia or schizoaffective disorder: a randomised double-blind study</TI>
<SO>Data on file</SO>
<YR>2001</YR>
<PB>Maryland Psychiatric Research Center</PB>
<CY>Baltimore, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:44:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Conley RR, Mahmoud R</AU>
<TI>Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:42:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Conley RR, Mahmoud R</AU>
<TI>Risperidone vs olanzapine in patients with schizophrenia &amp; schizoaffective disorder</TI>
<SO>Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30 - Jun 2; Boca Raton, Florida, USA</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:46:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conley RR, Mahmoud R</AU>
<TI>Risperidone vs olanzapine in patients with schizophrenia and schizo-affective disorder</TI>
<SO>International Drug Therapy Newsletter</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>10</NO>
<PG>77-8</PG>
<CY>USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:47:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey P, Meltzer H, Green M</AU>
<TI>Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder</TI>
<SO>Biological Psychiatry</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>8</NO>
<PG>123S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:47:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey P, Meltzer H, Green M</AU>
<TI>Risperidone cognitive effects in schizophrenia and schizoaffective patients</TI>
<SO>International Drug Therapy Newsletter</SO>
<YR>2001</YR>
<VL>36</VL>
<NO>8</NO>
<PG>59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:47:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Gharabawi G</AU>
<TI>Risperidone and cognition in schizophrenic elderly</TI>
<SO>Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan</SO>
<YR>2002</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12377405"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-09 10:42:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Green MF, McGurk SR, Meltzer HY</AU>
<TI>Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, RANDOMized study</TI>
<SO>Psychopharmacology</SO>
<YR>2003</YR>
<VL>169</VL>
<NO>3-4</NO>
<PG>404-11</PG>
<CY>Germany</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12590356"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:47:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Meltzer HY, Green MF</AU>
<TI>Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder</TI>
<SO>Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30 - Jun 2; Boca Raton, Florida, USA</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-24 10:42:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD</AU>
<TI>Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-09 10:42:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelly DL, Conley RR, Love RC, Morrison JA, McMahon RP</AU>
<TI>Metabolic risk with second-generation antipsychotic treatment: a double-blind RANDOMized 8-week trial of risperidone and olanzapine</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>2</NO>
<PG>71-8</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18568578"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:48:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lasser RA, Mao L, Gharabawi G</AU>
<TI>Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>66</VL>
<NO>2-3</NO>
<PG>163-7</PG>
<CY>Netherlands</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15061249"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:48:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Martinez RA, Berry SA, Gudelsky GA, Myers JE, Mahmoud RA</AU>
<TI>Serum prolactin levels in schizophrenia</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:48:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myers J, Mahmoud R, Berry S, Conley R</AU>
<TI>Risperidone versus olanzapine for the treatment of mood symptoms in patients with schizophrenia and schizoaffective disorder</TI>
<SO>Bipolar Disorders</SO>
<YR>2001</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:48:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Myers JE, Mahmoud RA, Berry SA, Conley RR</AU>
<TI>Risperidone versus olanzapine for the treatment of mood symptoms in patients with schizophrenia and schizoaffective disorder</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:48:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Myers JE, Mahmoud RA, Keith SJ, Csernansky JG</AU>
<TI>Long-term benefit of risperidone versus haloperidol for affective symptoms in patients with schizophrenia and schizoaffective disorder</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association</SO>
<YR>2002</YR>
<CY>Philadelphia, Pennsylvania, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burns-1998" NAME="Burns 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Burns PR, Reams SG, Sanger TM, Beasley CM Jr</AU>
<TI>Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders</TI>
<SO>21st Congress of the Collegium Internationale Neuro-psychopharmacologicum; 1998 Jul 12-16; Glasgow, Scotland</SO>
<YR>1998</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="67129859"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Burns PR, Reams SG, Sanger TM, Beasley CM Jr</AU>
<TI>Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders</TI>
<SO>9th Biennial Winter Workshop on Schizophrenia; 1998 Feb 7-13; Davos, Switzerland</SO>
<YR>1998</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="81101575"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lane LM, Burns PR, Reams SC, Sanger TM, Beasley CM Jr</AU>
<TI>Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders</TI>
<SO>11th Congress of The European College of Neuropsychopharmacology; 1998 Oct 31- Nov 4; Paris, France</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burns-2007" MODIFIED="2013-01-09 10:43:25 +0000" MODIFIED_BY="[Empty name]" NAME="Burns 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-09 10:43:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burns T, Catty J, Becker T, Drake RE, Fioritti A, Knapp M, Lauber C, Rossler W, Tomov T, Van Busschbach, White S, Wiersma D</AU>
<TI>The effectiveness of supported employment for people with severe mental illness: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>370</VL>
<NO>9593</NO>
<PG>1146-52</PG>
<CY>England</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17905167"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:49:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burns T, White SJ, Catty J</AU>
<TI>Individual placement and support in Europe: the EQOLISE trial</TI>
<SO>International Review of Psychiatry</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>6</NO>
<PG>498-502</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19085404"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Byerly-2001" MODIFIED="2008-10-22 09:15:09 +0100" MODIFIED_BY="[Empty name]" NAME="Byerly 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-10-22 09:15:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Byerly MJ, Weber MT, Brooks DL, Snow LR, Worley MA, Lescouflair E</AU>
<TI>Antipsychotic medications and the elderly: effects on cognition and implications for use</TI>
<SO>Drugs and Aging</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>1</NO>
<PG>45-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21122399"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cantillon-1998" NAME="Cantillon 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cantillon M, Arvanitis LA, Miller BG, Kowalcyk BB</AU>
<TI>'Seroquel' (Quetiapine Fumarate) reduces hositility and aggression in patients with acute schizophrenia</TI>
<SO>36th Annual Meeting of the American College of Neuropsychopharmacology; 1997</SO>
<YR>1997</YR>
<PG>171</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99173172"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cantillon M, Goldstein JM</AU>
<TI>Efficacy of quetiapine fumarate in affective symptoms of schizophrenia</TI>
<SO>151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4; Toronto, Canada</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cantillon M, Goldstein JM</AU>
<TI>Quetiapine fumarate reduces aggression and hostility in patients with schizophrenia</TI>
<SO>151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4; Toronto, Canada</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cantillon M</AU>
<TI>Quetiapine fumarate reduces aggression</TI>
<SO>11th Annual Meeting of the American Association for Geriatric Psychiatry; 1998 Mar 8-11; San Diego, USA</SO>
<YR>1998</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="69150440"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CATIE-2003" MODIFIED="2012-01-04 14:10:15 +0000" MODIFIED_BY="[Empty name]" NAME="CATIE 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-07-24 18:45:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anon</AU>
<TI>Newer antipsychotics similar to older agents</TI>
<SO>Journal of Family Practice</SO>
<YR>2005</YR>
<VL>54</VL>
<NO>12</NO>
<PG>1026</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16370079"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:49:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bick P, Knoesen N, Castle D</AU>
<TI>Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists</TI>
<SO>Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>6</NO>
<PG>465-9</PG>
<CY>England</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17999256"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:49:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chwastiak LA, Rosenheck RA, McEvoy JP, Stroup TS, Swartz MS, Davis SM, Lieberman JA</AU>
<TI>The impact of obesity on health care costs among persons with schizophrenia</TI>
<SO>General Hospital Psychiatry</SO>
<YR>2009</YR>
<VL>31</VL>
<NO>1</NO>
<PG>1-7</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19134502"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-24 19:32:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Covell NH</AU>
<TI>Antipsychotic medications do not differ substantially in ability to reduce violent behaviour in people with schizophrenia</TI>
<SO>Evidence-Based Mental Health</SO>
<YR>2009</YR>
<VL>12</VL>
<NO>1</NO>
<PG>13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:49:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck R, Davis SM, Hsiao JK, Stroup TS, Lieberman JA</AU>
<TI>Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>105</VL>
<NO>1-3</NO>
<PG>175-87</PG>
<CY>Netherlands</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:49:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis SM, Koch GG, Davis CE, LaVange LM</AU>
<TI>Statistical approaches to effectiveness measurement and outcome-driven re-RANDOMizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>1</NO>
<PG>73-80</PG>
<CY>United States of America</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12908662"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:50:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DeLisi LE, Nasrallah HA</AU>
<TI>The CATIE schizophrenia effectiveness trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>80</VL>
<NO>1</NO>
<PG>5-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:50:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glazer WM, Conley RR, Citrome L</AU>
<TI>Are we treating schizophrenia effectively? Understanding the primary outcomes of the catie study</TI>
<SO>CNS Spectrums</SO>
<YR>2006</YR>
<VL>11</VL>
<NO>Suppl 10</NO>
<PG>1-11</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16946697"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:50:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haddad PM, Dursun S</AU>
<TI>Selecting antipsychotics in schizophrenia: lessons from CATIE</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>3</NO>
<PG>332-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-24 19:02:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heinrichs RW</AU>
<TI>Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2007</YR>
<VL>64</VL>
<NO>6</NO>
<PG>631-2</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17548745"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:50:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heres S, Kissling W, Leucht S</AU>
<TI>Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia</TI>
<SO>Evidence-Based Mental Health</SO>
<YR>2007</YR>
<VL>10</VL>
<NO>4</NO>
<PG>112</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17962661"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:50:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keefe R, Bilder RM, Harvey PD, Davis S, Palmer B, McEvoy JP, Goldberg TE, Gold JM, Green MF, Swartz M, Stroup S, Rosenheck R, Perkins DO, Meltzer HY, Miller D, Canive J, Walker TM, Lieberman JA</AU>
<TI>Baseline neurocognitive assessment of 1364 patients with schizophrenia in the clinical antipsychotic trials for intervention effectiveness ( CATIE ) project</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>361-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:50:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA</AU>
<TI>Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2007</YR>
<VL>64</VL>
<NO>6</NO>
<PG>633-47</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17548746"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:50:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keefe RSE, Mohs RC, Bilder RM, Harvey PD, Green MF, Meltzer HY, Gold JM, Sano M</AU>
<TI>Neurocognitive assessment in the clinical antipsychotic trials of intervention effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>1</NO>
<PG>45-55</PG>
<CY>United States of America</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:51:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lieberman J, McEnvoy J, Stroup S</AU>
<TI>Protocol: comparative effectiveness of antipsychotic medications in patients with schizophrenia: revised in response to DSMB comments</TI>
<SO>National Institute of Mental Health</SO>
<YR>2000</YR>
<PB>University of North Carolina</PB>
<CY>Chapel Hill, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:51:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lieberman J, McEnvoy J, Stroup S</AU>
<TI>Trial design summary: comparative effectiveness of antipsychotic medications in patients with schizophrenia: draft</TI>
<SO>National Institute of Mental Health</SO>
<YR>2002</YR>
<PB>University of North Carolina</PB>
<CY>Chapel Hill, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:07:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lieberman JA, Schneider LS, McEroy J, Pariot P, Stroup S, Adiao J, Lebowitz BD</AU>
<TI>Effectiveness trials of antipsychotic drugs</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:07:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Keefe R, Perkins DO, Davis S, Davis CE, Lebowitz B, Hsiao J</AU>
<TI>CATIE trial results</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S184</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:07:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz B, Hsiao J, Severe J</AU>
<TI>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>Suppl 1</NO>
<PG>S32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:07:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Hsiao J, Severe J, Lebowitz BD</AU>
<TI>Dr. Lieberman and colleagues reply</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>3</NO>
<PG>555-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:07:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK</AU>
<TI>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<NO>12</NO>
<PG>1209-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:51:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Stroup TS</AU>
<TI>Schizophrenia, VI: Treatments</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2003</YR>
<VL>160</VL>
<NO>10</NO>
<PG>1748</PG>
<CY>United States of America</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14514482"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-24 19:04:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lieberman JA</AU>
<TI>Comparative effectiveness of antipsychotic medications in patients with schizophrenia (CATIE schizophrenia trial)</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-24 15:00:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lieberman JA</AU>
<TI>Research gaps and current research initiatives to improve the treatment of schizophrenia</TI>
<SO>Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:08:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA</AU>
<TI>Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>103</VL>
<NO>1-3</NO>
<PG>104-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:08:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, Patel JK, Keefe RS, Stroup TS, Lieberman JA</AU>
<TI>The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>80</VL>
<NO>1</NO>
<PG>9-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:08:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller DD, ,McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, Swartz MS, Keefe RSE, Rosenheck RA, Stroup TS, Lieberman JA</AU>
<TI>Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>80</VL>
<NO>1</NO>
<PG>33-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:08:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RSE, Stroup TS, Lieberman JA</AU>
<TI>Extrapyramidal side-effects of antipsychotics in a randomised trial</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>193</VL>
<NO>4</NO>
<PG>279-88</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18827289"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:08:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA</AU>
<TI>Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2009</YR>
<VL>35</VL>
<NO>2</NO>
<PG>336-46</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18586692"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:08:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RS</AU>
<TI>Relationship of cognition and psychopathology to functional impairment in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>165</VL>
<NO>8</NO>
<PG>978-87</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18450928"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:08:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nasrallah HA, Meyer JM, McEvoy JP, Davis VG, Goff DC, Davis SM</AU>
<TI>Inflammatory markers in schizophrenia: comparing antipsychotic effects in the CATIE schizophrenia trial</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2009</YR>
<VL>35</VL>
<NO>Suppl 1</NO>
<PG>37</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17165324"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:09:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Resnick SG, Rosenheck RA, Canive JM, De Souza C, Stroup TS, McEvoy J, Davis S, Keefe RSE, Swartz M, Lieberman J</AU>
<TI>Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia</TI>
<SO>Journal of Behavioral Health Services and Research</SO>
<YR>2008</YR>
<VL>35</VL>
<NO>2</NO>
<PG>215-25</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18246429"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:09:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, McEvoy J, Lieberman J</AU>
<TI>Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>107</VL>
<NO>1</NO>
<PG>22-9</PG>
<CY>Netherlands</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18993031"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-24 19:02:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenheck RA</AU>
<TI>Cost-effectiveness of atypical antipsychotics in the CATIE schizophrenia trial</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>Suppl 1</NO>
<PG>S32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:09:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RSE, Miller AL, Rosenheck RA, Hsiao JK</AU>
<TI>Results of phase 3 of the CATIE schizophrenia trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2009</YR>
<VL>107</VL>
<NO>1</NO>
<PG>1-12</PG>
<CY>Netherlands</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19027269"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:09:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA</AU>
<TI>The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>1</NO>
<PG>15-31</PG>
<CY>United States of America</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12908658"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-24 18:38:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroup TS</AU>
<TI>Baseline decision making capacity in the CATIE schizophrenia trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>67</VL>
<NO>1</NO>
<PG>209</PG>
<CY>Po Box 211, 1000 Ae Amsterdam, Netherlands</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:10:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Stroup TS. CATIE Study Group</AU>
<TI>Statistical methods and analytic plan</TI>
<SO>CATIE Protocol</SO>
<YR>2005</YR>
<PB>NIMH</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16370079"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:09:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swanson JW, Swartz MS, Van Dorn RA, Volavka J, Monahan J, Stroup TS, McEvoy JP, Wagner HR, Elbogen EB, Lieberman JA</AU>
<TI>Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2008</YR>
<VL>193</VL>
<NO>1</NO>
<PG>37-43</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:09:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC</AU>
<TI>Assessing clinical and functional outcomes in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>1</NO>
<PG>33-43</PG>
<CY>United States of America</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12908659"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:09:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RSE, Hsiao JK, Lieberman JA</AU>
<TI>What CATIE found: results from the schizophrenia trial</TI>
<SO>Psychiatric Services</SO>
<YR>2008</YR>
<VL>59</VL>
<NO>5</NO>
<PG>500-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:10:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, Miller DD, McGee M, Khan A, Canive JM, Davis SM, Hsiao JK, Lieberman JA</AU>
<TI>The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>100</VL>
<NO>1-3</NO>
<PG>39-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18191383"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2003a" MODIFIED="2012-01-04 14:10:28 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2003a" YEAR="2003">
<REFERENCE MODIFIED="2012-01-04 14:10:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen F, Liang L, Zhu XH</AU>
<TI>A control study of elderly patients with schizophrenia treated with olanzapine or clozapine</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>5</NO>
<PG>298-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2003b" MODIFIED="2012-01-04 14:10:36 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2003b" YEAR="2003">
<REFERENCE MODIFIED="2012-01-04 14:10:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen CY, Chen WX, Mao L</AU>
<TI>Nursing about side effects of old psychotic disease patients when taking medicine</TI>
<SO>Journal of Qilu Nursing</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>1</NO>
<PG>11-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2007" MODIFIED="2012-01-04 14:10:47 +0000" MODIFIED_BY="[Empty name]" NAME="Cheng 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-01-04 14:10:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng W</AU>
<TI>Comparative study on olanzapine and risperidone of treating elderly first - episode schizophrenia</TI>
<SO>Journal of Qiqihar Medical College [Qiqihar Yixueyuan xuebao]</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>18</NO>
<PG>2185-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crosthwaite-2000" MODIFIED="2012-01-04 14:10:59 +0000" MODIFIED_BY="[Empty name]" NAME="Crosthwaite 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-01-04 14:10:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crosthwaite CG, Reveley MA</AU>
<TI>Improved Sleep with Risperidone Compared with Conventional Antipsychotic Drugs in Older Patients with Psychosis</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>202</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12377405"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-2000" MODIFIED="2008-10-22 08:24:53 +0100" MODIFIED_BY="[Empty name]" NAME="Davidson 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-10-22 08:24:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson M, Harvey PD, Vervarcke J, Gagiano CA, De Hooge JD, Bray G, Dose M, Barak Y, Haushofer M</AU>
<TI>A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>6</NO>
<PG>506-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20321230"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delapena-2005" MODIFIED="2012-01-04 14:11:08 +0000" MODIFIED_BY="[Empty name]" NAME="Delapena 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-04 14:11:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Delapena J, Edwards S, Stirling C, Loh C, Granholm E</AU>
<TI>Functional rehabilitation of older patients with schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Depla-2003" MODIFIED="2012-01-04 14:11:16 +0000" MODIFIED_BY="[Empty name]" NAME="Depla 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-01-04 14:11:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Depla MFIA, De Graaf R, Van Busschbach JT, Heeren TJ</AU>
<TI>Community integration of elderly mentally ill persons in psychiatric hospitals and two types of residences</TI>
<SO>Psychiatric Services</SO>
<YR>2003</YR>
<VL>54</VL>
<NO>5</NO>
<PG>730-5</PG>
<CY>United States of America</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Docherty-2002" MODIFIED="2012-01-04 14:11:27 +0000" MODIFIED_BY="[Empty name]" NAME="Docherty 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-01-04 14:11:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Docherty JP, Napolitano J, Mahmoud RA, Martinez RA, Lasser RA, Pandina GJ, Gharabawi G</AU>
<TI>Anticholinergic effect of atypical antipsychotics in elderly patients</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-06 15:29:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tune L//Mulsant B//Gharabawi G</AU>
<TI>Anticholinergic effect of atypical antipsychotics in elderly patients</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>Suppl 3</NO>
<PG>S314</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drake-1993" MODIFIED="2012-01-04 14:11:35 +0000" MODIFIED_BY="[Empty name]" NAME="Drake 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-01-04 14:11:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Drake RE, Bebout RR, Roach JP</AU>
<TI>A research evaluation of social network case management for homeless persons with dual disorders</TI>
<SO>Case Management For Mentally Ill Patients: Theory and Practice</SO>
<YR>1993</YR>
<VL>1</VL>
<PG>83-98</PG>
<ED>Harris M//Bergman HC</ED>
<PB>Harwood Academic Publishers</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-08-10 23:12:25 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dunn-2002" MODIFIED="2012-01-04 14:11:55 +0000" MODIFIED_BY="[Empty name]" NAME="Dunn 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-01-04 14:11:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dunn LB, Liindamer LA, Schneiderman LJ, Jeste DV</AU>
<TI>Enhanced informed consent for research in older patients with psychotic disorders</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:11:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dunn LB, Lindamer LA, Palmer BW, Golshan S, Schneiderman LJ, Jeste DV</AU>
<TI>Improving understanding of research consent in middle-aged and elderly patients with psychotic disorders</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>2</NO>
<PG>142-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11925275"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dunn-2006" MODIFIED="2012-01-04 14:12:03 +0000" MODIFIED_BY="[Empty name]" NAME="Dunn 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-01-04 14:12:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dunn LB, Palmer BW, Keehan M</AU>
<TI>Understanding of PLACEBO controls among older people with schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2006</YR>
<VL>32</VL>
<NO>1</NO>
<PG>137-46</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16177271"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-2000" MODIFIED="2011-08-22 20:20:22 +0100" MODIFIED_BY="[Empty name]" NAME="Evans 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-08-22 20:20:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Evans M</AU>
<TI>Multi-centre double blind randomised parallel group comparison of seroquel and haloperidol in the treatment of elderly patients presenting with dementia, psychoses</TI>
<SO>National Research Register</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fleischhacker-2003" MODIFIED="2012-01-04 14:12:25 +0000" MODIFIED_BY="[Empty name]" NAME="Fleischhacker 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-01-04 14:12:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca P-M, Chrzanowski W, Martin S, Gefvert O</AU>
<TI>Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>10</NO>
<PG>1250-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14658976"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:12:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lasser RA, Bossie CA, Zhu Y, Gharabawi G, Eerdekens M, Davidson M</AU>
<TI>Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>9</NO>
<PG>898-905</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:12:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindenmayer J-P, Jarboe K, Bossie CA, Zhu Y, Mehnert A, Lasser R</AU>
<TI>Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>4</NO>
<PG>213-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerlach-1977" MODIFIED="2012-01-04 14:12:37 +0000" MODIFIED_BY="[Empty name]" NAME="Gerlach 1977" YEAR="1976">
<REFERENCE MODIFIED="2012-01-04 14:12:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerlach J, Thorsen K</AU>
<TI>The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment</TI>
<SO>International Pharmacopsychiatry</SO>
<YR>1976</YR>
<VL>11</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18450928"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glorioso-2005" MODIFIED="2012-01-04 14:12:56 +0000" MODIFIED_BY="[Empty name]" NAME="Glorioso 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-04 14:12:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Glorioso DK, Jeste DV</AU>
<TI>Metabolic effects of newer antipsychotics in older patients</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Granholm-2004" MODIFIED="2012-01-04 14:12:44 +0000" MODIFIED_BY="[Empty name]" NAME="Granholm 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-01-04 14:12:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Granholm E, McQuaid JR, Auslander LA, McClure FS</AU>
<TI>Group cognitive-behavioral social skills training for older outpatients with chronic schizophrenia</TI>
<SO>Journal of Cognitive Psychotherapy</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>3</NO>
<PG>265-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Granholm-2005" MODIFIED="2012-01-04 14:13:12 +0000" MODIFIED_BY="[Empty name]" NAME="Granholm 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-04 14:13:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Granholm E, McQuaid JR, Link PC, Fish S, Patterson T, Jeste DV</AU>
<TI>Neuropsychological predictors of functional outcome in cognitive behavioral social skills training for older people with schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>100</VL>
<NO>1-3</NO>
<PG>133-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18222648"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:13:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Granholm E, McQuaid JR, McClure FS, Auslander LA, Perivoliotis D, Pedrelli P, Patterson T, Jeste DV</AU>
<TI>A randomized, controlled trial of cognitive behavioral social skills training for middle-aged and older outpatients with chronic schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>162</VL>
<NO>3</NO>
<PG>520-9</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15741469"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Granholm-2007" MODIFIED="2012-01-04 14:13:27 +0000" MODIFIED_BY="[Empty name]" NAME="Granholm 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-01-04 14:13:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Granholm E, McQuaid JR, McClure FS, Link PC, Perivoliotis D, Gottlieb JD, Patterson TL, Jeste DV</AU>
<TI>Randomized Granholm E//McQuaid JR//McClure FS//Link PC//Perivoliotis D//Gottlieb JD//Patterson TL//Jeste DVcontrolled trial of cognitive behavioral social skills training for older people with schizophrenia: 12-month follow-up</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>5</NO>
<PG>730-7</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17503982"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-23 21:31:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Granholm E</AU>
<TI>Neurocognitive predictors of outcome in cognitive behavioral social skills training for people with chronic schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>2</NO>
<PG>431</PG>
<CY>England</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Granholm-2008" MODIFIED="2012-01-04 14:13:34 +0000" MODIFIED_BY="[Empty name]" NAME="Granholm 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-04 14:13:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Granholm EL, Edwards S, Loh C</AU>
<TI>Functional rehabilitation for older patients with schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harrigan-2004" MODIFIED="2012-01-04 14:13:52 +0000" MODIFIED_BY="[Empty name]" NAME="Harrigan 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-01-04 14:13:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiu CC, Chang WH, Huang MC, Chiu YW, Lane HY</AU>
<TI>Regular-dose risperidone on QTc intervals</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>4</NO>
<PG>391-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:13:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, Sramek J, Shiovitz T, Middle M</AU>
<TI>A randomized evaluation of the effects of six antipsychotic agents on QTC, in the absence and presence of metabolic inhibition</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>1</NO>
<PG>62-9</PG>
<CY>United States of America</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14709949"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harvey-2000a" MODIFIED="2011-09-21 14:24:44 +0100" MODIFIED_BY="[Empty name]" NAME="Harvey 2000a" YEAR="2000">
<REFERENCE MODIFIED="2008-10-22 09:17:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey P, Meltzer H, Green M</AU>
<TI>Long term cognitive effects of risperidone treatment in schizophrenia</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl. 1</NO>
<PG>154</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-21 14:34:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Lyons BE, Mahmoud R</AU>
<TI>Long term cognitive effects of risperidone</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>200-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-22 09:16:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Meltzer HY, Green MF</AU>
<TI>Long-term cognitive effects of risperidone treatment in schizophrenia</TI>
<SO>39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD</AU>
<TI>Long-term cognitive effects of risperidone treatment in schizophrenia</TI>
<SO>52nd Institute on Psychiatric Services; 2000 Oct 25-29; Philadelphia, USA</SO>
<YR>2000</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99173172"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harvey-2000b" MODIFIED="2011-09-21 14:24:57 +0100" MODIFIED_BY="[Empty name]" NAME="Harvey 2000b" YEAR="2000">
<REFERENCE MODIFIED="2008-10-22 08:36:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Gharabawi G</AU>
<TI>Cognition in elderly patients with schizophrenia: risperidone versus olanzapine</TI>
<SO>International Journal of Neuropsychopharmacology. Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>Suppl. 1</NO>
<PG>77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-22 08:37:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Mahmoud R, Meltzer HY, Green MP</AU>
<TI>Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder</TI>
<SO>European Neuropsychopharmacology. Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13-17; Istanbul, Turkey</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>3</NO>
<PG>257</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-21 13:43:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Mao L, Napolitano J, Gharabawi G</AU>
<TI>Improved cognition in elderly schizophrenic patients: risperidone versus olanzapine</TI>
<SO>Schizophrenia Research. Abstracts of the 11th Biennial Winter Workshop on Schizophrenia</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>Suppl. 1</NO>
<PG>28</PG>
<PB>Elsevier Science B.V</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-22 08:39:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Meltzer HY, Green M</AU>
<TI>Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder</TI>
<SO>39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-22 08:38:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Meltzer HY, Green M</AU>
<TI>Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder</TI>
<SO>39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD</AU>
<TI>Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder</TI>
<SO>153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD</AU>
<TI>Cognitive effects of risperidone and olanzapine in patients with schizophrenia</TI>
<SO>52nd Institute on Psychiatric Services; 2000 Oct 25-29; Philadelphia, USA</SO>
<YR>2000</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99173172"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harvey-2000c" MODIFIED="2011-09-21 14:25:06 +0100" MODIFIED_BY="[Empty name]" NAME="Harvey 2000c" YEAR="2000">
<REFERENCE MODIFIED="2008-10-22 08:47:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Meltzer HY, Romano S</AU>
<TI>Improvement in cognition following a switch to open label ziprasidone from olanzapine, risperidone and conventional antipsychotics</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl. 1</NO>
<PG>161</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-22 08:47:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Meltzer HY, Romano S</AU>
<TI>Improvement in cognition following a switch to open label ziprasidone from olanzapine, risperidone and conventional antipsychotics</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>Suppl. 3</NO>
<PG>288</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Harvey PD, Meltzer HY, Romano SJ</AU>
<TI>Improvement in cognition following a switch to open label ziprasidone in outpatients with schizophrenia treated with conventional antipsychotics, olanzapine or risperidone</TI>
<SO>153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harvey-2002" MODIFIED="2011-09-20 20:27:58 +0100" MODIFIED_BY="[Empty name]" NAME="Harvey 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-10-22 08:43:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Harvey P, Simpson GM, Loebel A</AU>
<TI>Effect of ziprasidone vs olanzapine on cognition in schizophrenia: a double-blind study</TI>
<SO>International Journal of Neuropsychopharmacology. Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>Suppl. 1</NO>
<PG>125</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-21 13:48:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Simpson G, Horne R, Weiden PJ, Bari M, Romano SJ</AU>
<TI>Effects of ziprasidone on cognitive function in patients with schizophrenia: results of a double-blind trial vs. olanzapine</TI>
<SO>Schizophrenia Research. Abstracts of the 11th Biennial Winter Workshop on Schizophrenia</SO>
<YR>2002</YR>
<VL>53</VL>
<NO>3 Suppl.1</NO>
<PG>195</PG>
<PB>Elsevier Science B.V</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-09-20 20:27:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Simpson GM, Weiden PJ, Loebel A</AU>
<TI>Ziprasidone vs olanzapine for cognitive function in schizophrenia</TI>
<SO>European Neuropsychopharmocology</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>Suppl. 3</NO>
<PG>293</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harvey-2003" MODIFIED="2013-01-09 10:42:58 +0000" MODIFIED_BY="[Empty name]" NAME="Harvey 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-01-04 14:14:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harvey PD, Napolitano JA, Mao L, Gharabawi G</AU>
<TI>Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>9</NO>
<PG>820-8</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12949850"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:14:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jeste D, Madhusoodanan S, Barak Y, Martinez RA, Mahmoud R, Kershaw P</AU>
<TI>Risperidone and olanzapine in elderly patients with schizophrenia and schizoaffective disorder</TI>
<SO>International Psychogeriatrics</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>2</NO>
<PG>295S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-09 10:42:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jeste DV, Barak Y, Madhusoodanan S, Grossman F, Gharabawi G</AU>
<TI>International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2003</YR>
<VL>11</VL>
<NO>6</NO>
<PG>638-47</PG>
<CY>United States of America</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14609804"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:14:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jeste DV, Madhusoodanan S, Barak F, Martinez RA</AU>
<TI>Risperidone versus olanzapine in elderly patients with schizophrenia</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hay-2004" MODIFIED="2012-01-04 14:14:45 +0000" MODIFIED_BY="[Empty name]" NAME="Hay 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-01-04 14:14:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hay D, Kinon B, Stauffer V, Kaiser C, Kollack-Walker S</AU>
<TI>Incidence of presumptive tardive dyskinesia in elderly patients treated with olanzapine or conventional antipsychotics</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>67</VL>
<NO>1</NO>
<PG>185-6</PG>
<CY>Po Box 211, 1000 Ae Amsterdam, Netherlands</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hellewell-2000" MODIFIED="2008-10-21 13:51:53 +0100" MODIFIED_BY="[Empty name]" NAME="Hellewell 2000" YEAR="">
<REFERENCE MODIFIED="2008-10-21 13:51:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hellewell JS, Westhead E</AU>
<TI>Safety during long-term exposure to quetiapine</TI>
<SO>39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87117078"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hellewell JSE, Westhead E</AU>
<TI>Safety during long-term exposure to quetiapine</TI>
<SO>Annual Meeting of the American Psychiatric Association; 2001 May 5-10; LA, USA</SO>
<YR>2001</YR>
<PB>Marathon Multimedia</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Howanitz-1996" MODIFIED="2008-10-22 09:13:40 +0100" MODIFIED_BY="[Empty name]" NAME="Howanitz 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-10-21 14:24:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Howanitz E, Pardo M, Smelson DA, Engelhart C, Eisenstein N, Losonczy MF</AU>
<TI>The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>1</NO>
<PG>41-4</PG>
<IDENTIFIERS MODIFIED="2008-10-21 14:24:35 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-21 14:24:35 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="99173172"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-22 09:13:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Howanitz E, Pardo M, Smelson DA, Engelhart C, Eisenstein N, Losonczy MF</AU>
<TI>The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia: erratum</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>5</NO>
<PG>341</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Howanitz EM, Pardo M, Litwin P, Stern RG, Wainwright KM, Flosonczy M</AU>
<TI>Efficacy of clozapine versus chlorpromazine in geriatric schizophrenia</TI>
<SO>149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9; New York, USA</SO>
<YR>1996</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="75116103"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inouye-2003" MODIFIED="2012-01-04 14:14:58 +0000" MODIFIED_BY="[Empty name]" NAME="Inouye 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-01-04 14:14:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inouye SK, Bogardus ST Jr, Williams CS, Leo-Summers L, Agostini JV</AU>
<TI>The role of adherence on the effectiveness of nonpharmacologic interventions: evidence from the Delirium Prevention Trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2003</YR>
<VL>163</VL>
<PG>958-64</PG>
<EN>8</EN>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12719206"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Isley-2003" MODIFIED="2012-01-04 14:15:06 +0000" MODIFIED_BY="[Empty name]" NAME="Isley 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-01-04 14:15:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Isley D, Lacro J</AU>
<TI>Medication adherence in older psychotic people</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jeste-2001" NAME="Jeste 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jeste DV, Madhusoodanan S, Barak F, Martinez RA</AU>
<TI>Risperidone versus olanzapine in elderly patients with schizophrenia</TI>
<SO>Annual Meeting of the American Psychiatric Association; 2001 May 5-10; LA, USA</SO>
<YR>2001</YR>
<PB>Marathon Multimedia</PB>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jeste-2005" MODIFIED="2010-06-24 19:57:59 +0100" MODIFIED_BY="[Empty name]" NAME="Jeste 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-06-24 19:57:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Jeste DV</AU>
<TI>Movement disorders caused by antipsychotic drugs in older patients</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-2000" MODIFIED="2012-01-04 14:15:14 +0000" MODIFIED_BY="[Empty name]" NAME="Kinon 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-01-04 14:15:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinon BJ, Milton DR, Gilmore JA</AU>
<TI>Continued improvement in quality of life despite weight change during olanzapine treatment</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S154</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-2001" MODIFIED="2011-09-20 20:37:32 +0100" MODIFIED_BY="Heather Maxwell" NAME="Kinon 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-09-20 20:37:32 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kinon BJ, Wang L, Stauffer VL</AU>
<TI>A comparison of prolactin concentrations in the elderly during treatment with olanzapine, haloperidol, and risperidone</TI>
<SO>14th Annual Meeting of the American Association for Geriatric Psychiatry; 2001 Feb 23-26; San Francisco, USA</SO>
<YR>2001</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20555729"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-2003" MODIFIED="2012-01-04 14:15:32 +0000" MODIFIED_BY="[Empty name]" NAME="Kinon 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-01-04 14:15:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinon BJ, Stauffer VL, Kaiser C, Hay DP, Kolack-Walker S</AU>
<TI>Incidence of presumptive tardive dyskinesia in elderly patients treated with olanzapine or conventional antipsychotics</TI>
<SO>International Psychogeriatrics</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>Suppl. 2</NO>
<PG>271</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17165324"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:15:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kinon BJ, Stauffer VL, Kaiser C, Walker SK</AU>
<TI>Incidence of presumptive tardive dyskinesia in elderly patients treated with olanzapine or conventional antipsychotics</TI>
<SO>Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kopala-2003" MODIFIED="2012-01-04 14:15:39 +0000" MODIFIED_BY="[Empty name]" NAME="Kopala 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-01-04 14:15:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kopala L, Rabinowitz J, Davidson M</AU>
<TI>Extra-pyramidal signs and symptoms (EPS) in recent onset schizophrenia: a comparison of risperidone and haloperidol</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>S338</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuntz-1998" NAME="Kuntz 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kuntz AJ, Sanger TM, Beasley CM</AU>
<TI>Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders</TI>
<SO>11th Annual Meeting of the American Association for Geriatric Psychiatry; 1998 Mar 8-11; San Diego, USA</SO>
<YR>1998</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92302393"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lane-2001" NAME="Lane 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lane H-Y, Chang W-H, Chui C-C, Huang M-C, Lee S-H, Chen J-Y</AU>
<TI>A pilot double-blind, dose comparison study of risperidone in drug niave, first-episode schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2001</YR>
<VL>62</VL>
<NO>12</NO>
<PG>994-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lapolla-1969" MODIFIED="2010-06-24 22:37:26 +0100" MODIFIED_BY="[Empty name]" NAME="Lapolla 1969" YEAR="1969">
<REFERENCE MODIFIED="2010-06-24 22:37:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lapolla</AU>
<TI>Acetophenazine versus thioridazine in the elderly</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1969</YR>
<VL>6</VL>
<NO>3</NO>
<PG>101-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leutwyler-2009" MODIFIED="2012-01-04 14:16:00 +0000" MODIFIED_BY="[Empty name]" NAME="Leutwyler 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-01-04 14:16:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Leutwyler H, Wallhagen M, McKibbin C</AU>
<TI>The impact of symptomatology on response to a health promoting intervention among older adults with schizophrenia</TI>
<SO>Proceedings of the 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16-21; San Francisco, CA</SO>
<YR>2009</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17165324"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2002" MODIFIED="2012-01-04 14:16:18 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-01-04 14:16:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li X, Xiao S, Lu Z</AU>
<TI>Cognitive function of elderly schizophrenics</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>2</NO>
<PG>85-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2002" MODIFIED="2012-01-04 14:16:25 +0000" MODIFIED_BY="[Empty name]" NAME="Lin 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-01-04 14:16:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin J, Huang Y, Chen G</AU>
<TI>A control study of treating elderly patients with schizophrenia with quetiapine or perphenazine</TI>
<SO>Chinese Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>2</NO>
<PG>99-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2005" MODIFIED="2012-01-04 14:16:31 +0000" MODIFIED_BY="[Empty name]" NAME="Lin 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-04 14:16:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin Z-Y, Li F-Q, Yu Y-Y, Zhong T-P</AU>
<TI>A controlled study of olanzapine and risperidol in the treatment of elderly patients with schizophrenia</TI>
<SO>Hainan Medical Journal</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>8</NO>
<PG>37-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2006" MODIFIED="2012-01-04 14:16:39 +0000" MODIFIED_BY="[Empty name]" NAME="Lin 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-01-04 14:16:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin L</AU>
<TI>Comparative study on risperidone and perphenazine in treatment of elderly schizophrenia</TI>
<SO>Journal of Qiqihar Medical College [Qiqihar Yixueyuan xuebao]</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>18</NO>
<PG>2184-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linden-2001" MODIFIED="2012-01-04 14:16:47 +0000" MODIFIED_BY="[Empty name]" NAME="Linden 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-01-04 14:16:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linden M, Godemann F, Gaebel W, Kopke W, Muller P, Muller-Spahn F, Pietzcker A, egeler J</AU>
<TI>A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2001</YR>
<VL>27</VL>
<NO>4</NO>
<PG>585-96</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11824485"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Liu-2007" MODIFIED="2012-01-04 14:16:57 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-01-04 14:16:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu L, Xinag H</AU>
<TI>Compared effect and safety analysis of aripiprazole in late-onset schizophrenia</TI>
<SO>Sichuan Mental Health</SO>
<YR>2007</YR>
<VL>20</VL>
<NO>3</NO>
<PG>142-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lovett-1987" MODIFIED="2008-10-21 13:57:05 +0100" MODIFIED_BY="[Empty name]" NAME="Lovett 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-10-21 13:57:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lovett WC, Stokes DK, Taylor LB, Young ML, Free SM, Phelan DG</AU>
<TI>Management of behavioral symptoms in disturbed elderly patients: comparison of trifluoperazine and haloperidol</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1987</YR>
<VL>48</VL>
<NO>6</NO>
<PG>234-6</PG>
<IDENTIFIERS MODIFIED="2008-10-21 13:56:26 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-21 13:56:26 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="80146237"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marcelli-2002" MODIFIED="2012-01-04 14:17:06 +0000" MODIFIED_BY="[Empty name]" NAME="Marcelli 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-01-04 14:17:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marcelli D, Rose-Reinhardt H, Fahs H, Kasolter-Pere MA</AU>
<TI>Adolescents and young adults (14-24-years old), acute psychotic episodes: Diagnostic therapeutic and ethical questions</TI>
<TO>Episode psychotique aigu de l'adolescent et du jeune adulte. Questions diagnostiques, therapeutiques et ethiques</TO>
<SO>Annales Medico-Psychologiques</SO>
<YR>2002</YR>
<VL>160</VL>
<NO>5-6</NO>
<PG>386-95</PG>
<CY>France</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matkovits_x002d_Gupta-1999" MODIFIED="2008-10-22 08:33:24 +0100" MODIFIED_BY="[Empty name]" NAME="Matkovits-Gupta 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-10-22 08:33:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matkovits-Gupta T, Lasser R, Young F, Happy J, Gharabawi G, Cucchiaro J, Fairweather D</AU>
<TI>Managing psychotic disorders through balanced receptor blockade: the zomaril tm clinical program</TI>
<SO>11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany</SO>
<YR>1999</YR>
<VL>2</VL>
<PG>163</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mazeh-2006" MODIFIED="2012-01-04 14:17:20 +0000" MODIFIED_BY="[Empty name]" NAME="Mazeh 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-01-04 14:17:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mazeh D, Zemishlani H, Barak Y, Mirecki I, Paleacu D</AU>
<TI>Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study</TI>
<SO>International Psychogeriatrics</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>3</NO>
<PG>429-36</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16478570"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McKibbin-2006" MODIFIED="2012-01-04 14:17:28 +0000" MODIFIED_BY="[Empty name]" NAME="McKibbin 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-01-04 14:17:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McKibbin CL, Patterson TL, Norman G, Patrick K, Jin H, Roesch S,Mudaliar S, Barrio C, Hanlon K, Griver K, Sirkin A, Jeste DV</AU>
<TI>A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2006</YR>
<VL>86</VL>
<NO>1-3</NO>
<PG>36-44</PG>
<CY>Netherlands</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16842977"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McQuaid-2001" MODIFIED="2012-01-04 14:17:35 +0000" MODIFIED_BY="[Empty name]" NAME="McQuaid 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-01-04 14:17:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>McQuaid J, Jeste DV, Patterson TL, McClure FS</AU>
<TI>Rehabilitation of older patients with schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mintzer-2000" MODIFIED="2008-10-22 09:22:14 +0100" MODIFIED_BY="[Empty name]" NAME="Mintzer 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-10-22 09:22:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matkovits-Gupta T, Cucchiaro J, El-Bizri H, Fairweather D, Klonowski E, Gharabawi G, Lasser R, E-VMCRFG</AU>
<TI>Safety and efficacy of iloperidone in patients with psychotic disorders: a randomized, double-blind multicenter study</TI>
<SO>Schizophrenia Research. Abstracts of 8th International Congress on Schizophrenia Research; 2001 Apr 28 - May 2; British Columbia, Canada</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>Suppl. 1-2</NO>
<PG>238</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99173172"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mintzer JE, Yeung PP, Mullen JA, Sweitzer D</AU>
<TI>EPS variations in elderly</TI>
<SO>153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, USA</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mintzer-2004" MODIFIED="2012-01-04 14:17:45 +0000" MODIFIED_BY="[Empty name]" NAME="Mintzer 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-01-04 14:17:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mintzer JE, Mullen JA, Sweitzer DE</AU>
<TI>A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>9</NO>
<PG>1483-91</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohler-1970" MODIFIED="2008-10-21 13:59:21 +0100" MODIFIED_BY="[Empty name]" NAME="Mohler 1970" YEAR="1970">
<REFERENCE MODIFIED="2008-10-21 13:59:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohler G</AU>
<TI>Clinical trial of thiothixene (Navane) in elderly chronic schizophrenics</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1970</YR>
<VL>12</VL>
<NO>6</NO>
<PG>377-86</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="70214784"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Myers-2002" MODIFIED="2012-01-04 14:17:52 +0000" MODIFIED_BY="[Empty name]" NAME="Myers 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-01-04 14:17:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Myers JE, Mahmoud RA, Keith SJ, Csernansky JG</AU>
<TI>Long-term benefit of risperidone versus haloperidol for affective symptoms in patients with schizophrenia and schizoaffective disorder</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naoki-2003" MODIFIED="2012-01-04 14:17:59 +0000" MODIFIED_BY="[Empty name]" NAME="Naoki 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-01-04 14:17:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naoki K, Nobuo A, Emi I</AU>
<TI>Randomized controlled trial on effectiveness of the community re-entry program to inpatients with schizophrenia spectrum disorder, centering around acquisition of illness self-management knowledge</TI>
<SO>Psychiatria et Neurologia Japonica [Seishin Shinkeigaku Zasshi]</SO>
<YR>2003</YR>
<VL>105</VL>
<NO>12</NO>
<PG>1514-31</PG>
<CY>Japan</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15027310"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nordentoft-1999" MODIFIED="2012-01-04 14:18:10 +0000" MODIFIED_BY="[Empty name]" NAME="Nordentoft 1999" YEAR="">
<REFERENCE MODIFIED="2012-01-04 14:18:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nordentoft M, Jeppesen P, Petersen L, Thorup A, Abel M, Ohlenschlaeger JK, Jorgensen P, Christensen T</AU>
<TI>OPUS project: A randomised controlled trial of integrated psychiatric treatment in first episode psychosis</TI>
<SO>Schizophrenia Research</SO>
<YR>2003</YR>
<VL>60</VL>
<PG>297</PG>
<EN>1</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ogunmefun-2009" MODIFIED="2012-01-04 14:18:18 +0000" MODIFIED_BY="[Empty name]" NAME="Ogunmefun 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-01-04 14:18:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ogunmefun A, Hasnain M, Alam A, Osuala T, Regenold WT</AU>
<TI>Effect of donepezil on tardive dyskinesia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>1</NO>
<PG>102-4</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19142126"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patterson-2003" MODIFIED="2012-01-04 14:18:25 +0000" MODIFIED_BY="[Empty name]" NAME="Patterson 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-01-04 14:18:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patterson TL, McKibbin C, Taylor M, Goldman S, Davila-Fraga W, Bucardo J, Jeste DV</AU>
<TI>Functional adaptation skills training (FAST): a pilot psychosocial intervention study in middle-aged and older patients with chronic psychotic disorders</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2003</YR>
<VL>11</VL>
<NO>1</NO>
<PG>17-23</PG>
<CY>United States of America</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patterson-2005" MODIFIED="2012-01-04 14:18:32 +0000" MODIFIED_BY="[Empty name]" NAME="Patterson 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-04 14:18:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patterson TL,/Bucardo J, McKibbin CL, Mausbach BT, Moore D, Barrio C, Goldman SR, Jeste DV</AU>
<TI>Development and pilot testing of a new psychosocial intervention for older Latinos with chronic psychosis</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<NO>4</NO>
<PG>922-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16037481"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patterson-2006" MODIFIED="2012-01-04 14:18:58 +0000" MODIFIED_BY="[Empty name]" NAME="Patterson 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-01-04 14:18:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mausbach BT, Cardenas V, McKibbin CL, Jeste DV, Patterson TL</AU>
<TI>Reducing emergency medical service use in patients with chronic psychotic disorders: results from the FAST intervention study</TI>
<SO>Behaviour Research and Therapy</SO>
<YR>2008</YR>
<VL>46</VL>
<NO>1</NO>
<PG>145-53</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17997395"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:18:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patterson TL, Mausbach BT, McKibbin C, Goldman S, Bucardo J, Jeste DV</AU>
<TI>Functional adaptation skills training (FAST): a RANDOMized trial of a psychosocial intervention for middle-aged and older patients with chronic psychotic disorders</TI>
<SO>Schizophrenia Research</SO>
<YR>2006</YR>
<VL>86</VL>
<NO>1-3</NO>
<PG>291-9</PG>
<CY>Netherlands</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16814526"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pfizer-2006" MODIFIED="2012-01-04 14:19:04 +0000" MODIFIED_BY="[Empty name]" NAME="Pfizer 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-01-04 14:19:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Pfizer</AU>
<TI>A randomized, parallel group, multiple dose, 6-week study to evaluate safety, tolerability, and pharmacokinetics of asenapine in elderly subjects with psychosis</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Phanjoo-1990" MODIFIED="2008-10-21 14:00:48 +0100" MODIFIED_BY="[Empty name]" NAME="Phanjoo 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-10-21 14:00:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phanjoo AL, Link C</AU>
<TI>Remoxipride versus thioridazine in elderly psychotic patients</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1990</YR>
<VL>358</VL>
<PG>181-5</PG>
<IDENTIFIERS MODIFIED="2008-10-21 14:00:20 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-21 14:00:20 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="91050687"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prat-2009" MODIFIED="2012-01-04 14:19:23 +0000" MODIFIED_BY="[Empty name]" NAME="Prat 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-01-04 14:19:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Prat SI, Hapenny AM</AU>
<TI>Individually based psychosocial rehabilitation for older people with serious mental illness (SMI)</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pratt-2005" MODIFIED="2010-06-25 13:10:12 +0100" MODIFIED_BY="[Empty name]" NAME="Pratt 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-06-25 13:10:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Pratt SI</AU>
<TI>Medication adherence in older adults</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pratt-2008" MODIFIED="2012-01-04 14:19:15 +0000" MODIFIED_BY="[Empty name]" NAME="Pratt 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-04 14:19:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pratt SI, Bartels SJ, Mueser KJ, Forester B</AU>
<TI>Helping older people experience success: an integrated model of psychosocial rehabilitation and health care management for older adults with serious mental illness</TI>
<SO>American Journal of Psychiatric Rehabilitation</SO>
<YR>2008</YR>
<VL>11</VL>
<NO>1</NO>
<PG>41-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reams-1998" MODIFIED="2008-10-21 14:01:28 +0100" MODIFIED_BY="[Empty name]" NAME="Reams 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-10-21 14:01:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reams SG, Sanger TM, Beasley CM</AU>
<TI>Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic disorders</TI>
<SO>Schizophrenia Research</SO>
<YR>1998</YR>
<VL>29</VL>
<NO>1-2</NO>
<PG>151</PG>
<IDENTIFIERS MODIFIED="2008-10-21 14:01:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-21 14:01:24 +0100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="82248457"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritchie-1999" MODIFIED="2012-01-04 14:19:31 +0000" MODIFIED_BY="[Empty name]" NAME="Ritchie 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-01-04 14:19:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritchie C, Ames D, Chiu E, O'Connor D, Hall K, Hassett A</AU>
<TI>Schizophrenia cohort study of olanzapine v risperidone in the elderly (score): analysis of conversion period</TI>
<SO>International Psychogeriatrics</SO>
<YR>1999</YR>
<VL>11</VL>
<NO>Suppl 1</NO>
<PG>157-8</PG>
<CY>Australia</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salganik-1998" MODIFIED="2008-10-21 14:03:28 +0100" MODIFIED_BY="[Empty name]" NAME="Salganik 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-10-21 14:03:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salganik I, Modai I, Bercovici BR, Kutzuk D, Weizman A</AU>
<TI>Clozapine vs haloperidol therapy in elderly chronic schizophrenic inpatients: preliminary results. A double blind, cross over randomized study</TI>
<SO>International Journal of Geriatric Psychopharmacology</SO>
<YR>1998</YR>
<VL>1</VL>
<NO>4</NO>
<PG>185-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salzman-2000" MODIFIED="2008-10-21 14:05:11 +0100" MODIFIED_BY="[Empty name]" NAME="Salzman 2000" YEAR="">
<REFERENCE MODIFIED="2008-10-21 14:05:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Salzman C, Naidoo U, Schwab EP, Czworka KJ</AU>
<TI>Elderly patients with schizophrenia</TI>
<SO>39th Annual Meeting of the American College of Neuropsychopharmacology; 2000; Dec 10-14; San Juan; Puerto Rico</SO>
<YR>2000</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87117078"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seager-1955" MODIFIED="2008-10-21 14:06:01 +0100" MODIFIED_BY="[Empty name]" NAME="Seager 1955" YEAR="1955">
<REFERENCE MODIFIED="2008-10-21 14:06:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seager CP</AU>
<TI>Chlorpromazine in treatment of elderly psychotic women</TI>
<SO>British Medical Journal</SO>
<YR>1955</YR>
<VL>1</VL>
<PG>882-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shen-2001" MODIFIED="2012-01-04 14:19:46 +0000" MODIFIED_BY="[Empty name]" NAME="Shen 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-01-04 14:19:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shen G, Han J, Song L</AU>
<TI>A comparative the results of serum testosterone levels in different age-group of male schizophrenics</TI>
<SO>Sichuan Mental Health</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>4</NO>
<PG>205-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shin-2004" MODIFIED="2010-06-25 14:30:50 +0100" MODIFIED_BY="[Empty name]" NAME="Shin 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-06-25 14:30:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shin S-K</AU>
<TI>Effects of culturally relevant psychoeducation for Korean American families of persons with chronic mental illness</TI>
<SO>Research on Social Work Practice</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>4</NO>
<PG>231-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sikich-2002" MODIFIED="2012-01-04 14:19:52 +0000" MODIFIED_BY="[Empty name]" NAME="Sikich 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-01-04 14:19:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sikich L, Horrigan JP, Lieberman JA, Barnhill LJ Jr, Sheitman BB, Courvoisie HE</AU>
<TI>Comparative use of olanzapine and risperidone in psychotic youth</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-08-10 10:43:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sikich L</AU>
<TI>Critical decisions in the treatment of adolescent and pediatric psychosis</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-Hui-2008" MODIFIED="2012-01-04 14:20:01 +0000" MODIFIED_BY="[Empty name]" NAME="Sun Hui 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-04 14:20:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun H, Jiao Y, Li J</AU>
<TI>A comparative study of quetiapine and risperidone in the treatment of old - men schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>1</NO>
<PG>14-5, 46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutton-2001" MODIFIED="2008-10-21 14:07:24 +0100" MODIFIED_BY="[Empty name]" NAME="Sutton 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-10-21 14:07:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sutton VK, Street JS, Kennedy JS, Feldman PD, Breier A</AU>
<TI>Superiority of olanzapine over risperidone in the control of negative symptoms of schizophrenia and related psychotic disorders in older patients</TI>
<SO>European Neuropsychopharmacology. Abstracts of the 14th Congress of the European College of Neuropsychopharmacology; 2001 Oct 13-17; Istanbul, Turkey</SO>
<YR>2001</YR>
<VL>11</VL>
<NO>3</NO>
<PG>276</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1972" MODIFIED="2008-10-21 14:07:51 +0100" MODIFIED_BY="[Empty name]" NAME="Svestka 1972" YEAR="1972">
<REFERENCE MODIFIED="2008-10-21 14:07:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Nahunek K</AU>
<TI>A comparison of pimozide with perphenazine in the treatment of acute schizophrenic psychoses</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1972</YR>
<VL>14</VL>
<NO>2</NO>
<PG>93-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="72225815"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1973" MODIFIED="2008-10-21 14:08:30 +0100" MODIFIED_BY="[Empty name]" NAME="Svestka 1973" YEAR="1973">
<REFERENCE MODIFIED="2008-10-21 14:08:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Rodova A, Nahunek K</AU>
<TI>Comparison of the short-term therapeutic effect of oxyprothepine and perphenazine in schizophrenic patients A controlled study</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1973</YR>
<VL>15</VL>
<NO>2</NO>
<PG>103-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="74101057"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1987" MODIFIED="2008-10-21 14:08:58 +0100" MODIFIED_BY="[Empty name]" NAME="Svestka 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-10-21 14:08:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Nahunek K, Rysanek R, Ceskova E</AU>
<TI>Double blind comparison of isofloxythepin and haloperidol in the treatment of acute schizophrenic and schizoaffective psychoses. 29th Annual Psychopharmacology Meeting (1987, Jesenik, Czechoslovakia)</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1987</YR>
<VL>29</VL>
<NO>3</NO>
<PG>205-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1989a" MODIFIED="2011-09-21 14:32:12 +0100" MODIFIED_BY="[Empty name]" NAME="Svestka 1989a" YEAR="1989">
<REFERENCE MODIFIED="2008-10-21 14:09:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Nahunek K, Ceskova E, Rysanek R, Balsikova J</AU>
<TI>Controlled cross over comparison of isofloxythepin and perphenazine in the treatment of schizophrenic psychoses</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1989</YR>
<VL>31</VL>
<NO>1</NO>
<PG>32-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="89389757"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1989b" MODIFIED="2011-09-21 14:32:22 +0100" MODIFIED_BY="[Empty name]" NAME="Svestka 1989b" YEAR="1989">
<REFERENCE MODIFIED="2008-10-21 14:10:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Rysanek R, Ceskova E, Nahunek K</AU>
<TI>Cross-over comparison of the therapeutic effects of sulpiride and perphenazine in schizophrenic and schizoaffective psychoses</TI>
<SO>Acta Nervosa Superior</SO>
<YR>1989</YR>
<VL>31</VL>
<NO>1</NO>
<PG>35-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99173172"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-21 14:11:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Rysanek R, Nahunek K, Ceskova E</AU>
<TI>Therapeutic results in schizophrenic and schizoaffective psychoses with sulpiride (Eglonyl Alkaloid), as compared with perphenazine (Perfenazin Spofa)</TI>
<TO>Vysledky lecby schizofrennich a schizoafektivnich nemocnych sulpiridem (Eglonyl alkaloid) ve srovnani s perfenazinem (Perfenazin Spofa)</TO>
<SO>Ceskoslovenska Psychiatrie</SO>
<YR>1990</YR>
<VL>86</VL>
<NO>3</NO>
<PG>145-56</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="91029658"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Svestka-1990" MODIFIED="2008-10-21 14:12:35 +0100" MODIFIED_BY="[Empty name]" NAME="Svestka 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-10-21 14:12:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svestka J, Ceskova E, Rysanek R, Obrovska V</AU>
<TI>Double blind clinical comparison of risperidon and haloperidol in acute schizophrenic and schizoaffective psychoses. 32nd Annual Psychopharmacological Meeting; 1990, Jesenik, Czechoslovakia</TI>
<SO>Activitas Nervosa Superior</SO>
<YR>1990</YR>
<VL>32</VL>
<NO>3</NO>
<PG>237-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tariot-2000" NAME="Tariot 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tariot PN, Salzman C, Yeung PP, Pultz JP, Rak IW</AU>
<TI>Long-term use of quetiapine in elderly patients with psychotic disorders</TI>
<SO>Clinical Therapeutics</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>9</NO>
<PG>1068-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tollefson-1997" MODIFIED="2012-01-04 14:25:21 +0000" MODIFIED_BY="[Empty name]" NAME="Tollefson 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-01-04 14:06:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Almond S, O'Donnell O</AU>
<TI>Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapine and haloperidol</TI>
<SO>Pharmacoeconomics</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>5 Pt 2</NO>
<PG>575-88</PG>
<CY>New Zealand</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17165324"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:21:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Basson B, Kinon BJ, Gilmore JA, Taylor CC, Tollefson GD, Czekalla J</AU>
<TI>Factors influencing weight change in patients with schizophrenia treated with olanzapine verus haloperidol or risperidone</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>3 Suppl</NO>
<PG>A60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:21:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beasley CM, Sayler ME, Keisler GM, Potvin JH, Sanger TM, Tollefson GD</AU>
<TI>The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1998</YR>
<VL>29</VL>
<NO>1-2</NO>
<PG>28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-24 18:13:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beasley CM</AU>
<TI>Safety of olanzapine</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>2</NO>
<PG>19-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14618553"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:21:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen LS, Goldstein JM, Lee H, Tohen M, Andersen S, Tollefson GD</AU>
<TI>Sex and neuroendocrine differences following treatment with typical and atypical antipsychotics</TI>
<SO>151st Annual Meeting of American Psychiatric Association;</SO>
<YR>1998</YR>
<VL>Toronto; Ontorio, Canada</VL>
<PG>May 30-June 4, 1998</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17165324"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:21:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crawford AMK, Gomez JC, Beasley CM Jr, Tollefson GD</AU>
<TI>Olanzapine versus haloperidol: analysis of schizophrenic patients from the multi-center international trial</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1997</YR>
<VL>7</VL>
<PG>P.2.015</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:21:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dellva MA, Beasley CM, Tamura RN, Tollefson GD</AU>
<TI>What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine?</TI>
<SO>Proceedings of XXIst Collegium Internationale Neuro-psychopharmacologicum;</SO>
<YR>1998</YR>
<VL>Glasgow; Scotland, UK</VL>
<PG>July 12-16, 1998</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17165324"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-24 18:33:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Eli Lilly and Company</AU>
<TI>Tollefson 1997 - olz vs hpl</TI>
<SO>Data on file</SO>
<YR>2001</YR>
<PG>22-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:21:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein JM, Cohen LS, Horton NJ, Lee H, Andersen S, Tohen M, Crawford A, Tollefson G</AU>
<TI>Sex differences in clinical response to olanzapine compared with haloperidol</TI>
<SO>Psychiatry Research</SO>
<YR>2002</YR>
<VL>110</VL>
<NO>1</NO>
<PG>27-37</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12007591"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:21:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gregor KJ, Hamilton SH, Edgell ET</AU>
<TI>Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>189</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12377405"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:22:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inada T, Beasley CM, JR//Tanaka Y, Walker DJ</AU>
<TI>Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>1</NO>
<PG>39-48</PG>
<PB>Lippincott Williams &amp; Wilkins</PB>
<CY>United States of America</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:25:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaton LA, Kinon BJ, Rotelli MD, Kaiser C, Kollack-Walker S</AU>
<TI>Differential rate of weight gain present among patients treated with olanazpine</TI>
<SO>Schizophrenia Research</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>1</NO>
<PG>357</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17165324"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:22:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jaton LA, Kinon BJ, Rotelli MD, Kaiser C, Kollack-Walker S</AU>
<TI>Differential rate of weight gain present among patients treated with olanzapine</TI>
<SO>Schizophrenia Research</SO>
<YR>2003</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14618553"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:22:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Johnstone BM, Obenchain RL, Croghan TW, Tunis SL, Kniesner TJ</AU>
<TI>To evaluate the cost-effectiveness of olanzolpine compared to haloperidol for schizophrenia</TI>
<SO>Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 - Jun 4; Toronto, Ontario, Canada</SO>
<YR>1998</YR>
<NO>Nr541</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:22:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kennedy JS, Jeste D, Kaiser CJ, Golsham S, Maguire GA, Tollefson G, Sanger T, Bymaster FP, Kinon BJ, Dossenbach M, Gilmore JA, Breier A</AU>
<TI>Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2003</YR>
<VL>18</VL>
<PG>1013-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14618553"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:22:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinon BJ, Basson BR, Tollefson GD</AU>
<TI>Effect of long-term olanzapine treatment on weight change in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1- Special Issue</NO>
<PG>195-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17165324"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:23:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinon BJ, Milton DR, Hill AL, Williamson DJ</AU>
<TI>Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>3 Suppl</NO>
<PG>A60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:23:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Shamsi SAR, Busch R, Kissling W, Kane JM</AU>
<TI>Predicting antipsychotic drug response--replication and extension to six weeks in an international olanzapine study</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>101</VL>
<NO>1-3</NO>
<PG>312-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18308513"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:23:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mallinckrodt C, David S, Burns P, Breier A</AU>
<TI>Long-term efficacy and safety of olanzapine in patients with inadequate initial response to haloperidol or olanzapine</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1998</YR>
<VL>8</VL>
<NO>Suppl 2</NO>
<PG>S228</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17165324"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:23:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mallinckrodt CH, David SR, Burns PR, Breier A</AU>
<TI>Long-term efficiacy and safety of olanzapine in patients with inadequate initial response to haloperidol or olanzapine</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>36</VL>
<PG>288</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12377405"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:23:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pilowsky LS, Busatto GF, Taylor M//Costa DC, Sharma T, Sigmundsson T, Ell P, Nohria V, Kerwin RW</AU>
<TI>Dopamine D-2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - A (123)I IBZM single photon emission tomography (SPET) study</TI>
<SO>Psychopharmacology</SO>
<YR>1996</YR>
<VL>124</VL>
<NO>1-2</NO>
<PG>148-53</PG>
<CY>Germany</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17165324"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:23:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Street JS, Tamura R, Sanger T, Tollefson G</AU>
<TI>Long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1996</YR>
<VL>32</VL>
<NO>3</NO>
<PG>522</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17165324"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:23:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Street JS, Tollefson GD, Tohen M, Sanger TM, Clark WS, Gannon KS, Wei HX</AU>
<TI>Olanzapine for psychotic conditions in the elderly</TI>
<SO>Psychiatric Annals</SO>
<YR>2000</YR>
<VL>30</VL>
<PG>191-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18450928"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:05:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson G, Lu Y</AU>
<TI>Comorbid mood disturbance in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>24</VL>
<PG>192</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:05:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Lu Y</AU>
<TI>Comorbid mood disturbance in schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>1997</YR>
<VL>41</VL>
<PG>101S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:24:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Sanger TD, Lieberman JA</AU>
<TI>Olanzapine versus haloperidol in the treatment of first episode psychosis</TI>
<SO>Biological Psychiatry</SO>
<YR>1997</YR>
<VL>41</VL>
<PG>73S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:24:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Sanger TM, Andersen SW</AU>
<TI>Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1998</YR>
<VL>8</VL>
<NO>Suppl 2</NO>
<PG>225</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:05:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Sanger TM</AU>
<TI>A blinded trial on the course and relationship of depressive symptoms in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1998</YR>
<VL>29</VL>
<NO>1,2</NO>
<PG>205</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:24:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Tran PV, Hamilton S, Kuntz A</AU>
<TI>Olanzapine versus risperidone in the treatment of psychosis. Preliminary report</TI>
<SO>Biological Psychiatry</SO>
<YR>1997</YR>
<VL>41</VL>
<PG>20S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:24:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tran P, Lu Y, Sanger T, Beasley C, Tollefson G</AU>
<TI>Olanzapine in the treatment of schizoaffective disorder</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1996</YR>
<VL>32</VL>
<NO>3</NO>
<PG>527</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:24:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CM Jr</AU>
<TI>Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>172</VL>
<PG>499-505</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19027269"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-24 11:19:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tunis SL</AU>
<TI>The impact of schizophrenic patient functionality on service utilization and cost. Based on a presentation by Sandra L. Tunis, PhD</TI>
<SO>American Journal of Managed Care</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>10 Suppl</NO>
<PG>S583-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10539493"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:24:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wright P, Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JII</AU>
<TI>A blinded, controlled, long-term study of the comparative incidence of treatement-emergent tardive dyskinesia with olanzapine or haloperidol</TI>
<SO>Schizophrenia Research</SO>
<YR>1998</YR>
<VL>29</VL>
<NO>1-2</NO>
<PG>206</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tran-1997" MODIFIED="2012-01-04 14:05:33 +0000" MODIFIED_BY="[Empty name]" NAME="Tran 1997" YEAR="">
<REFERENCE MODIFIED="2012-01-04 14:05:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahmed S, Zhang F, Lindborg S, Tohen M, Breier A</AU>
<TI>A comparison of olanzapine versus risperidone on improvement in negative symptoms and emotional discomfort in patients with schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2003</YR>
<VL>60</VL>
<PG>270</PG>
<EN>1</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:05:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ahmed S, Zhang F, Walker D, Beglinger L, Earley WR, Tran PV</AU>
<TI>Olanzapine versus risperidone for treatment of negative symptoms in schizophrenia</TI>
<SO>Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:05:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>David S, Crawford AM, Breier A</AU>
<TI>Prolactin levels in olanzapine versus typical and atypical antipsychotics</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1998</YR>
<VL>8</VL>
<NO>Suppl 2</NO>
<PG>s229</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:05:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>David SR, Meehan KM, Sutton VK/, Taylor CC</AU>
<TI>Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>s140</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:05:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A, Gavart S</AU>
<TI>Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia</TI>
<SO>European Psychiatry</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>Suppl 2</NO>
<PG>408s</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-24 18:35:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Eli Lilly and Company</AU>
<TI>Tran 1997 - olz vs risp</TI>
<SO>Data on file</SO>
<YR>2001</YR>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:04:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feldman PD, Kaiser C, Kennedy JS, Sutton VK, Tran PV, Tollefson GD, Zhang F, Breier A</AU>
<TI>Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2003</YR>
<VL>64</VL>
<NO>9</NO>
<PG>998-1004</PG>
<CY>United States of America</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14628974"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:04:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kennedy J, Basson B, Tran P, Beasley C, Bymaster F, Breier A</AU>
<TI>The comparative anti-muscarinic-like adverse event profiles of olanzapine and risperidone treatment in patients with schizophrenia spectrum psychosis</TI>
<SO>Proceedings of the 39th Annual Meeting of the New Clinical Drug Evaluation Unit; 1999 Jun 1-4; Boca Raton, Florida, USA</SO>
<YR>1999</YR>
<PG>89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:04:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kinon BJ, Zhao Z, Barber BL, Wirtz HS</AU>
<TI>Acute response to olanzapine predicts the continued improvement in patients with schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2003</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="14618553"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:04:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kollack-Walker S, Lipkovich I, Ahmed S</AU>
<TI>Treatment-emergent EPS symptoms during treatment with olanzapine or risperidone</TI>
<SO>Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-24 10:12:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Owens DG</AU>
<TI>Olanzapine produced a higher clinical response rate than risperidone in schizophrenia</TI>
<SO>Evidence-Based Mental Health</SO>
<YR>1998</YR>
<VL>1</VL>
<NO>2</NO>
<PG>55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-24 10:11:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pickar D</AU>
<TI>Clinical profiles of the new antipsychotic agents</TI>
<SO>Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, California, USA</SO>
<YR>1997</YR>
<CY>USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:04:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tran P, Dellva M, Rampey V, Tollefson G, Beasley C</AU>
<TI>Long-term continuation therapy with the novel antipsychotic olanzapine: a review of the clinical experience</TI>
<SO>Proceedings of the 9th European College of Neuropsychopharmacology Congress; 1996 Sep 21-25; Amsterdam, The Netherlands</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:04:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao Z, Kinon BJ, Barber BL, Wirtz HS</AU>
<TI>Acute response to olanzapine predicts continued improvement in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2003</YR>
<VL>60</VL>
<PG>308</PG>
<EN>1</EN>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Twamley-2005" MODIFIED="2012-01-04 14:03:58 +0000" MODIFIED_BY="[Empty name]" NAME="Twamley 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-04 14:03:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Twamley EW, Padin DS, Bayne KS, Narvaez JM, Williams RE, Jeste DV</AU>
<TI>Work rehabilitation for middle-aged and older people with schizophrenia: a comparison of three approaches</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>2005</YR>
<VL>193</VL>
<NO>9</NO>
<PG>596-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Twamley-2008" MODIFIED="2012-01-04 14:03:46 +0000" MODIFIED_BY="[Empty name]" NAME="Twamley 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-04 14:03:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Twamley EW, Narvaez JM, Becker DR, Bartels SJ, Jeste DV</AU>
<TI>Supported employment for middle-aged and older people with schizophrenia</TI>
<SO>American Journal of Psychiatric Rehabilitation</SO>
<YR>2008</YR>
<VL>11</VL>
<NO>1</NO>
<PG>76-89</PG>
<CY>United States</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tzimos-2007" MODIFIED="2012-01-04 14:03:25 +0000" MODIFIED_BY="[Empty name]" NAME="Tzimos 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-01-04 14:02:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tzimos A, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M</AU>
<TI>A 6-week placebo-controlled study on the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:03:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tzimos A, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M</AU>
<TI>A 6-week placebo-controlled study on the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients</TI>
<SO>Proceedings of the Collegium Internationale Neuro-Psychopharmacologium 25th Biennial Congress; 2006 July 9-13; Chicago, Illinois</SO>
<YR>2006</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18568578"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:03:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tzimos A, Kramer M, McLemore J, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M</AU>
<TI>A 6-week placebo-controlled study of the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>2</NO>
<PG>464</PG>
<CY>England</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 14:03:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M</AU>
<TI>Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2008</YR>
<VL>16</VL>
<NO>1</NO>
<PG>31-43</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="18165460"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vaglum-2002" MODIFIED="2012-01-04 14:03:32 +0000" MODIFIED_BY="[Empty name]" NAME="Vaglum 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-01-04 14:03:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Vaglum P, Friis S, Melle I, Opjordsmoen S, Larsen TK, Simonsen E, McGlashan TH</AU>
<TI>Does duration of untreated psychosis bias schizophrenia study samples?</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2002" MODIFIED="2012-01-04 14:02:40 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-01-04 14:02:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J, Xie S</AU>
<TI>Health economic impact of novel versus older anti-psychotic medications in schizophrenia</TI>
<SO>Sichuan Mental Health</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>1</NO>
<PG>8-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005" MODIFIED="2012-01-04 14:02:21 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-04 14:02:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Z-J, Du X-S, Wang J-L</AU>
<TI>Comparative study on treatment of aged schizophrenic patients with risperidone</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>5</NO>
<PG>289-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-LiLi-2008" MODIFIED="2012-01-04 14:01:55 +0000" MODIFIED_BY="[Empty name]" NAME="Wang LiLi 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-04 14:01:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang L, Xun Z, Wang Y</AU>
<TI>A comparative study of risperidone oral solution and risperidone tablets in the treatment of elderly schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>2</NO>
<PG>92-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-R-2002" MODIFIED="2011-10-04 15:21:35 +0100" MODIFIED_BY="[Empty name]" NAME="Wang R 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-10-04 15:20:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang R, Geng Y, Zhang S, Zhang R</AU>
<TI>Family support and psychological treatment of elderly schizophrenia recovery efficacy analysis</TI>
<SO>Modern Rehabilitation</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>9</NO>
<PG>1317</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-XiaoQuan-2008" MODIFIED="2012-01-04 14:01:43 +0000" MODIFIED_BY="[Empty name]" NAME="Wang XiaoQuan 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-04 14:01:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X-Q, Song C</AU>
<TI>Comparative study of efficacy and safety of quetiapine and risperidone in the treatment of elderly schizophrenia</TI>
<SO>Medical Journal of Chinese People's Health</SO>
<YR>2008</YR>
<VL>16</VL>
<NO>12</NO>
<PG>1394-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warner-2006" MODIFIED="2012-01-04 14:01:35 +0000" MODIFIED_BY="[Empty name]" NAME="Warner 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-01-04 14:01:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Warner J</AU>
<TI>Randomised controlled evaulation of home treatment for older people with mental illness</TI>
<SO>National Research Register</SO>
<YR>2006</YR>
<VL>2</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamashita-2005" MODIFIED="2012-01-04 14:01:21 +0000" MODIFIED_BY="[Empty name]" NAME="Yamashita 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-04 14:01:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamashita H, Mori K, Nagao M, Okamoto Y, Morinobu S, Yamawaki S</AU>
<TI>Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>5</NO>
<PG>377-84</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15879586"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamawaki-1996" NAME="Yamawaki 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Yamawaki S, Hayashi T, Yokota N, Takahashi T, Sato G, Tahara Y</AU>
<TI>Serotonin-dopamine antagonists in elderly schizophrenics</TI>
<SO>20th Congress of the Collegium Internationale Neuro-psychopharmacologicum; 1996 Jun 23-27; Melbourne, Australia</SO>
<YR>1996</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="67129859"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2002" MODIFIED="2012-01-04 14:01:13 +0000" MODIFIED_BY="[Empty name]" NAME="Yang 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-01-04 14:01:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang YK, Nelson L, Kamaraju L, Wilson W, McEvoy JP</AU>
<TI>Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia</TI>
<SO>Neuropyschopharmacology</SO>
<YR>2002</YR>
<VL>27</VL>
<NO>4</NO>
<PG>684-6</PG>
<PB>Elsevier Science, US</PB>
<CY>USA</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12377405"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-AiZhen-2008" MODIFIED="2012-01-04 14:01:05 +0000" MODIFIED_BY="[Empty name]" NAME="Yu AiZhen 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-01-04 14:01:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu A-Z, Peng Y-Y, Zeng C-Y, Luo Y-Z</AU>
<TI>Olanzapine and perphenazine in the treatment of senile schizophrenia</TI>
<SO>Chinese Healthcare Innoviation</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>8</NO>
<PG>107, 118</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zisook-2002" MODIFIED="2012-01-04 13:58:29 +0000" MODIFIED_BY="[Empty name]" NAME="Zisook 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-01-04 13:58:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zisook S, Kasckow JW, Golshan S, Fellows I, Solorzano E, Lehman D, Mohamed S, Jeste DV</AU>
<TI>Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2009</YR>
<VL>70</VL>
<NO>4</NO>
<PG>562-71</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19192468"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-25 19:55:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Zisook S</AU>
<TI>Citalopram augmentation in older patients with schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-01-09 10:55:23 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anon-2009" MODIFIED="2013-01-09 10:46:48 +0000" MODIFIED_BY="[Empty name]" NAME="Anon 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-09 10:46:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Anon</AU>
<TI>A multicentre, double-blind, randomised, parallel-group comparison of quetiapine and haloperidol in the treatment of elderly patients presenting with dementia and psychoses (5077il/0049)</TI>
<SO>AstraZeneca Clinical Trials [www.astrazenecaclinicaltrials.com]</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2013-01-09 10:46:48 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barak-2001" MODIFIED="2013-01-09 10:47:00 +0000" MODIFIED_BY="[Empty name]" NAME="Barak 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-01-09 10:47:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Barak Y, Zemishlani C, Mirecki I, Shamir E, Toren P, Weizman R</AU>
<TI>Olanzapine vs. haloperidol for elderly schizophrenia patients</TI>
<SO>Proceedings of the 10th Congress of the International Psychogeriatric Association; 2001 Sept 9-14; Nice, France</SO>
<YR>2001</YR>
<PG>202S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chu-2006" MODIFIED="2010-06-30 21:39:33 +0100" MODIFIED_BY="[Empty name]" NAME="Chu 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-06-30 21:39:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chu J</AU>
<TI>Comparative study of quetiapine and risperidone in the treatment of late onset schizophrenias</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>1</NO>
<PG>34-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dubovsky-2010" MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" NAME="Dubovsky 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubovsky SL, Frobose C, Phiri P, Panagides J</AU>
<TI>Short-term tolerability, safety, and pharmacokinetic profile of asenapine in older patients with psychosis</TI>
<SO>Schizophrenia Research</SO>
<YR>2010</YR>
<VL>117</VL>
<NO>2-3</NO>
<PG>263</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dubovsky-2010a" MODIFIED="2013-01-09 10:46:31 +0000" MODIFIED_BY="[Empty name]" NAME="Dubovsky 2010a" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:46:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dubovsky S, Colleen Frobose C, Phiri P, Panagides J</AU>
<TI>Short-term tolerability, safety, and pharmacokinetic profile of asenapine in older patients with psychosis</TI>
<SO>Proceedings of the 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22-26; New Orleans, LA</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dubovsky-2010b" MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" NAME="Dubovsky 2010b" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubovsky S, Frobose C, Phiri P, Panagides J</AU>
<TI>Asenapine: Short-term tolerability, safety, and pharmacokinetic profile in older patients with psychosis</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2010</YR>
<VL>1</VL>
<PG>489-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dubovsky-2011" MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" NAME="Dubovsky 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubovsky SL, Frobose C, Phiri P, Greef R, Panagides J</AU>
<TI>Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2011</YR>
<VL>27</VL>
<NO>5</NO>
<PG>472-82</PG>
<IDENTIFIERS MODIFIED="2013-01-09 10:42:09 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="21755540"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kircher-2002" MODIFIED="2013-01-09 10:43:25 +0000" MODIFIED_BY="[Empty name]" NAME="Kircher 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-01-09 10:43:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kircher TTJ, Meisner C, Schwrzler F, Buchkremer G, Wormstall H</AU>
<TI>The efficacy of specialised old age psychiatric wards: a multicenter randomised clinical trial</TI>
<SO>European Psychiatry</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>Suppl 1</NO>
<PG>146s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luo-2009" MODIFIED="2013-01-09 10:47:41 +0000" MODIFIED_BY="[Empty name]" NAME="Luo 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-09 10:47:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luo Y</AU>
<TI>quetiapine and risperidone in the treatment of elderly schizophrenia [Google Translate]</TI>
<TO>&#21945;&#30827;&#24179;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2009</YR>
<VL>12</VL>
<NO>24</NO>
<PG>3110-214</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGuire-2002" MODIFIED="2013-01-09 10:42:58 +0000" MODIFIED_BY="[Empty name]" NAME="McGuire 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-01-09 10:42:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGuire G, Kennedy JS, Shaw SC, Kaiser CJ, Sutton V, Street J, et al</AU>
<TI>Acute double-blind comparison of olanzapine and haloperidol in schizophrenia patients age &gt;= 60</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2002</YR>
<VL>10</VL>
<NO>2 Suppl 1</NO>
<PG>168</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mintzer-2001" MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" NAME="Mintzer 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mintzer JE, Mullen JA, Sweitzer DE</AU>
<TI>Extrapyramidal symptoms in elderly patients treated with quetiapine or risperidone</TI>
<SO>Proceedings of the 10th Congress of the International Psychogeriatric Association; 2001 Sept 9-14; Nice, France</SO>
<YR>2001</YR>
<PG>201S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00f6_ller-2005" MODIFIED="2012-01-04 13:58:10 +0000" MODIFIED_BY="[Empty name]" NAME="Möller 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-04 13:58:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Möller HJ, Riedel M, Eich FX</AU>
<TI>A randomised, double-blind clinical trial comparing treatment with amisulpride or risperidone for six weeks in elderly patients with schizophrenia</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl 3</NO>
<PG>S511</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01625897" MODIFIED="2013-01-09 10:46:40 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01625897" YEAR="2012">
<REFERENCE MODIFIED="2013-01-09 10:46:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01625897</AU>
<TI>A long-term study of mp-214 in patients with chronic phase or elderly schizophrenia</TI>
<SO>http://ClinicalTrials.gov/show/NCT01625897</SO>
<YR>2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Riedel-2009" MODIFIED="2013-01-09 10:48:06 +0000" MODIFIED_BY="[Empty name]" NAME="Riedel 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-09 10:48:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riedel M, Eich FX, Moller HJ</AU>
<TI>A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients</TI>
<SO>European Psychiatry</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>3</NO>
<PG>149-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritchie-2003" MODIFIED="2012-01-04 13:57:57 +0000" MODIFIED_BY="[Empty name]" NAME="Ritchie 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-01-04 13:57:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritchie CW, Chiu E, Harrigan S, Hall K, Hassett A, Macfarlane SMM, O'Connor DW, Opie J, Ames D</AU>
<TI>The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>5</NO>
<PG>432-40</PG>
<CY>England</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12766921"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-01-04 13:57:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritchie CW, Chiu E, Harrigan S, Macfarlane S, Mastwyk M, Halliday G, Hustig H, Hall K, Hassett A, O'Connor DW, Opie J, Nagalingam V, Snowdon J, Ames D</AU>
<TI>A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>2</NO>
<PG>171-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16416458"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritchie-2010" MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" NAME="Ritchie 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritchie CW, Harrigan S, Mastwyk M, Macfarlane S, Cheesman M, Ames D</AU>
<TI>Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 31/2 years duration</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>4</NO>
<PG>411-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutton-2001a" MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" NAME="Sutton 2001a" YEAR="2001">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sutton VK, Street JS, Kennedy JS, Feldman PD, Breier A, Eli L&amp;C</AU>
<TI>Superiority of olanzapine over risperidone in the control of negative symptoms in older patients</TI>
<SO>Proceedings of the 10th Congress of the International Psychogeriatric Association; 2001 Sept 9-14; Nice, France</SO>
<YR>2001</YR>
<PG>201S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2009" MODIFIED="2013-01-09 10:48:44 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-09 10:48:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Zhang B</AU>
<TI>aripiprazole in the treatment of schizophrenia in old age [Google Translate]</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#27835;&#30103;&#32769;&#24180;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#24403;&#20195;&#21307;&#33647;</SO>
<YR>2009</YR>
<VL>16</VL>
<NO>18</NO>
<PG>47-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhe-2007" MODIFIED="2012-01-04 13:57:43 +0000" MODIFIED_BY="[Empty name]" NAME="Zhe 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-01-04 13:57:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhe J, Shi X-Y, Tan T-C, Liu W-X, Tao P-Y, Wang J, Liu G-F, Cao J-X, Xue Q-X, Rong L-Z</AU>
<TI>Comparative study of aripiprazole and risperidone in treatment of late onset schizophrenia</TI>
<SO>Linchuang Jingshen Yixue Zazhi</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>5</NO>
<PG>327-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x4f0f__x5f69__x971e_-2010" MODIFIED="2013-01-09 10:55:09 +0000" MODIFIED_BY="[Empty name]" NAME="&#20239;&#24425;&#38686; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:55:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#20239;&#24425;&#38686;, &#32735;&#27462;&#26126;, &#26446;&#25289;&#29634;, &#29579;&#23453;&#23433;</AU>
<TI>Aripiprazole in the treatment of senile schizophrenia [Google Translate]</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#27835;&#30103;&#32769;&#24180;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Modern Medicine and Health [&#29616;&#20195;&#21307;&#33647;&#21355;&#29983;]</SO>
<YR>2010</YR>
<VL>26</VL>
<NO>7</NO>
<PG>1001-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x4f59__x6210__x56fd_-2009" MODIFIED="2013-01-09 10:55:16 +0000" MODIFIED_BY="[Empty name]" NAME="&#20313;&#25104;&#22269; 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-09 10:55:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#20313;&#25104;&#22269;, &#33931;&#22269;&#24198;, &#20873;&#27743;&#23792;</AU>
<TI>Aripiprazole and risperidone in the treatment of senile schizophrenia [Google Translate]</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#32769;&#24180;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Chongqing Medical Journal</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>7</NO>
<PG>785</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5201__x7aef__x5fe0_-2010" MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" NAME="&#20993;&#31471;&#24544; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#20993;&#31471;&#24544;</AU>
<TI>Controlled observation of quetiapine and perphenazine in the treatment of senile schizophrenia</TI>
<TO>&#22862;&#30827;&#24179;&#19982;&#22859;&#20035;&#38745;&#27835;&#30103;&#32769;&#24180;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#35266;&#23519;</TO>
<SO>&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>23</NO>
<PG>3047-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5218__x91d1__x5149_-2010" MODIFIED="2013-01-09 10:44:30 +0000" MODIFIED_BY="[Empty name]" NAME="&#21016;&#37329;&#20809; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#21016;&#37329;&#20809;, &#20811;&#32435;&#26032;</AU>
<TI>Olanzapine and risperidone in the treatment of elderly schizophrenia [Google Translate]</TI>
<TO>&#22885;&#27694;&#24179;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Shanxi Clinical Medicine</SO>
<YR>2010</YR>
<VL>19</VL>
<NO>8A</NO>
<PG>575-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5415__x658c__x519b_--2009" MODIFIED="2013-01-09 10:55:23 +0000" MODIFIED_BY="[Empty name]" NAME="&#21525;&#25996;&#20891;  2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-09 10:55:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#21525;&#25996;&#20891;, &#29579;&#24314;&#26519;, &#26519;&#27704;&#28165;</AU>
<TI>Quetiapine and risperidone in the treatment of elderly schizophrenia [Google Translate]</TI>
<TO>&#21945;&#30827;&#24179;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Shanghai Archives of Psychiatry [&#19978;&#28023;&#31934;&#31070;&#21307;&#23398;] [&#19978;&#28023;&#31934;&#31070;&#37291;&#23416;]</SO>
<YR>2009</YR>
<VL>21</VL>
<NO>1</NO>
<PG>34-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5468__x76ca__x8f89_-2010" MODIFIED="2013-01-09 10:44:39 +0000" MODIFIED_BY="[Empty name]" NAME="&#21608;&#30410;&#36745; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21608;&#30410;&#36745;, &#29579;&#20853;&#21326;, &#26366;&#24503;&#24535;, &#38047;&#36291;&#23792;</AU>
<TI>Aripiprazole impact on the quality of life of elderly patients with schizophrenia</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#23545;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#29983;&#27963;&#36136;&#37327;&#30340;&#24433;&#21709;</TO>
<SO>&#28023;&#21335;&#21307;&#23398;&#38498;&#23398;&#25253;</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>11</NO>
<PG>1424-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5b8b__x4e3d_-2009" MODIFIED="2013-01-09 10:50:10 +0000" MODIFIED_BY="[Empty name]" NAME="&#23435;&#20029; 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-09 10:50:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#23435;&#20029;, &#27146;&#20940;&#23039;</AU>
<TI>Olanzapine and risperidone in the treatment of elderly schizophrenia [Google Translate]</TI>
<TO>&#22885;&#27694;&#24179;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medicine World</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>10</NO>
<PG>583-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5d14__x660e__x4f1f_-2011" MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" NAME="&#23828;&#26126;&#20255; 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#23828;&#26126;&#20255;</AU>
<TI>Ziprasidone, and perphenazine in the treatment of elderly schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#22859;&#20035;&#38745;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;</SO>
<YR>2011</YR>
<VL>23</VL>
<NO>16</NO>
<PG>1970-2055</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f20__x4fdd__x5229_-2010" MODIFIED="2013-01-09 10:44:50 +0000" MODIFIED_BY="[Empty name]" NAME="&#24352;&#20445;&#21033; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#24352;&#20445;&#21033;, &#20848;&#24535;&#25935;, &#26446;&#30456;&#26726;, &#20911;&#38155;</AU>
<TI>Aripiprazole and quetiapine in the treatment of senile schizophrenia</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#19982;&#22862;&#30827;&#24179;&#27835;&#30103;&#32769;&#24180;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>05</NO>
<PG>340-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f20__x5cfb__x5cad_-2009" MODIFIED="2013-01-09 10:50:27 +0000" MODIFIED_BY="[Empty name]" NAME="&#24352;&#23803;&#23725; 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-09 10:50:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#24352;&#23803;&#23725;</AU>
<TI>Clinical analysis of 104 cases older schizophrenia [Google Translate]</TI>
<TO>&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;104&#20363;&#30103;&#25928;&#20998;&#26512;</TO>
<SO>&#20013;&#22269;&#29616;&#20195;&#21307;&#29983;</SO>
<YR>2009</YR>
<VL>47</VL>
<NO>18</NO>
<PG>66-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f20__x7586__x8389_-2010" MODIFIED="2013-01-09 10:50:46 +0000" MODIFIED_BY="[Empty name]" NAME="&#24352;&#30086;&#33673; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:50:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#24352;&#30086;&#33673;, &#24352;&#24314;&#23439;, &#30003;&#24426;</AU>
<TI>Aripiprazole orally disintegrating tablets in the treatment of schizophrenia in old age were observed [Google Translate]</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#21475;&#33108;&#23849;&#35299;&#29255;&#27835;&#30103;&#32769;&#24180;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#30103;&#25928;&#30340;&#23545;&#29031;&#35266;&#23519;</TO>
<SO>&#20013;&#22269;&#29616;&#20195;&#33647;&#29289;&#24212;&#29992;</SO>
<YR>2010</YR>
<VL>4</VL>
<NO>14</NO>
<PG>119-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f20__x8273__x7426_-2010" MODIFIED="2013-01-09 10:50:59 +0000" MODIFIED_BY="[Empty name]" NAME="&#24352;&#33395;&#29734; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:50:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24352;&#33395;&#29734;, &#20110;&#25391;&#19996;</AU>
<TI>Aripiprazole and perphenazine in schizophrenia compared treatment of elderly [Google Translate]</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#19982;&#22859;&#20035;&#38745;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#30103;&#25928;&#27604;&#36739;</TO>
<SO>&#20013;&#22806;&#21307;&#30103;</SO>
<YR>2010</YR>
<VL>5</VL>
<PG>114</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f20__x8273__x7426_-2010a" MODIFIED="2013-01-09 10:51:09 +0000" MODIFIED_BY="[Empty name]" NAME="&#24352;&#33395;&#29734; 2010a" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:51:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#24352;&#33395;&#29734;, &#20110;&#25391;&#19996;</AU>
<TI>Ziprasidone treatment of elderly schizophrenia [Google Translate]</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>3</NO>
<PG>198-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f90__x6e05_-2010" MODIFIED="2013-01-09 10:51:22 +0000" MODIFIED_BY="[Empty name]" NAME="&#24464;&#28165; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:51:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24464;&#28165;, &#33931;&#24184;&#34893;, &#38470;&#38597;&#23068;, &#37045;&#34183;</AU>
<TI>Aripiprazole and risperidone in the treatment of senile schizophrenia [Google Translate]</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#32769;&#24180;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Chinese Journal of Health Psychology [&#20013;&#22269;&#20581;&#24247;&#24515;&#29702;&#23398;&#26434;&#24535;]</SO>
<YR>2010</YR>
<VL>18</VL>
<NO>9</NO>
<PG>1036-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x66fe__x5e86__x7ff0_-2010" MODIFIED="2013-01-09 10:51:36 +0000" MODIFIED_BY="[Empty name]" NAME="&#26366;&#24198;&#32752; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:51:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26366;&#24198;&#32752;, &#21016;&#23781;&#23896;, &#37060;&#26195;&#26126;</AU>
<TI>Olanzapine and perphenazine in treatment of elderly schizophrenia [Google Translate]</TI>
<TO>&#22885;&#27694;&#24179;&#19982;&#22859;&#20035;&#38745;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22806;&#21307;&#30103;</SO>
<YR>2010</YR>
<VL>15</VL>
<PG>125-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x674e__x56fd__x5170_-2010" MODIFIED="2013-01-09 10:51:50 +0000" MODIFIED_BY="[Empty name]" NAME="&#26446;&#22269;&#20848; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:51:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26446;&#22269;&#20848;, &#23391;&#20964;&#21326;, &#20919;&#26641;&#19996;</AU>
<TI>Quetiapine and perphenazine in the treatment of senile schizophrenia observed [Google Translate]</TI>
<TO>&#21945;&#30827;&#24179;&#19982;&#22859;&#20035;&#38745;&#27835;&#30103;&#32769;&#24180;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#35266;&#23519;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>2</NO>
<PG>127</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x674e__x6c38__x7ea2_-2010" MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" NAME="&#26446;&#27704;&#32418; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26446;&#27704;&#32418;</AU>
<TI>Risperidone treatment in elderly schizophrenia clinical observation</TI>
<TO>&#21033;&#22521;&#37230;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>&#38738;&#28023;&#21307;&#33647;&#26434;&#24535;</SO>
<YR>2010</YR>
<VL>40</VL>
<NO>08</NO>
<PG>41-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x674e__x6d77__x6d9b_-2010" MODIFIED="2013-01-09 10:52:08 +0000" MODIFIED_BY="[Empty name]" NAME="&#26446;&#28023;&#28059; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:52:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#26446;&#28023;&#28059;, &#36213;&#26126;&#20255;</AU>
<TI>Aripiprazole and quetiapine in the treatment of elderly schizophrenia [Google Translate]</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#19982;&#21945;&#30827;&#24179;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>10</NO>
<PG>1250-326</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6768__x4ec1__x767b_-2010" MODIFIED="2013-01-09 10:45:31 +0000" MODIFIED_BY="[Empty name]" NAME="&#26472;&#20161;&#30331; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26472;&#20161;&#30331;, &#23828;&#26519;&#26757;, &#26446;&#24681;</AU>
<TI>Ziprasidone, and perphenazine in the treatment of elderly schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#22859;&#20035;&#38745;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>24</NO>
<PG>312-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6768__x96c0__x5c4f_-2010" MODIFIED="2013-01-09 10:52:28 +0000" MODIFIED_BY="[Empty name]" NAME="&#26472;&#38592;&#23631; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:52:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#26472;&#38592;&#23631;, &#24352;&#24658;, &#21253;&#28836;&#21326;, &#21608;&#20806;&#26032;</AU>
<TI>Aripiprazole and olanzapine in elderly patients clinical analysis of first-episode schizophrenia [Google Translate]</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#19982;&#22885;&#27694;&#24179;&#27835;&#30103;&#32769;&#24180;&#26399;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#20020;&#24202;&#20998;&#26512;</TO>
<SO>Chinese Journal of Health Psychology [&#20013;&#22269;&#20581;&#24247;&#24515;&#29702;&#23398;&#26434;&#24535;]</SO>
<YR>2010</YR>
<VL>18</VL>
<NO>7</NO>
<PG>773-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x6881__x52c7_-2011" MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" NAME="&#26753;&#21191; 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26753;&#21191;</AU>
<TI>Olanzapine in the Psychogeriatric</TI>
<TO>&#22885;&#27694;&#24179;&#29255;&#22312;&#32769;&#24180;&#31934;&#31070;&#31185;&#20013;&#30340;&#24212;&#29992;</TO>
<SO>&#24403;&#20195;&#21307;&#23398;</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>21</NO>
<PG>11-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x77f3__x4fdd__x9752_-2011" MODIFIED="2013-01-09 10:45:46 +0000" MODIFIED_BY="[Empty name]" NAME="&#30707;&#20445;&#38738; 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#30707;&#20445;&#38738;, &#33931;&#25104;&#23075;, &#26446;&#29141;</AU>
<TI>Aripiprazole and risperidone treatment in elderly schizophrenia</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;</SO>
<YR>2011</YR>
<VL>23</VL>
<NO>16</NO>
<PG>1971-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x7ba1__x92ae__x53cb_-2009" MODIFIED="2013-01-09 10:52:49 +0000" MODIFIED_BY="[Empty name]" NAME="&#31649;&#37550;&#21451; 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-09 10:52:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#31649;&#37550;&#21451;</AU>
<TI>Ziprasidone and quetiapine in the treatment of senile schizophrenia [Google Translate]</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#22862;&#30827;&#24179;&#27835;&#30103;&#32769;&#24180;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Journal of Military Surgeon in Southwest China</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>5</NO>
<PG>843-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x7f57__x7426_-2010" MODIFIED="2013-01-09 10:53:05 +0000" MODIFIED_BY="[Empty name]" NAME="&#32599;&#29734; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:53:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#32599;&#29734;, &#38472;&#31601;&#31456;, &#29066;&#20856;&#27167;, &#37049;&#26524;&#26524;</AU>
<TI>Palley risperidone and perphenazine in the treatment of senile [Google translate]</TI>
<TO>&#24085;&#21033;&#21708;&#37230;&#19982;&#22859;&#20035;&#38745;&#27835;&#30103;&#32769;&#24180;&#26399;</TO>
<SO>Journal of the Yichun University [&#23452;&#26149;&#23398;&#38498;&#23398;&#25253;]</SO>
<YR>2010</YR>
<VL>32</VL>
<NO>4</NO>
<PG>80, 153</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8463__x6653__x8339_-2009" MODIFIED="2013-01-09 10:45:56 +0000" MODIFIED_BY="[Empty name]" NAME="&#33891;&#26195;&#33593; 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#33891;&#26195;&#33593;, &#23385;&#21033;, &#27494;&#26195;&#26480;</AU>
<TI>The clinical investigation of benazepril and amiodipine on elderly hypertension by 24-hours ambulatory blood pressure monitoring</TI>
<TO>&#22885;&#27694;&#24179;&#19982;&#27695;&#19993;&#21994;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#21307;&#33647;&#23548;&#25253;</SO>
<YR>2009</YR>
<VL>6</VL>
<NO>20</NO>
<PG>56-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8463__x7ee7__x627f_-2009" MODIFIED="2013-01-09 10:53:23 +0000" MODIFIED_BY="[Empty name]" NAME="&#33891;&#32487;&#25215; 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-09 10:53:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#33891;&#32487;&#25215;, &#24109;&#24039;&#30495;, &#32554;&#31454;&#35802;</AU>
<TI>Quetiapine and risperidone in the treatment of elderly schizophrenia [Google Translate]</TI>
<TO>&#21945;&#30827;&#24179;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Shandong Archives of Psychiatry [&#23665;&#19996;&#31934;&#31070;&#21307;&#23398;]</SO>
<YR>2009</YR>
<VL>22</VL>
<NO>4</NO>
<PG>289-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x848b__x5e78__x884d_-2009" MODIFIED="2013-01-09 10:53:38 +0000" MODIFIED_BY="[Empty name]" NAME="&#33931;&#24184;&#34893; 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-09 10:53:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#33931;&#24184;&#34893;, &#40644;&#23493;&#24179;, &#24464;&#28165;, &#38470;&#38597;&#23068;</AU>
<TI>Aripiprazole in elderly patients with schizophrenia quality of life [Google Translate]</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#23545;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#29983;&#27963;&#36136;&#37327;&#30340;&#24433;&#21709;</TO>
<SO>Chinese Journal of Health Psychology [&#20013;&#22269;&#20581;&#24247;&#24515;&#29702;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>17</VL>
<NO>12</NO>
<PG>1421-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8bf8__x6625__x660e_-2010" MODIFIED="2013-01-09 10:53:48 +0000" MODIFIED_BY="[Empty name]" NAME="&#35832;&#26149;&#26126; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:53:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#35832;&#26149;&#26126;</AU>
<TI>Quetiapine in elderly patients with schizophrenia quality of life [Google Translate]</TI>
<TO>&#22862;&#30827;&#24179;&#23545;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#29983;&#27963;&#36136;&#37327;&#30340;&#24433;&#21709;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2010</YR>
<VL>20</VL>
<NO>4</NO>
<PG>262-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8c22__x56fd__x5efa_-2010" MODIFIED="2013-01-09 10:46:13 +0000" MODIFIED_BY="[Empty name]" NAME="&#35874;&#22269;&#24314; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#35874;&#22269;&#24314;, &#32599;&#25463;, &#20873;&#27743;&#23792;</AU>
<TI>Domestic quetiapine and perphenazine treatment in elderly schizophrenia control study</TI>
<TO>&#22269;&#20135;&#22862;&#30827;&#24179;&#19982;&#22859;&#20035;&#38745;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#22235;&#24029;&#31934;&#31070;&#21355;&#29983;</SO>
<YR>2010</YR>
<VL>23</VL>
<NO>04</NO>
<PG>238-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9648__x6c38__x7ea2_-2010" MODIFIED="2013-01-09 10:54:01 +0000" MODIFIED_BY="[Empty name]" NAME="&#38472;&#27704;&#32418; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:54:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#38472;&#27704;&#32418;</AU>
<TI>Aripiprazole and risperidone in the treatment of senile schizophrenia [Google Translate]</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#21644;&#21033;&#22521;&#37230;&#27835;&#30103;&#32769;&#24180;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#23454;&#29992;&#21307;&#33647;</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>27</NO>
<PG>31-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9ec4__x5cf0_-2010" MODIFIED="2013-01-09 10:54:14 +0000" MODIFIED_BY="[Empty name]" NAME="&#40644;&#23792; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:54:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#40644;&#23792;</AU>
<TI>Ziprasidone clinical study of elderly patients with schizophrenia [Google Translate]</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>&#20869;&#31185;</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>1</NO>
<PG>5-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9ec4__x5cf0_-2010a" MODIFIED="2013-01-09 10:54:26 +0000" MODIFIED_BY="[Empty name]" NAME="&#40644;&#23792; 2010a" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:54:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#40644;&#23792;</AU>
<TI>Ziprasidone and risperidone in the treatment of elderly clinical controlled study of schizophrenia [Google Translate]</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21033;&#22521;&#37230;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#20020;&#24202;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>10</NO>
<PG>1214-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9ec4__x5cf0_-2010b" MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" NAME="&#40644;&#23792; 2010b" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#40644;&#23792;</AU>
<TI>Controlled study of ziprasidone treatment of senile negative symptoms of schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#32769;&#24180;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#38452;&#24615;&#30151;&#29366;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#29616;&#20195;&#21307;&#33647;&#21355;&#29983;</SO>
<YR>2010</YR>
<VL>26</VL>
<NO>18</NO>
<PG>2745-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9ec4__x632f__x82f1_-2010" MODIFIED="2013-01-09 10:46:20 +0000" MODIFIED_BY="[Empty name]" NAME="&#40644;&#25391;&#33521; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-09 10:42:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#40644;&#25391;&#33521;, &#39038;&#24191;&#21892;</AU>
<TI>Ziprasidone and quetiapine in the treatment of elderly schizophrenia control analysis</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#19982;&#21945;&#30827;&#24179;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#20998;&#26512;</TO>
<SO>&#20013;&#22269;&#21307;&#33647;&#25351;&#21335;</SO>
<YR>2010</YR>
<VL>8</VL>
<NO>35</NO>
<PG>297-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2010-08-09 11:02:00 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Barnes-2002" MODIFIED="2010-07-29 21:07:22 +0100" MODIFIED_BY="[Empty name]" NAME="Barnes 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-07-29 21:07:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Barnes T</AU>
<TI>A prospective study of tardive dyskinesia in the elderly; single blind comparison of amisulpride and risperidone</TI>
<SO>National Research Register</SO>
<YR>2003</YR>
<VL>1</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-24 11:24:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Barnes T</AU>
<TI>A prospective study of tardive dyskinesia in the elderly; single-blind comparison of amisulpride and risperidone</TI>
<SO>National Research Register</SO>
<YR>2002</YR>
<VL>3</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lacro-2001" MODIFIED="2008-10-21 14:16:43 +0100" MODIFIED_BY="[Empty name]" NAME="Lacro 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-10-21 14:16:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lacro J</AU>
<TI>Antipsychotic treatment in late life schizophrenia</TI>
<SO>CRISP database. https://www-commons.cit.nih.gov/crisp/index.html</SO>
<YR>accessed 19th February 2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-01-05 11:54:42 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-01-05 11:54:42 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Allison-1999" MODIFIED="2010-06-14 10:47:24 +0100" MODIFIED_BY="[Empty name]" NAME="Allison 1999" TYPE="JOURNAL_ARTICLE">
<AU>Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ</AU>
<TI>Antipsychotic-induced weight gain: a comprehensive research synthesis</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<NO>11</NO>
<PG>1686-96</PG>
<IDENTIFIERS MODIFIED="2010-06-14 10:47:24 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Almeida-1995" MODIFIED="2012-01-04 13:57:29 +0000" MODIFIED_BY="[Empty name]" NAME="Almeida 1995" TYPE="JOURNAL_ARTICLE">
<AU>Almeida OP, Howard RJ, Levy R. David AS</AU>
<TI>Psychotic states arising in late life (late paraphrenia) psychopathology and nosology</TI>
<SO>The British Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>166</VL>
<PG>205-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="HLDS020600"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Arndt-1998" MODIFIED="2012-01-04 13:57:16 +0000" MODIFIED_BY="[Empty name]" NAME="Arndt 1998" TYPE="JOURNAL_ARTICLE">
<AU>Arndt J, Skarsfeldt T</AU>
<TI>Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<PG>63&#8211;101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Castle-1991" MODIFIED="2012-01-04 13:57:09 +0000" MODIFIED_BY="[Empty name]" NAME="Castle 1991" TYPE="JOURNAL_ARTICLE">
<AU>Castle DJ, Murray RM</AU>
<TI>The neurodevelopmental basis of sex differences in schizophrenia</TI>
<SO>Psychological Medicine</SO>
<YR>1991</YR>
<VL>21</VL>
<PG>565-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Castle-1993" MODIFIED="2012-01-04 13:57:01 +0000" MODIFIED_BY="[Empty name]" NAME="Castle 1993" TYPE="JOURNAL_ARTICLE">
<AU>Castle DJ, Murray RM</AU>
<TI>The epidemiology of late-onset schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1993</YR>
<VL>19</VL>
<PG>691&#8211;700</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2000" MODIFIED="2008-10-22 08:58:18 +0100" MODIFIED_BY="[Empty name]" NAME="Clarke 2000" TYPE="OTHER">
<AU>Clarke M, Oxman AD</AU>
<TI>Cochrane Reviewers' Handbook 4.0</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Copeland-1992" MODIFIED="2012-01-04 13:56:53 +0000" MODIFIED_BY="[Empty name]" NAME="Copeland 1992" TYPE="JOURNAL_ARTICLE">
<AU>Copeland JRM, Davidson IA, Dewey ME, Gilmore C, Larkin BA, McWilliam C, Saunders PA, Scott A, Sharma V, Sullivan C</AU>
<TI>Alzheimer&#8217;s disease, other dementias, depression and pseudodementia: prevalence, incidence and three-year outcome in Liverpool</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1992</YR>
<VL>161</VL>
<PG>230&#8211;9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Copeland-1998" MODIFIED="2012-01-04 13:56:38 +0000" MODIFIED_BY="[Empty name]" NAME="Copeland 1998" TYPE="JOURNAL_ARTICLE">
<AU>Copeland JRM, Dewey ME, Scott A, Gilmore C, Larkin BA, Cleave N, McCracken CFM, McKibbin PE</AU>
<TI>Schizophrenia and delusional disorder in older age: community prevalence, incidence, comorbidity and outcome</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1998</YR>
<VL>24</VL>
<PG>153&#8211;61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Creese-1976" MODIFIED="2012-01-04 13:56:23 +0000" MODIFIED_BY="[Empty name]" NAME="Creese 1976" TYPE="JOURNAL_ARTICLE">
<AU>Creese I, Burt IR, Snyder SH</AU>
<TI>Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs</TI>
<SO>Science</SO>
<YR>1976</YR>
<VL>192</VL>
<PG>481&#8211;3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davis-1991" MODIFIED="2012-01-04 13:56:16 +0000" MODIFIED_BY="[Empty name]" NAME="Davis 1991" TYPE="JOURNAL_ARTICLE">
<AU>Davis KL, Kahn RS, Ko G, Davidson M</AU>
<TI>Dopamine in schizophrenia: a review and reconceptualization</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1991</YR>
<VL>148</VL>
<PG>1474&#8211;86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeLisi-1992" MODIFIED="2012-01-05 11:54:42 +0000" MODIFIED_BY="[Empty name]" NAME="DeLisi 1992" TYPE="JOURNAL_ARTICLE">
<AU>DeLisi LE</AU>
<TI>The significance of age of onset for schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1992</YR>
<VL>18</VL>
<PG>209&#8211;15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Devanand-1998" MODIFIED="2012-01-04 13:56:01 +0000" MODIFIED_BY="Heather Maxwell" NAME="Devanand 1998" TYPE="JOURNAL_ARTICLE">
<AU>Devanand DP, Marder K, Michaels KS, Sackeim HA, Bell K, Sullivan MA, Cooper TB, Pelton GH, Mayeux R</AU>
<TI>A randomized, placebo-controlled dose comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>155</VL>
<PG>1512-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Di-Giovanni-1998" MODIFIED="2012-01-04 13:55:54 +0000" MODIFIED_BY="[Empty name]" NAME="Di Giovanni 1998" TYPE="JOURNAL_ARTICLE">
<AU>Di Giovanni G, Di Mascio M, Di Matteo V, Esposito E</AU>
<TI>Effects of acute and repeated administration of amisulpride, a dopamine D2/D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>1998</YR>
<VL>28</VL>
<PG>51&#8211;7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-2001" MODIFIED="2011-08-22 20:49:36 +0100" MODIFIED_BY="[Empty name]" NAME="Duggan 2001" TYPE="OTHER">
<AU>Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S</AU>
<TI>Olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford, UK</CY>
<IDENTIFIERS MODIFIED="2008-10-22 09:10:17 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-22 09:10:17 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001359.pub2   "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Frenchman-1997" MODIFIED="2011-09-21 10:13:58 +0100" MODIFIED_BY="Heather Maxwell" NAME="Frenchman 1997" TYPE="JOURNAL_ARTICLE">
<AU>Frenchman IB, Prince T</AU>
<TI>Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances</TI>
<SO>International Journal of Psychogeriatrics</SO>
<YR>1997</YR>
<VL>9</VL>
<PG>431-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilbody-2002" MODIFIED="2011-08-22 20:49:12 +0100" MODIFIED_BY="[Empty name]" NAME="Gilbody 2002" TYPE="OTHER">
<AU>Gilbody SM, Bagnall AM, Duggan L,Tuunainen A</AU>
<TI>Gilbody SM, Bagnall AM, Duggan L,Tuunainen A Risperidone versus other atypical antipsychotic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<PB>Update software</PB>
<CY>Oxford, UK</CY>
<IDENTIFIERS MODIFIED="2011-08-22 20:49:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-08-22 20:49:12 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002306   "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Green-1997" MODIFIED="2012-01-04 13:55:40 +0000" MODIFIED_BY="[Empty name]" NAME="Green 1997" TYPE="JOURNAL_ARTICLE">
<AU>Green MF, Marshall BD Jr, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J</AU>
<TI>Does risperidone improve verbal working memory in treatment-resistant schizophrenia?</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<PG>799-804</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harris-1988" MODIFIED="2012-01-04 13:55:32 +0000" MODIFIED_BY="[Empty name]" NAME="Harris 1988" TYPE="JOURNAL_ARTICLE">
<AU>Harris MJ, Jeste DV</AU>
<TI>Late-onset schizophrenia: an overview</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1988</YR>
<VL>14</VL>
<PG>39-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harris-1988a" MODIFIED="2012-01-04 13:55:25 +0000" MODIFIED_BY="[Empty name]" NAME="Harris 1988a" TYPE="JOURNAL_ARTICLE">
<AU>Harris MJ, Cullum CM, Jeste DV</AU>
<TI>Clinical presentation of late-onset schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1988</YR>
<VL>49</VL>
<PG>356-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henderson-1998" NAME="Henderson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Henderson AS, Korten AE, Levings C, Jorm AF, Christensen H, Jacomb PA, Rodgers B</AU>
<TI>Psychotic symptoms in the elderly: a prospective study in a population sample</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>7</NO>
<PG>484-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-07-23 17:49:19 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1</SO>
<YR>2008</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS MODIFIED="2010-07-23 17:46:35 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-07-23 17:46:35 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Available from www.cochrane-handbook.org"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Honigfeld-1965" MODIFIED="2012-01-04 13:55:17 +0000" MODIFIED_BY="[Empty name]" NAME="Honigfeld 1965" TYPE="JOURNAL_ARTICLE">
<AU>Honigfeld G, Rosebaum MP, Blumenthal IJ, Lambert HL, Roberts AJ</AU>
<TI>Behavioral improvement in the older schizophrenic patient: drug and social therapies</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1965</YR>
<VL>13</VL>
<PG>57-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Howard-1992a" MODIFIED="2008-10-22 09:35:50 +0100" MODIFIED_BY="[Empty name]" NAME="Howard 1992a" TYPE="JOURNAL_ARTICLE">
<AU>Howard RJ, Forstl H, Naguib M, Burns A, Levy R</AU>
<TI>First-rank symptoms of Schneider in late paraphrenia. Cortical structural correlates</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1992</YR>
<VL>160</VL>
<PG>108-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Howard-1992b" NAME="Howard 1992b" TYPE="JOURNAL_ARTICLE">
<AU>Howard RJ</AU>
<TI>Late paraphrenia: an update</TI>
<SO>Journal of the Royal Society of Medicine</SO>
<YR>1992</YR>
<VL>3</VL>
<PG>63-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Howard-1993" NAME="Howard 1993" TYPE="JOURNAL_ARTICLE">
<AU>Howard RJ, Almeida O, Levy R</AU>
<TI>Phrenomenology of late-onset schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1993</YR>
<VL>9</VL>
<PG>100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Howard-1993a" MODIFIED="2012-01-04 13:55:05 +0000" MODIFIED_BY="[Empty name]" NAME="Howard 1993a" TYPE="JOURNAL_ARTICLE">
<AU>Howard R, Castle D, Wessely S, Murray R</AU>
<TI>A comparative study of 470 cases of early-onset and late-onset schizophrenia</TI>
<SO>The British Journal of Psychiatry</SO>
<YR>1993</YR>
<VL>163</VL>
<PG>352-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Howard-1997" MODIFIED="2012-01-04 13:54:58 +0000" MODIFIED_BY="[Empty name]" NAME="Howard 1997" TYPE="JOURNAL_ARTICLE">
<AU>Howard RJ, Graham C, Sham P, Dennehey J, Castle DJ, Levy R, Murray R</AU>
<TI>A controlled family study of late-onset non-affective psychosis (late paraphrenia)</TI>
<SO>The British Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>170</VL>
<PG>511-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Howard-2000" MODIFIED="2012-01-04 13:54:50 +0000" MODIFIED_BY="[Empty name]" NAME="Howard 2000" TYPE="JOURNAL_ARTICLE">
<AU>Howard R, Rabins PV, Seeman MV Jeste DV and the International Late-Onset, Schizophrenia Group</AU>
<TI>Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>157</VL>
<PG>172-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jeste-1993" MODIFIED="2012-01-04 13:54:36 +0000" MODIFIED_BY="[Empty name]" NAME="Jeste 1993" TYPE="JOURNAL_ARTICLE">
<AU>Jeste DV, Lacro JP, Gilbert PL, Kline J, Kline N</AU>
<TI>Treatment of late-life schizophrenia with neuroleptics</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1993</YR>
<VL>19</VL>
<PG>817-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jeste-1995" NAME="Jeste 1995" TYPE="JOURNAL_ARTICLE">
<AU>Jeste DV, Harris MJ, Krull A, Kuck J, McAdams LA, Heaton R</AU>
<TI>Clinical and neuropsychological characteristics of patients with late-onset schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>152</VL>
<PG>722-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jeste-1996" MODIFIED="2012-01-04 13:54:26 +0000" MODIFIED_BY="[Empty name]" NAME="Jeste 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jeste DV, Eastham JH, Lacro JP, Gierz M, Field MG, Harris MJ</AU>
<TI>Management of late life psychosis</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1996</YR>
<VL>57(suppl 3)</VL>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jeste-1997" NAME="Jeste 1997" TYPE="BOOK_SECTION">
<AU>Jeste DV, McClure FS</AU>
<TI>Psychoses: Diagnosis and treatment in the elderly</TI>
<SO>Updates in Geriatric Psychiatry, New Directions for Mental Health Services</SO>
<YR>1997</YR>
<EN>1</EN>
<ED>Schneider L</ED>
<PB>Jossey-Bass</PB>
<CY>San Francisco</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jeste-1998" NAME="Jeste 1998" TYPE="JOURNAL_ARTICLE">
<AU>Jeste DV, Lohr JB, Eastham JH, Rockwell E, Caligiuri MP</AU>
<TI>Adverse effect of long-term use of neuroleptics: human and animal studies</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>1998</YR>
<VL>32</VL>
<PG>201-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jeste-1999" MODIFIED="2012-01-04 13:54:12 +0000" MODIFIED_BY="[Empty name]" NAME="Jeste 1999" TYPE="JOURNAL_ARTICLE">
<AU>Jeste DV, Rockwell E, Harris MJ, Lohr JB, Lacro J</AU>
<TI>Conventional versus newer antipsychotics in elderly</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>1999</YR>
<VL>7</VL>
<PG>70-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jeste-1999a" MODIFIED="2012-01-04 13:54:03 +0000" MODIFIED_BY="[Empty name]" NAME="Jeste 1999a" TYPE="JOURNAL_ARTICLE">
<AU>Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP</AU>
<TI>Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1999</YR>
<VL>47</VL>
<PG>716-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Katz-1999" NAME="Katz 1999" TYPE="JOURNAL_ARTICLE">
<AU>Katz IR, Jeste DV, Minter JE, and the Risperidone Study Group</AU>
<TI>Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60</VL>
<PG>107-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keith-1991" MODIFIED="2012-01-04 13:53:54 +0000" MODIFIED_BY="[Empty name]" NAME="Keith 1991" TYPE="BOOK">
<AU>Keith SJ, Regier DA, Rae DS</AU>
<SO>Schizophrenic disorders, in Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. Edited by Robins LN, Regier DA, pp 33&#8211;52</SO>
<YR>1991</YR>
<PB>Free Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kennedy-2001" MODIFIED="2011-08-22 20:50:01 +0100" MODIFIED_BY="[Empty name]" NAME="Kennedy 2001" TYPE="OTHER">
<AU>Kennedy E, Song F, Hunter R, Clarke A, Gilbody S</AU>
<TI>Risperidone versus typical antipsychotic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford, UK</CY>
<IDENTIFIERS MODIFIED="2008-10-22 09:08:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-22 09:08:46 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000440   "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Koro-2002" NAME="Koro 2002" TYPE="JOURNAL_ARTICLE">
<AU>Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW</AU>
<TI>Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study</TI>
<SO>BMJ</SO>
<YR>2002</YR>
<VL>325</VL>
<NO>7358</NO>
<PG>243</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kraepelin-1909" MODIFIED="2011-09-21 10:31:06 +0100" MODIFIED_BY="[Empty name]" NAME="Kraepelin 1909" TYPE="BOOK">
<AU>Kraepelin E</AU>
<SO>Psychiatrie ein Lehrbuch fur Studierende und Aertzte, 8th ed</SO>
<YR>1909</YR>
<PB>Barth</PB>
<CY>Leipzig</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kua-1992" MODIFIED="2012-01-04 13:53:41 +0000" MODIFIED_BY="[Empty name]" NAME="Kua 1992" TYPE="JOURNAL_ARTICLE">
<AU>Kua EHA</AU>
<TI>Community study of mental disorders in elderly Singaporean Chinese using the GMS-AGECAT package</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>1992</YR>
<VL>26</VL>
<PG>502&#8211;6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lawler-1999" MODIFIED="2012-01-04 13:53:24 +0000" MODIFIED_BY="[Empty name]" NAME="Lawler 1999" TYPE="JOURNAL_ARTICLE">
<AU>Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB</AU>
<TI>Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>20</VL>
<PG>612&#8211;27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lohr-1992" MODIFIED="2012-01-04 13:53:12 +0000" MODIFIED_BY="[Empty name]" NAME="Lohr 1992" TYPE="BOOK">
<AU>Lohr JB, Jeste DV, Harris MJ, Salzman C</AU>
<SO>Treatment of disordered behavior. In: Salzman C, ed. Clinical geriatric psychopharmacology. pp.79-113</SO>
<YR>1992</YR>
<PB>Williams &amp; Wilkins</PB>
<CY>Baltimore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lohr-1997" MODIFIED="2011-09-21 10:45:48 +0100" MODIFIED_BY="Heather Maxwell" NAME="Lohr 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lohr JB, Alder M, Flynn K, Harris MJ, McAdams LA</AU>
<TI>Minor physical anomalies in older patients with late-onset schizophrenia, early onset schizophrenia, depression, and Alzheimer's disease</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>1997</YR>
<VL>5</VL>
<PG>318-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marriott-2006" MODIFIED="2012-01-04 13:53:04 +0000" MODIFIED_BY="[Empty name]" NAME="Marriott 2006" TYPE="COCHRANE_REVIEW">
<AU>Marriott R, Neil W, Waddingham S</AU>
<TI>Antipsychotic medication for elderly people with schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-08-22 20:42:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-08-22 20:42:31 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005580"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Meltzer-1976" MODIFIED="2012-01-04 13:52:52 +0000" MODIFIED_BY="[Empty name]" NAME="Meltzer 1976" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY, Stahl SM</AU>
<TI>The dopamine hypothesis of schizophrenia: a review</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1976</YR>
<VL>2</VL>
<PG>19&#8211;76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meltzer-1989" MODIFIED="2012-01-04 13:52:43 +0000" MODIFIED_BY="[Empty name]" NAME="Meltzer 1989" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY, Matsubara S, Lee J-C</AU>
<TI>Classification of typical andatypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin-2 pKi values</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>1989</YR>
<VL>251</VL>
<PG>238&#8211;46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olshansky-1993" NAME="Olshansky 1993" TYPE="JOURNAL_ARTICLE">
<AU>Olshansky SJ</AU>
<TI>The human life span: are we reaching the outer limits?</TI>
<SO>Geriatrics</SO>
<YR>1993</YR>
<VL>48</VL>
<NO>3</NO>
<PG>85-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" MODIFIED="2012-01-04 13:52:21 +0000" MODIFIED_BY="[Empty name]" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pearlson-1989" NAME="Pearlson 1989" TYPE="JOURNAL_ARTICLE">
<AU>Pearlson GD, Kreger L, Rabins PV, Chase GA, Cohen B, Wirth JB, Schlaepfer TB, Tune LE</AU>
<TI>A chart review study of late-onset and early-onset schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>146</VL>
<NO>12</NO>
<PG>1568-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Regier-2000" NAME="Regier 2000" TYPE="JOURNAL_ARTICLE">
<AU>Regier DA</AU>
<TI>Community diagnosis counts</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2000</YR>
<VL>57</VL>
<NO>3</NO>
<PG>223-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salzman-1990" NAME="Salzman 1990" TYPE="BOOK_SECTION">
<AU>Salzman C</AU>
<TI>Principles of psychopharmacology</TI>
<SO>Verwoerdt's Clinical Geropsychiatry</SO>
<YR>1990</YR>
<PG>235-49</PG>
<EN>1</EN>
<ED>Bienenfeld D</ED>
<PB>Williams and Wilkins</PB>
<CY>Baltimore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2008" MODIFIED="2012-01-04 14:43:41 +0000" MODIFIED_BY="[Empty name]" NAME="Schünemann 2008" TYPE="BOOK_SECTION">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>359-83</PG>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomas-1998" MODIFIED="2012-01-04 13:52:11 +0000" MODIFIED_BY="[Empty name]" NAME="Thomas 1998" TYPE="JOURNAL_ARTICLE">
<AU>Thomas CS, Lewis S</AU>
<TI>Which atypical antipsychotic?</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>172</VL>
<PG>106-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsuang-1971" MODIFIED="2012-01-04 13:51:50 +0000" MODIFIED_BY="[Empty name]" NAME="Tsuang 1971" TYPE="JOURNAL_ARTICLE">
<AU>Tsuang MM, Lu LM, Stotsky BA, Cole JO</AU>
<TI>Haloperidol versus thioridazine for hospitalized psychogeriatric patients: double-blind study</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1971</YR>
<VL>19</VL>
<PG>593-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Os-1995" MODIFIED="2012-01-04 13:51:57 +0000" MODIFIED_BY="[Empty name]" NAME="Van Os 1995" TYPE="JOURNAL_ARTICLE">
<AU>Van Os J, Howard R, Takei N, Murray RM</AU>
<TI>Increasing age is a risk factor for psychosis in the elderly</TI>
<SO>Social Psychiatry and Psychiatric Epidemiology</SO>
<YR>1995</YR>
<VL>30</VL>
<PG>161&#8211;4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Webster-1998" NAME="Webster 1998" TYPE="JOURNAL_ARTICLE">
<AU>Webster J, Grossberg GT</AU>
<TI>Late-life onset of psychotic symptoms</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>1998</YR>
<VL>6</VL>
<NO>3</NO>
<PG>196-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wirshing-1998" NAME="Wirshing 1998" TYPE="JOURNAL_ARTICLE">
<AU>Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC</AU>
<TI>Novel antipsychotics and new onset diabetes</TI>
<SO>Biological Psychiatry</SO>
<YR>1998</YR>
<VL>44</VL>
<NO>8</NO>
<PG>778-83</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2010-06-30 23:01:40 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-01-09 11:42:40 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-01-05 11:07:30 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-01-05 11:07:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2007">
<CHAR_METHODS MODIFIED="2012-01-05 11:06:51 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised by admission sequence.</P>
<P>Blinding: no blinding.</P>
<P>Duration: 8 weeks.</P>
<P>Design: parallel.</P>
<P>Country: China.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-05 11:06:26 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (CCMD-3).<BR/>N = 44.</P>
<P>Age: adults over 60 years (risperidone group mean age ~ 64.3 years (SD = 3.2), olanzapine group mean age ~ 63 years (SD = 3.9)) - check 80% value etc</P>
<P>Sex: 23M, 21F.</P>
<P>History: recent onset: risperidone group mean duration of illness ~1.6 years (SD = 1.1), olanzapine group mean duration of illness 1.8 years (SD = 1.4).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-05 11:06:37 +0000" MODIFIED_BY="[Empty name]">
<P>1. Risperidone: fixed dose mean 4.1 mg/day (SD = 2.1). N = 22.<BR/>2. Olanzapine: fixed dose mean 10.2 mg/day (SD = 5.9). N = 22.   </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-05 11:07:18 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.</P>
<P>Unable to use:</P>
<P>Mental state: BPRS: (no SD).</P>
<P>BMI (kg/m2): (no SD).</P>
<P>FBS (mmol/L): (no SD).</P>
<P>Serum Cholesterol (mmol/L): (no SD).</P>
<P>Serum Triglycerides (mmol/L): (no SD).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-05 11:07:30 +0000" MODIFIED_BY="[Empty name]">
<P>This study was included although we were unable to confirm that 80% of the participants were 65 or older. The age of onset, however, is clearly after the age of 60. This study provided unusable data (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BMI: Body Mass Index<BR/>BPRS: Brief Psychiatric Rating Scale<BR/>CCMD-3: Chinese Classification of Mental Disorders (third revision)<BR/>FBS: Fasting Blood Sugar<BR/>SD: standard deviation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-01-05 11:59:37 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:24:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anon-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:24:24 +0000" MODIFIED_BY="[Empty name]">
<P>Participants: not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anon-2008a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. Double blind.</P>
<P>Participants: elderly people (mean age 70 years) with schizophrenia - not late-onset schizophrenia.</P>
<P>Interventions: paliperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anon-2008b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. Double blind.</P>
<P>Participants: people with early-onset schizophrenia.</P>
<P>Interventions: risperidone and olanzapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:25:18 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Bamrah-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:25:18 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 114 elderly people with dementia and psychosis, not late-onset schizophrenia.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:25:26 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Barak-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:25:26 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 51 "geriatric inpatients with chronic schizophrenia", not late-onset schizophrenia.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barak-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants:elderly people with chronic schizophrenia, mean age 72.7 ± 5.9 years, mean disease duration 33.1 ± 12.0 years - not late-onset schizophrenia.</P>
<P>Interventions: olanzapine and haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bartels-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: elderly people with serious mental illness.</P>
<P>Interventions: health management and supported rehabilitation.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:25:53 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Berman-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:25:53 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 20 "geriatric patients with schizophrenia", not late-onset schizophrenia.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bjorndal-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: psychiatric patients with tardive dyskinesia.</P>
<P>Interventions: naloxone, enkephalins, morphine.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blum-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Interventions: naloxone, placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:26:10 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Branchey-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:26:10 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: unclear, "double-blind, crossover".<BR/>Participants: 30 elderly inpatients with chronic schizophrenia, not late-onset schizophrenia.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brecher-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Double blind.</P>
<P>Participants: adult and elderly people with schizophrenia or schizoaffective disorder, mean age &lt; 41 years.</P>
<P>Interventions: risperdone and olanzepine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:26:24 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Burns-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:26:24 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 59 "geriatric patients with schizophrenia, schizophreniform disorder, schizoaffective disorder", not late-onset schizophrenia.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-10 23:24:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burns-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-10 23:24:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with severe mental illness - not elderly people.</P>
<P>Interventions: supported employment (Individual Placement and Support programme) vs. vocational training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:26:40 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Byerly-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:26:40 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: unclear, "comparing the efficacy....".<BR/>Participants: 60 people with schizophrenia, not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:26:48 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Cantillon-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:26:48 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 351 (in trial 1 -fixed dose), 296 (in trial 2 -titrated dose) people with acute exacerbation of schizophrenia, age group not specified, not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CATIE-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Double blind.</P>
<P>Participants: people with schizophrenia - not late-onset schizophrenia.</P>
<P>Interventions: typical and atypical antipsychotic medications.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
<P>Participants: elderly people with schizophrenia.</P>
<P>Interventions: olanzapine and clozapine.</P>
<P>Age at onset: unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2003b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear.</P>
<P>Participants: elderly people with psychotic disease.</P>
<P>Interventions: nursing education.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheng-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised - according to illness severity.</P>
<P>Participants: elderly people with first episode schizophrenia.</P>
<P>Interventions: olanzapine vs risperdone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:27:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Crosthwaite-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:27:22 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear.</P>
<P>Participants: older patients with psychosis (age.&gt;.50 years) - not late-onset psychosis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:27:30 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Davidson-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:27:30 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: unclear, "double-blind".<BR/>Participants: 180 chronic psychotic patients aged 54 to 89 years, not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Delapena-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: older patients with schizophrenia.</P>
<P>Interventions: group therapy and cognitive behavioral social skills training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-28 12:53:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Depla-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-28 12:53:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised - post test only design to assess community integration of elderly mentally ill persons.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Docherty-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. Double blind.</P>
<P>Participants: elderly people with schizophrenia or schizoaffective disorder - not late-onset.</P>
<P>Interventions: risperidone and olanzapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Drake-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear.</P>
<P>Participants: homeless people with dual diagnosis, age range 18 to 50 years.</P>
<P>Interventions: social network case management and intensive case management.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dunn-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: middle-aged and elderly people with schizophrenia.</P>
<P>Interventions: enhanced consent procedure and routine consent procedure.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dunn-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: middle-aged and older patients with schizophrenia and schizoaffective disorder.</P>
<P>Interventions: Brief Patient Education, Computer-Assisted Instruction.</P>
<P>Outcome: understanding of placebo control.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:28:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Evans-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:28:42 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with Alzheimer's disease and psychosis, not late-onset psychosis.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fleischhacker-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, open-label.</P>
<P>Participants: symptomatically stable people with schizophrenia or schizoaffective disorder.</P>
<P>Interventions: long-acting risperidone at three different doses.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerlach-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: hospitalised psychiatric patients with neuroleptic-induced tardive dyskinesia - not elderly patients.</P>
<P>Interventions: alpha-Methyl-para-tyrosine, Baclofen, Biperiden.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glorioso-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: middle-aged and elderly patients with schizophrenia or dementia - not late-onset schizophrenia.</P>
<P>Interventions: four atypical antipsychotic drugs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Granholm-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: older people with schizophrenia.</P>
<P>Interventions: group cognitive-behavioural social skills training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Granholm-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: middle-aged and elderly people with chronic schizophrenia.</P>
<P>Interventions: cognitive behavioural social skills training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Granholm-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: not aged patients.</P>
<P>Interventions: Cognitive Behavioral Therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-28 12:57:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Granholm-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-28 12:57:28 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. Single blind (outcome assessor).</P>
<P>Participants: older patients with schizophrenia.</P>
<P>Interventions:computer-assisted cognitive behavioral social skill training, goal-focused supportive contact.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:29:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harrigan-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:29:31 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>No blinding.</P>
<P>Participants: people with psychotic disorders, age range 18 to 65 - not late-onset.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:29:40 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Harvey-2000a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:29:40 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 367 people with schizophrenia living in a community, not late-onset schizophrenia.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:29:51 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Harvey-2000b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:29:51 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 377 people with schizophrenia, schizoaffective outpatients. Subgroup analysis for 153 elderly patients with schizophrenia, but not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:29:58 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Harvey-2000c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:29:58 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 222 people with schizophrenia, not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:30:24 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Harvey-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:30:24 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 269 patients with schizophrenia or schizoaffective disorder, not late-onset schizophrenia.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harvey-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. Double blind.</P>
<P>Participants: elderly people with schizophrenia or schizoaffective disorder - not late-onset schizophrenia (mean duration of illness 36.5 years, age of onset 33 to 36 years).</P>
<P>Interventions: risperidone and olanzapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hay-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: acutely psychotic or agitated elderly people.</P>
<P>Interventions: olanzapine and conventional antipsychotic drugs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:30:44 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Hellewell-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:30:44 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 455 patients with schizophrenia, schizoaffective disorder, age 18 to 89 years old, including only 18 elderly patients, not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:30:50 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Howanitz-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:30:50 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 42 chronic schizophrenic inpatients aged 55 years or older, not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Inouye-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Delirium Prevention Trial.</P>
<P>Interventions: adherence to nonpharmacologic interventions.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Isley-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. Double blind.<BR/>Participants: older patients with psychosis.</P>
<P>Interventions: Medication Adherence Therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:31:25 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Jeste-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:31:25 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised,<BR/>Participants: 176 "geriatric" patients with schizophrenia or schizoaffective disorder, not late-onset schizophrenia.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:31:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jeste-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:31:32 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: middle-aged and elderly psychiatric patients - not late-onset psychosis.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:31:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinon-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:31:45 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: Double blind.</P>
<P>Method and participants: data were obtained from patients (n = 760 participants) enrollment into a large (n = 1996 not aged participants). not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:31:52 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Kinon-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:31:52 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 43 "elderly dementia patients with behavioural disturbance and psychosis living in nursing homes", not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:59:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinon-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:59:37 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: acutely psychotic or agitated elderly people without tardive dyskinesia - not late-onset psychosis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:59:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kopala-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:59:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Blinding: unclear.</P>
<P>Participants: people with recent onset schizophrenia. Not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:32:20 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Kuntz-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:32:20 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 59 "geriatric" patients with schizophrenia, schizophreniform disorder, schizoaffective disorder, not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:42:41 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Lane-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:42:41 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 24 people with first episode schizophrenia, age 18 to 45 years old, not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lapolla-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
<P>Participants: elderly (age range 55 to 80 years) - not late-onset psychosis.</P>
<P>Interventions: acetophenazine and thioridazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leutwyler-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. (Secondary data analysis of a lifestyle intervention programme).</P>
<P>Participants: persons over age 40 with schizophrenia or schizoaffective disorder.</P>
<P>Interventions: Rehabilitation Training or Usual Care plus Information.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-28 13:08:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-28 13:08:34 +0100" MODIFIED_BY="[Empty name]">
<P>Design: cross-sectional study.</P>
<P>Participants: elderly people with schizophrenia and normal adults.</P>
<P>Outcome: assessment of cognitive functions.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
<P>Participants: elderly people with schizophrenia.</P>
<P>Interventions: quetiapine and perphenazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-28 13:09:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-28 13:09:03 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: 'randomised' by admission sequence - odd for olanzapine, even for risperdone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-08-10 23:33:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-08-10 23:33:05 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: 'randomised' by admission sequence - odd for risperidone, even for perphenazine</P>
<P>Participants: elderly people with schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:33:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Linden-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:33:19 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.<BR/>Participants: people who had left early from a clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: 'randomised' by sequence - The author stated that allocation was according to odd or even numbers (phone call by Chunbo Li on 26th July, 2010).</P>
<P>Participants: elderly people with late-onset schizophrenia.</P>
<P>Interventions: aripiprazole vs risperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:33:38 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Lovett-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:33:38 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 54 "geriatric patients with chronic brain syndrome and senile psychosis", not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:33:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marcelli-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:33:49 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: adolescent and young adults (age 14 to 24 years) with first acute psychotic episode.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:33:54 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Matkovits_x002d_Gupta-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:33:54 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia including the elderly, not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mazeh-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. Double blind, cross-over.</P>
<P>Participants: elderly patients with schizophrenia.</P>
<P>Interventions: donepezil, placebos.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McKibbin-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia or schizophrenic disorder and diabetes mellitus.</P>
<P>Age: older than 40 years.</P>
<P>Interventions: diabetes awareness and rehabilitation training vs. usual care plus information.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McQuaid-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: older people with schizophrenia, age 45 years and above.</P>
<P>Interventions: Cognitive Behavioural Social Skills Training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:34:25 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Mintzer-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:34:25 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 92 elderly people, 31 with schizophrenia, 22 who with schizoaffective disorder, 5 with delusional disorder, 12 with mood disorders and 12 with dementia, not late-onset schizophrenia.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:34:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mintzer-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:34:31 +0000" MODIFIED_BY="[Empty name]">
<P>Design: post hoc analysis of a subset of older patients from and open-label RCT.</P>
<P>Participants: elderly people with psychosis, age 60 to 80 years - not late-onset psychosis.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mohler-1970">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: non randomised, case-control comparative study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-28 13:14:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Myers-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-28 13:14:10 +0100" MODIFIED_BY="[Empty name]">
<P>Design: RCT.</P>
<P>Allocation: blinding - double.</P>
<P>Participants: not aged patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naoki-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Interventions: community re-entry programme.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-28 13:14:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nordentoft-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-28 13:14:37 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: 18 to 45 years old with first time diagnosis of schizophrenia spectrum disorder.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ogunmefun-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. Double-blind, cross-over.</P>
<P>Participants: people with tardive dyskinesia.</P>
<P>Interventions: placebos and donepezil.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patterson-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: middle-aged and older patients with chronic schizophrenia.</P>
<P>Interventions: functional adaptation skills training and group therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patterson-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: middle aged and older Latino patients with psychosis.</P>
<P>Interventions: psychosocial intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patterson-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Participants: middle-aged and elderly people with chronic psychotic disorders.</P>
<P>Interventions: functional adaptation skills training.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pfizer-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: elderly people with psychosis, age &gt; 65 years - not late-onset schizophrenia.</P>
<P>Interventions: asenapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Phanjoo-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 18 "geriatric inpatients with schizophrenia and paranoid disorder ", 16 with late-onset schizophrenia.<BR/>Interventions: remoxipride versus thioridazine, remoxipride withdrawn from the market (1994), last batch produced (1999).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prat-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: older people with serious mental illness.</P>
<P>Interventions: psychosocial rehabilitation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pratt-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: older people with serious mental illness, age 50 years and above.</P>
<P>Interventions: the Using Medications Effectively programme.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pratt-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: older people with serious mental illness.</P>
<P>Interventions: social rehabilitation and health care management (Helping Older People Experience Success; HOPES) vs. usual care.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:35:54 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Reams-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:35:54 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 59 "geriatric" patients with schizophrenia, schizophreniform disorder, schizoaffective disorder, not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ritchie-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised (a cohort study).</P>
<P>Participants: elderly people on antipsychotic medications - not late-onset psychosis.</P>
<P>Interventions: olanzapine and risperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:36:06 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Salganik-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:36:06 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 17 "geriatric patients with chronic refractory schizophrenia", not late-onset schizophrenia.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Salzman-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, descriptive study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seager-1955">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear, "divided into two groups".<BR/>Participants: 48 people including 13 with schizophrenia or paraphrenia.<BR/>Interventions: chlorpromazine different doses.<BR/>Outcome: no data reported for subgroup of people with paraphrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-28 13:17:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shen-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-28 13:17:50 +0100" MODIFIED_BY="[Empty name]">
<P>Design: cross-sectional study.</P>
<P>Participants: young, middle-aged and elderly male people with schizophrenia.</P>
<P>Outcome: serum testosterone levels.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shin-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Interventions: psycho education and supportive therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sikich-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. Double blind.</P>
<P>Participants: children and adolescents with psychosis.</P>
<P>Interventions: risperidone, olanzapine and haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-Hui-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: elderly men with schizophrenia - not late-onset schizophrenia.</P>
<P>Interventions: quetiapine and risperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:41:08 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Sutton-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:41:08 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 339 people with schizophrenia, schizoaffective outpatients age 18 to 65. Subgroup analysis for 39 elderly patients(age 50 to 65) with schizophrenia, not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svestka-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: 44 elderly women with schizophrenia including 21 with paraphrenia.<BR/>Interventions: pimozide versus perphenazine.<BR/>Outcome: no data reported for subgroup of women with parapharenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svestka-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear "double-blind".<BR/>Participants: 46 people with schizophrenia or paraphrenia.<BR/>Interventions: oxyprothepine versus perphenazine.<BR/>Outcome: no data reported for subgroup of women with parapharenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Svestka-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear "double-blind".<BR/>Participants: 40 people with schizophrenia, schizoaffective disorder, including 9 paraphrenia.<BR/>Interventions: isofloxythepine versus haloperidol.<BR/>Outcomes: no data reported for subgroup of people with parapharenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:36:58 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Svestka-1989a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:36:58 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: randomised.<BR/>Participants: 40 people with chronic schizophrenia or schizoaffective disorder, aged 17 to 67. No mention of late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:37:13 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Svestka-1989b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:37:13 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: unclear "cross-over".<BR/>Participants: 34 inpatients with chronic schizophrenia, no mention of late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:37:23 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Svestka-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:37:23 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: unclear, "double-blind".<BR/>Participants: 36 patients with schizophrenia or schizoaffective disorder, not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tariot-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, open-label trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:37:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tollefson-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:37:32 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. Double blind.</P>
<P>Participants: people with schizophrenia, onset of illness by the age of 45 years in 87% of the participants - not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tran-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. Double blind.</P>
<P>Participants: people with chronic schizophrenia and related psychotic disorders, aged 18 to 65 years - not late-onset schizophrenia.</P>
<P>Interventions: risperidone, olanzapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Twamley-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: middle-aged and older people with schizophrenia.</P>
<P>Interventions: three work rehabilitation approaches.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Twamley-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: middle-aged and older people with severe mental illness.<BR/>Interventions: a supported employment model (Individual Placement and Support) and conventional vocational rehabilitation.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tzimos-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised. Double blind.</P>
<P>Interventions: placebos and paliperidone.</P>
<P>Participants: elderly people with schizophrenia.</P>
<P>mean age at onset of schizophrenia 34 years - not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vaglum-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
<P>Participants: people with first episode schizophrenia, without age limit.</P>
<P>Interventions: early detection programme.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-09-28 13:23:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-09-28 13:23:22 +0100" MODIFIED_BY="[Empty name]">
<P>Design: cross-sectional study.</P>
<P>Participants: people with schizophrenia taking novel or traditional antipsychotic drugs.</P>
<P>Outcome: direct cost of treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
<P>Participants: elderly people with primary-onset schizophrenia.</P>
<P>Interventions: risperidone and perphenazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-LiLi-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: elderly people with schizophrenia - not late-onset schizophrenia.</P>
<P>Interventions: risperidone oral solution and risperidone tablets.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-R-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Interventions: family support and psychological treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-XiaoQuan-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: elderly people with schizophrenia - not late-onset schizophrenia.</P>
<P>Interventions: quetiapine and risperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Warner-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: older people with mental illness.</P>
<P>Interventions: home treatment and standard care.<BR/>This is only a study proposal.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamashita-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: unclear.</P>
<P>Participants: people with schizophrenia receiving conventional antipsychotic drugs. Mean age 61.4 years - not late-onset schizophrenia.</P>
<P>Interventions: olanzapine, perospirone, quetiapine and risperidone.</P>
<P>Outcome: sleep quality.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:39:49 +0000" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Yamawaki-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:39:49 +0000" MODIFIED_BY="Heather Maxwell">
<P>Allocation: unclear, "double-blind".<BR/>Participants: 35 elderly people with schizophrenia, not late-onset schizophrenia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: 20 to 53 years old people with schizophrenia.<BR/>Interventions: nicotine patch and placebo patch.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-AiZhen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: elderly people with schizophrenia - not late-onset schizophrenia.</P>
<P>Interventions: olanzapine and perphenazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zisook-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-05 11:56:01 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: older people with schizophrenia, age 40 years and above.</P>
<P>Interventions: placebo vs citaloprams.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-01-09 11:42:40 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anon-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:18 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barak-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:20 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-01-05 11:07:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chu-2006">
<CHAR_METHODS MODIFIED="2012-01-05 11:07:44 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: quasi-randomised according to admission sequence. <BR/>Blindness: none. <BR/>Duration: 8 weeks.<BR/>Design: parallel.</P>
<P>Country of origin: China.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-28 13:29:25 +0100" MODIFIED_BY="[Empty name]">
<P>N = 60.</P>
<P>Diagnosis: schizophrenia (CCMD-3). <BR/>Age: 63.7 (SD = 2.1) for the quetiapine group and 64.2 (SD = 2.5) for the risperidone group.<BR/>Sex (male/female): quetiapine group (16/14), risperidone group (17/13).<BR/>Duration of illness: quetiapine group 4.3 months (SD = 2.2), risperidone group 4.0 months (SD = 2.3).<BR/>Age at onset: older than 60 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-28 13:33:45 +0100" MODIFIED_BY="[Empty name]">
<P>1. Quetiapine: fixed dose, 200 ~ 350mg/day. N = 30.<BR/>2. Risperidone: fixed dose, 2 ~ 3 mg/day. N = 30.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-28 13:33:54 +0100" MODIFIED_BY="[Empty name]">
<P>Mental state: PANSS (Positive and Negative Syndrome Scale for Schizophrenia).</P>
<P>Adverse effects: extra pyramidal side effects, sleepiness, orthostatic hypotension, dry mouth, constipation, ECG changes, elevated alanine aminotransferase, weight gain.</P>
<P>Leaving the study early.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-28 13:34:18 +0100" MODIFIED_BY="[Empty name]">
<P>Further details about the allocation procedure are required. Chunbo Li couldn't contact the author by telephone, and an inquiry email was sent to the author on 26th July, 2010 with no response. The outcome data of this study is presented in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dubovsky-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:32 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dubovsky-2010a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:33 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dubovsky-2010b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:34 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dubovsky-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:37 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kircher-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:39 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luo-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:40 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McGuire-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:42 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mintzer-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:44 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-01-05 11:08:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-M_x00f6_ller-2005">
<CHAR_METHODS MODIFIED="2012-01-05 11:08:03 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details. <BR/>Blindness: double, no further details. <BR/>Duration: 6 weeks. <BR/>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-28 13:34:32 +0100" MODIFIED_BY="[Empty name]">
<P>N = 36.</P>
<P>Diagnosis: schizophrenia (DSM-IV), schizophreniform disorder, schizoaffective disorder, delusional disorder or shared psychotic disorder. <BR/>Age: 65 years or more.<BR/>Sex: not described. <BR/>Duration of illness: not described. <BR/>Age at onset: not described. <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-10-04 14:24:51 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride: flexible dose. Allowed dose range: 100 to 400 mg/day. N = 24.<BR/>2. Risperidone: flexible dose. Allowed dose range: 1 to 4 mg/day. N = 12.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-05-26 21:07:21 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: adverse events. <BR/>Cognitive functioning: MMSE (Mini Mental State Examination). <BR/>Adverse effects: open interviews.<BR/>Unable to use- <BR/>Mental State: PANSS total score, BPRS total score (no usable data). <BR/>Cardiac effects: (QTc), laboratory tests (no data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-28 13:35:54 +0100" MODIFIED_BY="[Empty name]">
<P>Age at onset: Unclear - requires full texts.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01625897">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:46 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-01-05 11:19:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Riedel-2009">
<CHAR_METHODS MODIFIED="2011-09-28 13:36:18 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details. <BR/>Blindning: double blind.<BR/>Duration: 6 weeks.<BR/>Design: parallel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-28 13:36:33 +0100" MODIFIED_BY="[Empty name]">
<P>N = 38.</P>
<P>Diagnosis: DSM IV-diagnostic criteria for psychotic disorders with psychotic symptoms severe enough to require antipsychotic medication.<BR/>Age: 72.7 ± 7.4 years.<BR/>Sex: predominantly female (80.6%).<BR/>Duration of illness: not described.</P>
<P>Age of onset: not clear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-28 13:36:43 +0100" MODIFIED_BY="[Empty name]">
<P>1. Risperidone.<BR/>2. Amisulpride.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-05 11:19:27 +0000" MODIFIED_BY="[Empty name]">
<P>Global state: Improvement, Clinical Global Impression (CGI), Clinical Global Impression - Change Scale (CGI-C).<BR/>Mental state: Brief Psychiatric Rating Scale (BPRS), Positive and Negative Syndrome Scale for Schizophrenia (PANSS), Simpson &amp; Angus Neurological Rating Scale for Extrapyramidal Effects /Simpson-Angus Scale (SAS), Depressive symptoms, Positive symptoms, Anxiety, Mini Mental State Examination (MMSE), Calgary Depression Scale (CDS).</P>
<P>Leaving the study early (or loss of contact between carer and patient/client).<BR/>Adverse effects: Barnes Akathisia Scale (BAS), Abnormal Involuntary Movement Scale (AIMS), Tardive dyskinesia, Agitation, Parkinsonism, Insomnia, Nausea<BR/>Restlessness, Headache, Hypotension, Dizziness, Tolerability, Treatment Emergent Adverse Event (TEAT), Tachycardia, Diarrohea, Fatigue, Tiredness, Influenza,</P>
<P>Dyspnea, Prostate symptom, Nutrition, Conjunctivitis.<BR/>Cognitive: Memory, Cognitive function.<BR/>Death.<BR/>Medication used.<BR/>Laboratory tests: Blood pressure, Electrocardiogram (ECG), QTc Interval, Cardiac functioning, Metabolism, Heamatology, Hypertension, Biochemistry, Uric acid levels, Respiration.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-28 13:37:37 +0100" MODIFIED_BY="[Empty name]">
<P>Age at onset: unclear - author was contacted at riedel@med.uni-muenchen.de on June 16, 2010 with no response.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-01-05 11:22:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ritchie-2003">
<CHAR_METHODS MODIFIED="2011-09-28 13:37:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details. <BR/>Blinding: no.</P>
<P>Duration: unclear.<BR/>Design: open-label cross-over.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-28 13:38:12 +0100" MODIFIED_BY="[Empty name]">
<P>N = 66.</P>
<P>Diagnosis: schizophrenia treated with conventional neuroleptics.<BR/>Age: elderly people (mean age 69.6 SD 6.2).<BR/>Sex: unclear.<BR/>Age of onset of schizophrenia: unclear.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-05 11:19:40 +0000" MODIFIED_BY="[Empty name]">
<P>Switching elderly patients from typical antipsychotics (either as depot or oral preparations) to:</P>
<P>1. olanzapine.</P>
<P>2. risperidone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-05 11:22:46 +0000" MODIFIED_BY="[Empty name]">
<P>Mental state: Brief Psychiatric Rating Scale (BPRS), Mini Mental State (MMS), Scale for the Assessment of Negative Symptoms (SANS), Montgomery and Asberg Depression Rating Scale (MADRS)</P>
<P>Leaving the study early.<BR/>Adverese effects: Barnes Akathisia Scale (BAS), Abnormal Involuntary Movement Scale (AIMS), Parkinsonism, Simpson &amp; Angus Neurological Rating Scale for Extrapyramidal Effects / Simpson-Angus Scale (SAS), Extrapyramidal side effects (EPS).<BR/>Quality of Life: WHO Quality of Life [Brief] Scale (WHO-QOL-BREF).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-28 13:38:32 +0100" MODIFIED_BY="[Empty name]">
<P>Age at onset: unclear - the author was contacted three times at C.Ritchie@medsch.ucl.ac.uk in June 2010 with no response.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ritchie-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:49 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sutton-2001a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:50 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:51 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-01-05 11:20:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhe-2007">
<CHAR_METHODS MODIFIED="2012-01-05 11:20:28 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation:  randomised by admission sequence - no further detail.</P>
<P>Blinding: No blinding.</P>
<P>Duration: 6 weeks.</P>
<P>Design: parallel.</P>
<P>Country of origin: China.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-28 13:39:35 +0100" MODIFIED_BY="[Empty name]">
<P>N = 62.</P>
<P>Diagnosis: schizophrenia (CCMD-3), antipsychotic naive.<BR/>Age: 64.2 (SD = 1.9) for the aripiprazole group and 63.9 (SD = 2.2) years for the risperidone group.<BR/>Sex (male/female): 17/13 in the aripiprazole group and 18/14 in the risperidone group.<BR/>Duration of illness: 5.5 months (SD = 2.1) for the aripiprazole group and 4.9 months (SD = 2.3) for the risperidone group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-01-05 11:20:19 +0000" MODIFIED_BY="[Empty name]">
<P>1. Aripiprazole fixed dose (within 14 days) 15~20 mg/d.</P>
<P>2. Risperidone fixed dose (within 14 days)  2~3 mg/d.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-28 13:39:49 +0100" MODIFIED_BY="[Empty name]">
<P>Mental state: PANSS (Positive and Negative Syndrome Scale for Schizophrenia).</P>
<P>Adverse effects/events: anxiety, headache, sleepiness, nausea.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-28 13:40:06 +0100" MODIFIED_BY="[Empty name]">
<P>Further details about the allocation procedure are required. Chunbo Li couldn't contact the author by telephone, and an inquiry email was sent to the author on 26th July, 2010 with no response. The outcome data of this study is presented in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x4f0f__x5f69__x971e_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:54 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x4f59__x6210__x56fd_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:55 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5201__x7aef__x5fe0_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:56 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5218__x91d1__x5149_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:58 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:41:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5415__x658c__x519b_--2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:41:59 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5468__x76ca__x8f89_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:00 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5b8b__x4e3d_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:02 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5d14__x660e__x4f1f_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:03 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f20__x4fdd__x5229_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:04 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f20__x5cfb__x5cad_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:05 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f20__x7586__x8389_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:06 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f20__x8273__x7426_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:09 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f20__x8273__x7426_-2010a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:10 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f90__x6e05_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:11 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x66fe__x5e86__x7ff0_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:12 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x674e__x56fd__x5170_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:14 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x674e__x6c38__x7ea2_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:15 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x674e__x6d77__x6d9b_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:17 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6768__x4ec1__x767b_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:18 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6768__x96c0__x5c4f_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:20 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x6881__x52c7_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:22 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x77f3__x4fdd__x9752_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:22 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x7ba1__x92ae__x53cb_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:24 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x7f57__x7426_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:25 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8463__x6653__x8339_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:26 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8463__x7ee7__x627f_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:29 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x848b__x5e78__x884d_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:30 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8bf8__x6625__x660e_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:32 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8c22__x56fd__x5efa_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:33 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9648__x6c38__x7ea2_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:35 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9ec4__x5cf0_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:36 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9ec4__x5cf0_-2010a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:37 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9ec4__x5cf0_-2010b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:39 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-09 11:42:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9ec4__x632f__x82f1_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-09 11:42:40 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>DSM-IV: Diagnostic and Statistical Manual of Mental Disorders</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-01-05 11:23:32 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2012-01-05 11:23:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barnes-2002">
<CHAR_STUDY_NAME MODIFIED="2012-01-05 11:23:11 +0000" MODIFIED_BY="[Empty name]">
<P>A prospective study of tardive dyskinesia in the elderly; single-blind comparison of amisulpride and risperidone.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-01-05 11:23:09 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective single-blind study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-04 14:24:51 +0100" MODIFIED_BY="[Empty name]">
<P>Elderly people with tardive dyskinesia, not clear if including late-onset schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-09-28 13:40:42 +0100" MODIFIED_BY="[Empty name]">
<P>1. Amisulpride.</P>
<P>2. Risperidone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-28 13:40:47 +0100" MODIFIED_BY="[Empty name]">
<P>Tardive dyskinesia.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-09-28 13:40:48 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-09-28 13:40:52 +0100" MODIFIED_BY="[Empty name]">
<P>National Research Register 2002;3. National Research Register 2003;1.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-04-05 12:48:44 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-01-05 11:23:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lacro-2001">
<CHAR_STUDY_NAME>
<P>Antipsychotic treatment in late life schizophrenia.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-01-05 11:23:17 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-10-04 14:24:51 +0100" MODIFIED_BY="[Empty name]">
<P>Older people with schizophrenia, not clear if including late-onset schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Risperidone.<BR/>2. Haloperidol.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1. Clinical response (reduction in psychopathology).<BR/>2. Cognitive performance (a battery of neuropsychological tests).<BR/>3. Health-related quality of life.<BR/>4. Plasma level of antipsychotic drug.<BR/>5. Adverse effects.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Unclear ~ 2001.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-01-05 11:23:32 +0000" MODIFIED_BY="[Empty name]">
<P>CRISP database<BR/>(https://www-commons.cit.nih.gov/crisp/index.html.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-09-28 12:40:53 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-04-05 12:32:10 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-05 12:32:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2007">
<DESCRIPTION>
<P>Randomised via random number table. Chumbo Li phoned the author on 26th July, 2010. The author stated that allocation was according to random number table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-09-28 12:40:50 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-28 12:40:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2007">
<DESCRIPTION>
<P>Allocation concealment not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-09-28 12:40:51 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-09-28 12:40:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Huang-2007">
<DESCRIPTION>
<P>There was no blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-09-28 12:40:52 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-09-28 12:40:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2007">
<DESCRIPTION>
<P>No participants left the study early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-04-05 12:32:58 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-05 12:32:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2007">
<DESCRIPTION>
<P>The protocol was not located, unsure if selective reporting occurred.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-09-28 12:40:53 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-28 12:40:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2007">
<DESCRIPTION>
<P>There was no industry funding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-06-08 13:58:41 +0100" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2011-12-07 10:10:29 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-12-07 10:10:29 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-12-07 10:10:29 +0000" MODIFIED_BY="[Empty name]">Unusable outcome data due to lack of standard deviations</TITLE>
<TABLE COLS="5" ROWS="7">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Risperidone</P>
<P>n (male/female) 22 (12/10)</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Olanzapine</P>
<P>n (male/female) 22 (11/11)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Before</P>
</TD>
<TD VALIGN="TOP">
<P>After</P>
</TD>
<TD VALIGN="TOP">
<P>Before</P>
</TD>
<TD VALIGN="TOP">
<P>After</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>BPRS</P>
</TD>
<TD VALIGN="TOP">
<P>65.41</P>
</TD>
<TD VALIGN="TOP">
<P>36.14</P>
</TD>
<TD VALIGN="TOP">
<P>64.32</P>
</TD>
<TD VALIGN="TOP">
<P>33.91</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>BMI (kg/m2)</P>
</TD>
<TD VALIGN="TOP">
<P>22.97</P>
</TD>
<TD VALIGN="TOP">
<P>23.09</P>
</TD>
<TD VALIGN="TOP">
<P>22.65</P>
</TD>
<TD VALIGN="TOP">
<P>23.62</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>FBS(Fasting Blood Sugar) (mmol/L)</P>
</TD>
<TD VALIGN="TOP">
<P>4.37</P>
</TD>
<TD VALIGN="TOP">
<P>4.44</P>
</TD>
<TD VALIGN="TOP">
<P>4.30</P>
</TD>
<TD VALIGN="TOP">
<P>4.52</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Serum Cholesterol (mmol/L)</P>
</TD>
<TD VALIGN="TOP">
<P>4.31</P>
</TD>
<TD VALIGN="TOP">
<P>4.37</P>
</TD>
<TD VALIGN="TOP">
<P>4.29</P>
</TD>
<TD VALIGN="TOP">
<P>5.10</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Serum Triglycerides (mmol/L)</P>
</TD>
<TD VALIGN="TOP">
<P>1.02</P>
</TD>
<TD VALIGN="TOP">
<P>1.01</P>
</TD>
<TD VALIGN="TOP">
<P>0.99</P>
</TD>
<TD VALIGN="TOP">
<P>1.27</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>BPRS: Brief Psychiatric Rating Scale<BR/>BMI: Body Mass Index<BR/>FBS: Fasting Blood Sugar</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2011-10-04 14:24:51 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-05-26 19:37:18 +0100" MODIFIED_BY="[Empty name]">Outcomes of Chu 2006</TITLE>
<TABLE COLS="3" ROWS="15">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Quetiapine</P>
<P>n (male/female): 30 (16/14)</P>
</TD>
<TD VALIGN="TOP">
<P>Risperidone</P>
<P>n (male/female): 30 (17/13)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Endpoint score of PANSS (+)</P>
</TD>
<TD VALIGN="TOP">
<P>8.1 (SD = 1.7)</P>
</TD>
<TD VALIGN="TOP">
<P>8.1 (SD = 2.9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Endpoint score of PANSS (-)</P>
</TD>
<TD VALIGN="TOP">
<P>11.1 (SD = 5.1)</P>
</TD>
<TD VALIGN="TOP">
<P>10.2 (SD = 5.1)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>General Mental state</P>
</TD>
<TD VALIGN="TOP">
<P>21.0 (SD = 6.7)</P>
</TD>
<TD VALIGN="TOP">
<P>20.1 (SD = 5.9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Endpoint score of PANSS</P>
</TD>
<TD VALIGN="TOP">
<P>38.2 (SD = 11.7)</P>
</TD>
<TD VALIGN="TOP">
<P>38.1 (11.7)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>TESS</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Extra Pyramidal Symptoms</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>8</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Sleepiness</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Orthostatic hypotension</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Dry mouth </P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Constipation</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>ECG changes</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Elevated alanine aminotransferase</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Gain weight</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Leaving the study early</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
<TD VALIGN="TOP">
<P>0</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>PANSS: Positive and Negative Syndrome Scale</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2011-10-04 14:24:51 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-05-26 20:24:38 +0100" MODIFIED_BY="[Empty name]">Outcomes of Zhe 2007</TITLE>
<TABLE COLS="3" ROWS="10">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Aripiprazole</P>
<P>n (male/female): 30 (17/13)</P>
</TD>
<TD VALIGN="TOP">
<P>Risperidone</P>
<P>n (male/female): 32 (18/14)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Endpoint score of PANSS (+)</P>
</TD>
<TD VALIGN="TOP">
<P>10.5 (SD = 2.9)</P>
</TD>
<TD VALIGN="TOP">
<P>12.6 (SD = 4.7)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Endpoint score of PANSS (-)</P>
</TD>
<TD VALIGN="TOP">
<P>9.8 (SD = 8.3)</P>
</TD>
<TD VALIGN="TOP">
<P>9.9 (SD = 7.3)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Endpoint score of Psychopathology</P>
</TD>
<TD VALIGN="TOP">
<P>26.1 (SD = 7.3)</P>
</TD>
<TD VALIGN="TOP">
<P>22.7 (SD = 7.3)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Endpoint score of PANSS</P>
</TD>
<TD VALIGN="TOP">
<P>46.4 (SD = 20.7)</P>
</TD>
<TD VALIGN="TOP">
<P>45.2 (SD = 19.4)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>TESS</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Anxiety</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Headache</P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Sleepiness </P>
</TD>
<TD VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>5</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Nausea</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>1</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>PANSS: Positive and Negative Syndrome Scale</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-04-04 16:03:45 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-04-04 16:03:45 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>RISPERIDONE versus OLANZAPINE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-04-04 16:03:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" WEIGHT="0.0" Z="0.0">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Risperidone</GROUP_LABEL_1>
<GROUP_LABEL_2>OLanzapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours risperidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours olanzapine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-04-04 16:03:45 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.0" STUDY_ID="STD-Huang-2007" TOTAL_1="22" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-09-28 12:40:54 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-09-28 12:40:54 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-09-28 12:40:54 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-10-04 14:24:51 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2011-10-04 14:24:51 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-07-22 16:50:00 +0100" MODIFIED_BY="[Empty name]">Previous searches</TITLE>
<APPENDIX_BODY MODIFIED="2011-10-04 14:24:51 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Electronic searches</HEADING>
<P>We searched the Cochrane Schizophrenia Groups Trials Register (September 2002) using the phrase:</P>
<P>[(((elderly* or *elderly* in abstract terms or title) or (old* or * old * in title) or (*paraphrenia* or *late onset* in abstract, index terms or title) or (aged* in index terms) of REFERENCE) or (elderly in participants of STUDY))].</P>
<P>This register is compiled by up-to-date methodical searches of BIOSIS, <I>The Cochrane Library</I>, CINAHL, Dissertation abstracts, EMBASE, LILACS, MEDLINE, PSYNDEX, PsycINFO, RUSSMED, Sociofile, and is supplemented with handsearching of relevant journals and numerous conference proceedings (see Group Module).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Searching other resources</HEADING>
<P>1. Reference searching<BR/>We also inspected the references of all identified studies for more trials.</P>
<P>2. Personal contact<BR/>The first author of each included study would have been contacted for information regarding unpublished trials.</P>
<P>3. Drug companies<BR/>We contacted the manufacturers of amisulpride, or aripiprazole, or clozapine, or iloperidone, or olanzapine, or quetiapine, or risperidone, or sulpiride, or ziprasidone, or zotepine, or typical antipsychotics for additional data.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2011-10-04 14:24:51 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-08-22 20:58:45 +0100" MODIFIED_BY="[Empty name]">Previous data collection and analysis</TITLE>
<APPENDIX_BODY MODIFIED="2011-10-04 14:24:51 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous (binary) data:</HEADING>
<P>For binary (yes/no) outcomes, we planned to to calculate a standard estimation of the fixed-effect risk ratio (RR) and its 95% confidence interval (95% CI). For statistically significant results, we would have calculated the number needed to treat/harm statistic (NNT/H), and its 95% CI. If heterogeneity had been found, we would have used a random-effects model.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data:</HEADING>
<P>We intended to include continuous data from rating scales in this review only if the measuring instrument had been described in a peer-reviewed journal and the instrument was either a self report or completed by an independent rater or relative (not the therapist). Where possible, we made efforts to convert continuous outcome measures to binary data by identifying cut-off points on rating scales and dividing participants accordingly. Otherwise, endpoint data would have been presented and if both endpoint and change data had been available for the same outcomes, only the former would have been reported in this review. A weighted mean difference (WMD) between groups was to be estimated as a summary statistics for continuous data, and, if heterogeneity had been found, a random-effects model would have been applied.</P>
<P>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, the following standards would have been applied to all data before inclusion: (a) standard deviations and means are reported in the paper or are obtainable from the authors; (b) when a scale starts from the finite number zero, the standard deviation, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>); (c) if a scale starts from a positive value the calculation described above in (b) should be modified to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S-Smin), where S is the mean score and Smin is the minimum score. Endpoint scores on scales often have a finite start and end point and these rules can be applied to them. When continuous data are presented on a scale which includes a possibility of negative values (such as change on a scale), there is no way of telling whether data are non-normally distributed (skewed) or not. It is thus preferable to use scale endpoint data, which typically cannot have negative values. If endpoint data were not available, then we would have used change data, but these would not have been subjected to a meta-analysis, and would have been reported in the 'Additional data' tables.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Unit of analysis issues  </HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Cluster trials</HEADING>
<P>Where clustering had been incorporated into the analysis of primary studies, we would have presented these data as if from a non-cluster randomised study, but adjusted for the clustering effect. Otherwise, clustering would have been dealt with in this review as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK> Section 16.3).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cross-over design</HEADING>
<P>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. This makes cross-over trials inappropriate for unstable conditions such as schizophrenia. Accordingly, we would have only used data of the first phase of cross-over studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Studies with multiple treatment groups</HEADING>
<P>Where a study involved more than two treatment arms, if relevant, we would have presented the additional treatment arms in comparisons. Where the additional treatment arms were not relevant, we would not have reproduced these data.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dealing with missing data  </HEADING>
<P>An intention to treat analysis would have been carried out. Studies would have been excluded from this review if they reported a drop out rate higher than 50% of participants in any group. In studies with less than 50% dropout rates, people leaving early would have been considered to have had the negative outcome, except for the event of death. The impact of including studies with high attrition rates would also have been analysed in a sensitivity analysis. If inclusion of data from this latter group had resulted in a substantive change in estimate of effects of the primary outcomes, their data would have been presented separately.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of heterogeneity  </HEADING>
<P>We would have considered all included studies without any comparison to judge clinical heterogeneity. Statistical heterogeneity would have been investigated by visual inspection of graphs and by calculating the I<SUP>2</SUP> statistics. The I<SUP>2</SUP> test provides an estimate of the percentage of heterogeneity thought to be due to chance, and it indicates high levels of heterogeneity when it gives a result of 75% or more (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). We would then have re-analysed data using a random-effects model to see if this made a substantial difference. If it did, and the I<SUP>2</SUP> statistics fell below 75% indicating more consistent results, we would have added the studies to the main body trials. If using the random-effects model did not make a difference and heterogeneity remained high, data would not have been summated, but presented separately and reasons for heterogeneity investigated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of reporting biases  </HEADING>
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. These are described in section 10.1 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>(<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). We would have tried to locate protocols of included trials. If the protocol was available, we would have compared outcomes in the protocol and in the published report. If the protocol was not available, we would have compared outcomes listed in the methods section of the trial report with actually reported results. In addition, we would have used a funnel plot (included trial effect size versus included trial size) in an attempt to investigate the likelihood of publication bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data synthesis  </HEADING>
<P>Where possible we would have employed a fixed-effect model for analyses. However, as discussed above, a random-effects model would have been applied if heterogeneity had been found.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subgroup analysis and investigation of heterogeneity  </HEADING>
<P>It has been proposed that elderly people may be more sensitive to neuroleptic drugs, and that the outcome may be affected by the specific diagnosis of the late-onset psychosis. Accordingly, we would have performed subgroup analyses to test these proposals.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis  </HEADING>
<P>We intended to undertake an analysis of the primary outcomes comparing the results when completer-only data were used with analyses on an intention-to-treat basis. We would have also performed a sensitivity analysis to compare between low-quality and high-quality studies. A third sensitivity analysis would have compared between acute, short-term, medium-term and long-term (as defined above) randomised controlled trials.<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-10-04 14:24:51 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-08-22 20:59:38 +0100" MODIFIED_BY="[Empty name]">Assessment of methodological quality</TITLE>
<APPENDIX_BODY MODIFIED="2011-10-04 14:24:51 +0100" MODIFIED_BY="[Empty name]">
<P>In the first version of this review, we planned to assess the methodological quality of included trials using the criteria described in the Cochrane Handbook (<LINK REF="REF-Clarke-2000" TYPE="REFERENCE">Clarke 2000</LINK>) and the Jadad Scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). The former is based on the evidence of a strong relationship between allocation concealment and direction of effect. The categories are defined below.</P>
<P>A. Low risk of bias (adequate allocation concealment)<BR/>B. Moderate risk of bias (some doubt about the results)<BR/>C. High risk of bias (inadequate allocation concealment)</P>
<P>The Jadad Scale measures a wider range of factors that impact on the quality of a trial. It includes three items.<BR/>1. Was the study described as randomised?<BR/>2. Was the study described as double-blind?<BR/>3. Was there a description of withdrawals and dropouts?</P>
<P>Each item receives one point if the answer is positive. In addition, a point can be deducted if either the randomisation or the blinding/masking procedures described were inadequate.<BR/>For the purpose of the analysis in this first version of the review, trials would have been included if they met the Cochrane Handbook criteria A or B. If the study did not gain at least two points on the Jadad Scale it would not have been included.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>